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Sherry Kathleen Pittman 
AN IN VITRO STUDY OF THE MECHANISMS THAT UNDERLIE CHANGES IN 
NEURONAL SENSITIVITY AND NEURITE MORPHOLOGY FOLLOWING 
TREATMENT WITH MICROTUBULE TARGETING AGENTS 
 
 Microtubule targeting agents (MTAs) are chemotherapeutics commonly 
used in the treatment of breast, ovarian, lung, and lymphoma cancers.  There are 
two main classes of MTAs based upon their effects on microtubule stability.  The 
two classes are the destabilizing agents, which include the drug vincristine, and 
the stabilizing agents, which include paclitaxel and epothilone B.  These drugs 
are highly effective antineoplastics, but their use is often accompanied by several 
side effects, one of which is peripheral neuropathy.  Peripheral neuropathy can 
be characterized by burning pain, tingling, loss of proprioception, or numbness in 
the hands and feet.  In some patients, the MTA-induced peripheral neuropathy is 
debilitating and dose-limiting; however, there are no effective prevention 
strategies or treatment options for peripheral neuropathy as the mechanisms 
mediating this side effect are unknown.  The goal of this work was to investigate 
MTA-induced effects on neuronal activity and morphology in order to elucidate 
the underlying mechanisms involved in the development of MTA-induced 
peripheral neuropathy. 
 As an indicator of sensory neuronal activity, the basal and 
stimulated release of the putative nociceptive peptide, calcitonin gene-related 
peptide (CGRP), was measured from sensory neurons in culture after exposure 
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to the MTAs paclitaxel, epothilone B, and vincristine.  Neurite length and 
branching were also measured in sensory neuronal cultures after treatment with 
these MTAs.  The results described in this thesis demonstrate that MTAs alter 
the stimulated release of CGRP from sensory neurons in differential ways 
depending on the MTA agent employed, the CGRP evoking-stimulus used, the 
concentration of the MTA agent, the duration of exposure to the MTA agent, and 
the presence of NGF.  It was also observed that MTA agents decrease neurite 
length and branching, independent of the concentration of NGF in the culture 
media.  Thus, this thesis describes MTA-induced alterations of sensory neuronal 
sensitivity and neurite morphology and begins to elucidate the underlying 
mechanisms involved in MTA-induced alterations of sensory neurons. These 
findings will undoubtedly be used to help elucidate the mechanisms underlying 
MTA-induced peripheral neuropathy. 
 
Jill C. Fehrenbacher, Ph.D., Chairperson 
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INTRODUCTION 
 
1) Description of Primary Afferent Sensory Neurons 
Primary afferent sensory neurons transmit sensory information from the 
periphery to the spinal cord.  These neurons are a heterogeneous population, 
and different classes of sensory neurons transmit peripheral information including 
touch, proprioception, temperature, itch, vibration, pressure, and nociception, 
which is the signaling of a noxious stimulus (Sternini 1997, Julius and Basbaum 
2001).   The cell bodies of the primary sensory neurons are located within the 
dorsal root ganglia (DRG), which are lateral to the vertebrae in the spinal column, 
and the neurons are pseudo-unipolar in that they have one axon leaving the cell 
body that bifurcates into two separate branches.  One branch innervates the 
periphery, including the skin, organs, and muscle, and the other branch 
terminates in the spinal cord (Kandel and Schwartz, 2000).  This branching 
system allows for primary sensory neurons to transmit peripheral sensory input to 
the neuronal cell body in the DRG and also onto the spinal cord for signaling to 
higher brain systems (Kandel and Schwartz, 2000). 
This work is focused on functional and morphological effects of a class of 
anticancer drugs called microtubule targeting agents (MTAs) on a particular 
subclass of peripheral sensory neurons that process and transmit noxious 
peripheral sensations (Loeser and Treede 2008).  Peripheral nociceptive neurons 
are able to detect and transmit noxious signals from chemical, mechanical, and 
thermal stimuli (Julius and Basbaum 2001).  There are two main subdivisions of 
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peripheral nociceptive neurons based upon the myelination state of their axons.  
Unmyelinated nociceptors are termed C fibers, and lightly myelinated nociceptors 
are Aδ fibers.  These C and Aδ nociceptive neurons are also termed small and 
medium diameter sensory neurons, respectively, since the diameters of their cell 
bodies (small: < 27 µm, medium: 27-45 µm) are smaller than the Aα and Aβ 
sensory neurons, or large diameter neurons (large: > 45 µm), that detect non-
noxious stimuli such as proprioception, touch, vibration, and pressure 
(Schmalbruch 1986, Scroggs and Fox 1992, Yusaf, Goodman et al. 2001).  The 
nociceptive neurons have a slower conduction velocity and higher thresholds to 
activation compared to the large diameter sensory neurons.  Researchers utilize 
conduction velocity as a way to differentiate the subsets of sensory neurons; C 
fibers have a slower conduction velocity than Aδ fibers (Harper and Lawson 
1985, Harper and Lawson 1985). 
Small and medium diameter sensory neurons can be further subdivided 
into peptidergic and nonpeptidergic neurons.  The peptidergic neurons express 
the neuropeptides substance P and calcitonin-gene related peptide (CGRP) 
(Lawson, Perry et al. 1993, Hiruma, Saito et al. 2000).  CGRP is synthesized in 
the cell bodies of the sensory neurons and then trafficked to the central and 
peripheral terminals in large dense core vesicles (Kashihara, Sakaguchi et al. 
1989).  The neuropeptides are important in nociceptive signaling (Besson and 
Chaouch 1987) as evidenced by studies that have shown that capsaicin-induced 
allodynia can be alleviated by the administration of substance P and CGRP 
receptor antagonists in animal models (Sun, Lawand et al. 2003, Sun, Lawand et 
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al. 2004).  Also, studies have shown that following noxious stimulation, there is a 
release of neuropeptides from sensory neurons into the spinal cord (Kuraishi, 
Hirota et al. 1985, Holzer 1988), which also suggests that the neuropeptides are 
involved in nociceptive signaling.  In rat DRG neurons, approximately 50% of the 
neurons express substance P and 47% express CGRP, and there is substantial 
overlap of the neuropeptides in approximately 45% of the DRG neurons (Kai-Kai, 
Anderton et al. 1986, McCarthy and Lawson 1990, Price and Flores 2007).  
Approximately 49% of the CGRP-expressing DRG also express TRPV1 (Price 
and Flores 2007).   
CGRP has several physiological functions that are important in mediating 
neuronal sensitization and neurogenic inflammation.  After stimulation with 
noxious stimuli, CGRP is released from the central terminals to signal to the 
second order neurons which in turn signal to higher brain regions (Ryu, Gerber et 
al. 1988, Ryu, Gerber et al. 1988).  The peripheral terminals also release CGRP.  
One function of CGRP in the periphery is autocrine; CGRP binds to its G-protein 
coupled receptor and activates the cAMP/PKA signaling cascade, augmenting 
neuronal sensitivity (Sun, Tu et al. 2004).  CGRP can also elevate intracellular 
calcium levels and enhance inward sodium currents via PKA and PKC signaling 
within DRG neurons, thereby modulating synaptic transmission (Natura, von 
Banchet et al. 2005).  Other functions of CGRP in the periphery include 
vasodilatation of blood vessels and activation and recruitment of proinflammatory 
immune cells (Richardson and Vasko 2002, Gracias, Cummins et al. 2011).  The 
CGRP receptor is broadly expressed throughout the entire organism including 
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within sensory neuron cell bodies, the dorsal horn of the spinal cord, and the 
brain (van Rossum, Hanisch et al. 1997).  It is also expressed in non-nervous 
system tissues and cells including vascular smooth muscle, kidney, heart, 
spleen, liver, skeletal muscle, endothelial cells, and mast cells (van Rossum, 
Hanisch et al. 1997).  
This work uses the release of CGRP from sensory neurons in culture as 
an indicator of sensory neuronal activity.  Dougherty and co-workers suggest that 
a predominant clinical effect of a commonly used MTA agent, paclitaxel, is on 
discrimination of sensations conducted by large diameter fibers, and his group 
theorizes that the function of small diameter sensory neurons is maintained 
(Dougherty, Cata et al. 2004); however, a role for the small diameter sensory 
neurons has been intimated based upon in vivo endpoints (Polomano, Mannes et 
al. 2001, Gracias, Cummins et al. 2011).  As described below, low-dose 
paclitaxel altered nociceptive endpoints in an animal model without altering motor 
function (Polomano, Mannes et al. 2001).  Systemic administration of paclitaxel 
also decreased CGRP release and subsequent capsaicin-evoked vasodilatation 
in the rat hindpaw, suggesting that the release of CGRP and function of 
nociceptive peripheral neurons is altered after treatment with paclitaxel (Gracias, 
Cummins et al. 2011).  This work examines the effects of MTA agents on CGRP 
release from sensory neurons in culture as a measure of MTA-induced 
alterations of neuronal sensitization. 
 
 
4 
 
2) Neuronal Sensitization and Nerve Growth Factor 
Sensitization of nociceptive neurons occurs following tissue injury by overt 
damage and/or infection, and sensitization is often mediated by inflammatory 
mediators (Basbaum, Bautista et al. 2009, Gold and Gebhart 2010).  A short-
lived, acute sensitization of the sensory neurons is considered to be beneficial to 
an organism as it can prevent further tissue damage and protect the organism 
during tissue repair processes, which is the underlying function of nociception 
(Reichling and Levine 2009).  Sensitization of sensory neurons can also persist 
for long periods of time, which is termed chronic sensitization.  This form of 
sensitization serves no beneficial role to the organism and is considered to be 
pathological in nature (Tsuda, Inoue et al. 2005, Basbaum, Bautista et al. 2009).  
The work in this thesis is directed at investigating the chronic sensitization of 
sensory neurons by MTA agents since MTAs produce chronic pain states in 
patients, which may be mediated by chronic sensitization of the sensory neurons.  
I specifically investigated the sensitization of sensory neurons of the peripheral 
nervous system since systemic paclitaxel administration in rats resulted in high 
concentrations of accumulated paclitaxel within DRG and to a slightly lesser 
extent within the sciatic nerve (Cavaletti, Cavalletti et al. 2000).  Low 
concentrations were found within brain tissue and spinal cord of the central 
nervous system, suggesting that the peripheral nervous system is more 
susceptible to paclitaxel exposure (Cavaletti, Cavalletti et al. 2000).   
Neurons are termed sensitized when they become more responsive to a 
given stimulus, in other words, a given stimulus elicits a greater response from 
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the neurons than prior to the sensitization event (Castellucci and Kandel 1976, 
Lewin, Ritter et al. 1993, Hingtgen and Vasko 1994).  Sensitization of the 
peripheral nociceptor neurons, or peripheral sensitization, results in increased 
transmitter release from the peripheral and central terminals upon stimulation.  
This hypersensitivity of the nociceptive neurons can contribute to the 
development of hyperalgesia and allodynia (Basbaum 1999, Basbaum and Woolf 
1999).  Sensitization of sensory neurons often occurs after exposure to 
inflammatory mediators that augment neuronal function via transcriptional 
changes or post-translational modifications of receptors, ion channels, or proteins 
important in modulation of neuronal activity (Bhave and Gereau 2004).   
One inflammatory mediator involved in neuronal sensitization during tissue 
injury is nerve growth factor (NGF).  NGF is a trophic factor that is an important 
mediator of neuronal hypersensitivity and can augment nociceptive responses 
and pain in humans (Petty, Cornblath et al. 1994, Svensson, Cairns et al. 2003).  
NGF is produced and released from a variety of cells after tissue injury including 
macrophages, monocytes, mast cells, and Schwann cells (Lindholm, Heumann 
et al. 1987, Leon, Buriani et al. 1994, Lambiase, Bonini et al. 1995).  Acute 
exposure to NGF can sensitize adult DRG neurons by several mechanisms 
including activation of phosphoinositide 3-kinase (PI3-K), mitogen-activated 
protein kinase (MAPK), and phospholipase C (PLC) signaling cascades, likely 
resulting in phosphorylation of the Transient Receptor Potential Vanilloid 1 
(TRPV1) channel, which is a non-selective cation channel important for the 
perception of noxious stimuli (Caterina, Schumacher et al. 1997, Julius and 
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Basbaum 2001, Zhu and Oxford 2007, Park, Fehrenbacher et al. 2010).  There is 
some debate about the pathways mediating NGF-induced sensitization of 
sensory neurons as PLC inhibitors prevent NGF-induced augmentation of 
capsaicin-evoked CGRP release whereas MEK and PI3-K inhibitors do not, 
suggesting that PLC signaling mediates NGF-induced changes in neuropeptide 
release (Park, Fehrenbacher et al. 2010).  Interestingly, there is a developmental 
shift in the dependency of DRG neurons on NGF for survival as well as the ability 
of NGF to sensitize neurons (Buchman and Davies 1993, Acosta, Fabrega et al. 
2001, Zhu, Galoyan et al. 2004); NGF can sensitize TRPV1 to capsaicin and 
noxious heat stimuli in DRG harvested from adult rats, but it does not sensitize 
TRPV1 in DRG from embryonic rats (Zhu, Galoyan et al. 2004).  The 
mechanisms underlying these developmental shifts in response to NGF within 
sensory neurons are unknown. 
  Long-term exposure to NGF alters the sensitivity of sensory neurons via 
several mechanisms, including increases in the expression of several channels 
and neuropeptides involved in neuronal sensitization, intimating NGF’s 
involvement in peripheral sensitization.  NGF regulates the expression of 
substance P and CGRP within peripheral sensory neurons (Lindsay, Lockett et 
al. 1989).  In DRG cultures from adult rats, maintaining the sensory neurons in 
the absence of added NGF resulted in a decline of CGRP mRNA.  After 5 days of 
continual growth in 25 ng/ml of NGF, CGRP mRNA increased 15-fold and CGRP 
peptide content increased 4-fold compared to control cultures (Lindsay and 
Harmar 1989).    Similarly, growing adult DRG neurons in either 30 ng/ml or 100 
7 
 
ng/ml of NGF for 7 days increased CGRP content and potassium-stimulated 
release of CGRP from sensory neurons in culture (Park, Fehrenbacher et al. 
2010).  This NGF-induced increase in CGRP content was determined to be 
partially mediated by the Ras signaling cascade; Ras-GTP levels increased in 
neurons grown in 30 ng/ml or 100 ng/ml NGF without increasing total Ras protein 
levels, and blocking the pathway with either a lentivirus expressing a dominant 
negative Ras construct or with a MEK inhibitor attenuated the increase in CGRP 
content (Park, Fehrenbacher et al. 2010).  
NGF also alters the expression of membrane channels involved in 
neuronal sensitivity.  In adult DRG cultures, NGF increased TRPV1 mRNA levels 
in a trkA-dependent and concentration-dependent manner (Winston, Toma et al. 
2001), and NGF increased the translocation and insertion of TRPV1 in the 
plasma membrane of HEK293 cells and sensory neurons in culture (Zhang, 
Huang et al. 2005).  After inflammation, TRPV1 protein expression increased in 
rat DRG, and this increase was prevented with an anti-NGF antibody (Amaya, 
Shimosato et al. 2004).  NGF has also been found to modulate sodium channel 
expression; in adult sensory neurons in culture and PC12 cells, NGF increased 
sodium channel mRNA expression by a trkA-dependent mechanism (Fjell, 
Cummins et al. 1999, Choi, Toledo-Aral et al. 2001).  These NGF-induced 
changes in ion channels can contribute to sensitization of sensory neurons, 
leading to augmented responses to noxious stimuli.  
NGF can also indirectly alter neuronal sensitivity by modulating the activity 
of immune cells that release inflammatory mediators and cytokines involved in 
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neuronal sensitization.   NGF increased the number and size of mast cells in 
several tissue types in neonatal rats receiving NGF injections (Aloe and Levi-
Montalcini 1977), and the release of proinflammatory and sensitizing substances 
such as histamine increased from mast cells after exposure to NGF in vitro  (Aloe 
and De Simone 1989).  NGF affects several other immune system cells, which 
potentially can augment neuronal sensitization by releasing proinflammatory 
cytokines and chemokines, including B- and T-lymphocytes, neutrophils, and 
monocytes (Gee, Boyle et al. 1983, Ehrhard, Erb et al. 1994, Torcia, Bracci-
Laudiero et al. 1996, Aloe, Simone et al. 1999).  NGF likely alters the sensitivity 
of sensory neurons directly and indirectly by altering signaling cascades, 
membrane ion channels, and immune cells that can all contribute to neuronal 
sensitization. 
 
3) Cytoskeleton and NGF Involvement in Neurite Length 
Neurons undergo complicated remodeling of axonal neurites in order to 
functionally adapt during development, learning, and following injury (Niwa, 
Hayakawa et al. 2002, Skaper 2005, Tucker and Mearow 2008).  Axons undergo 
periods of both neurite outgrowth and retraction based upon cellular 
environmental demands, and the needs of the cell are communicated to neurite 
structural machinery via intricate signaling cascades (Spira, Oren et al. 2001, 
Zheng and Poo 2007).   The processes involved in neurite outgrowth and 
retraction are delicately balanced, and microtubules, actin, motor proteins, and 
growth factors are all important components of neurite growth, maintenance, and 
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retraction (Heidemann, Joshi et al. 1985, Smith and Skene 1997, Wang, Naruse 
et al. 2001, Niwa, Hayakawa et al. 2002, Zheng and Poo 2007, Feng, Kang et al. 
2010).   
A growing body of evidence suggests that neurites are maintained by 
opposing forces between actin microfilament structures and microtubules (Wang, 
Naruse et al. 2001).  These opposing forces between microfilaments and 
microtubules are thought to be generated by myosin motors on the 
microfilaments and dynein motors on the microtubules via hydrolysis of ATP 
(Ahmad, Hughey et al. 2000).  A counterbalance of forces between the 
microfilaments and microtubules is important for maintaining neurite terminals 
and morphology (Wang, Naruse et al. 2001).  Inhibition of microtubule dynamics 
or motor proteins disrupts the counterbalance of forces and causes neurite 
retraction that can be prevented by disassembly of microfilaments (Letourneau, 
Shattuck et al. 1987, Ahmad, Hughey et al. 2000).  In an embryonic chick DRG 
culture model, nocodazole, a microtubule destabilizing drug, or microinjection of 
dynamitin, a protein that causes cessation of dynein motor activity, induced 
neurite retraction, suggesting that a disruption in microtubule dynamics results in 
neurite retraction.  This neurite retraction was prevented with pre-treatment of the 
neurites with latrunculin, a microfilament disassembly agent, or microinjection 
with a dominant-negative myosin motor.  Treatment with latrunculin or the 
dominant-negative myosin motor alone did not cause neurite retraction.  This 
suggests that functional microfilaments and microfilament-motor proteins are 
necessary for neurite retraction, and the forces generated by microfilaments are 
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counterbalanced by microtubule forces (Ahmad, Hughey et al. 2000).  Agents 
that disrupt the counterbalance between the cytoskeleton structures and motor 
protein forces can alter neurite maintenance and result in neurite retraction 
(Letourneau, Shattuck et al. 1987, Ahmad, Hughey et al. 2000, Wang, Naruse et 
al. 2001). 
Coordinated efforts of microfilaments and microtubules are also involved 
in neurite outgrowth.  During outgrowth in development and after injury, 
microfilaments organize into web-like structures, known as growth cones, that 
are responsible for elongation of the neurite and are supported by the 
microtubule structures (da Silva and Dotti 2002, Oertle, van der Haar et al. 2003, 
Erturk, Hellal et al. 2007).  Destabilization of the microtubule network in DRG 
cultures with nocodazole caused growth cones to form into retraction bulb-like 
structures, thereby preventing growth cone elongation and inhibiting neurite 
growth (Erturk, Hellal et al. 2007).  This suggests that microtubule deregulation 
can decrease neurite length not only by enhancing neurite retraction but also by 
preventing neurite elongation through the disruption of growth cones. 
    There are several key signaling pathways involved in the regulation of 
neurite length including the downstream signaling cascades initiated by NGF.  
NGF has been shown within numerous systems to promote DRG neurite growth 
(Kimpinski, Campenot et al. 1997, Hoke, Redett et al. 2006, Lykissas, Batistatou 
et al. 2007).   Using DRG neuronal cultures derived from adult rats, Gavazzi et al. 
(Gavazzi, Kumar et al. 1999) showed that growing DRG neurons in 100 ng/ml 
NGF increased the number of process-bearing neurons and increased the total 
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neurite length of the neurons.  Similarly Niwa et al. (Niwa, Hayakawa et al. 2002) 
cultured DRG explant cultures derived from embryonic, neonatal, young adult, 
and aged animals and found that 50 ng/ml of NGF significantly increased the 
neurite length from all ages of explants.  In an autonomic, superior cervical 
ganglia explant model from adult rats, NGF promotes outgrowth of the neurites 
over time (Hayakawa, Sobue et al. 1994, Hayakawa, Itoh et al. 1999), and in an 
adult DRG culture model, NGF promotes the outgrowth of neurons in a 
concentration-dependent manner (Malgrange, Delree et al. 1994).  NGF 
promotes neurite growth by initiating signaling cascades through the TrkA 
receptor, and both the phosphatidylinositol 3-kinase (PI3-K) and Ras/MAPK 
signaling cascades have been implicated in mediating NGF-induced neurite 
growth (Edstrom and Ekstrom 2003, Tucker, Rahimtula et al. 2008).  Although 
still a subject of investigation, PI3-K activates Akt, a serine/threonine protein 
kinase necessary for neurite elongation in several model systems (Edstrom and 
Ekstrom 2003).  Both PI3-K and Ras signaling mediate neurite growth by 
activating downstream effectors including the cAMP response element-binding 
protein (CREB) and tau, a microtubule-associated protein (Tucker and Mearow 
2008).    
 
4) Microtubule Targeting Agents 
Microtubules are dynamic cellular structures that have crucial roles in 
many functions including cell signaling, mitosis and cell division, intracellular 
organelle and vesicular transport, cell shape and motility, and intracellular 
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organization (Burnside 1975, Wilson and Jordan 2004).  Microtubules are fibrous 
polymers that are formed by heterodimers of two types of tubulin monomers, β 
and α.  The β and α heterodimers form slender tube-like structures, called 
polymers, which undergo dynamic rearrangement. This dynamic rearrangement 
property of microtubules is characterized by a continuous exchange between free 
β and α heterodimer pools and the microtubule polymer structure.  Tubulin 
heterodimers are continuously added to the growing, or plus end, of the polymer 
and removed from the shortening, or minus, end of the polymer, depending on 
the demands of the cell (Mandelkow and Mandelkow 1989, Mandelkow, 
Mandelkow et al. 1989).  This dynamic rearrangement is necessary for 
microtubule physiology (Gelfand and Bershadsky 1991).  The ends of a 
microtubule polymer are never stationary, and the rates of polymerization and 
depolymerization of the two ends are different (Horio and Hotani 1986).  Because 
of the dynamic characteristics of microtubules and the necessity for this dynamic 
rearrangement in cell physiology, especially in cell division, microtubule polymers 
and tubulin monomers have become major targets for cancer therapeutics 
(Morris and Fornier 2008). 
There are two main classes of MTAs, which are compounds that bind 
directly to the tubulin subunits to alter the dynamic rearrangement of 
microtubules.  Compounds that bind the β-tubulin subunit and prevent 
polymerization of microtubules are called depolymerizing or destabilizing agents 
and include vincristine, vinblastine, vinorelbine, vindesine, nocodazole, and 
colchicine (Johnson, Armstrong et al. 1963, Sartorelli and Creasey 1969, Zhou 
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and Rahmani 1992).  The other class of MTAs binds β-tubulin comprising the 
microtubule polymer and prevents the depolymerization of the microtubule 
polymer.  These agents are called polymerizing or stabilizing agents and include 
paclitaxel, docetaxel, and the epothilones (Sackett and Fojo 1999, Altaha, Fojo et 
al. 2002).  Although they have opposite effects on microtubules, both classes 
interfere with the dynamic rearrangement of microtubules.  Alterations in 
microtubule dynamics is a common mechanism of blocking mitosis within dividing 
cells, which leads to subsequent apoptosis in cancer cells (Jordan, Wendell et al. 
1996), thus MTAs have been developed and used extensively as anticancer 
drugs (Wilson and Jordan 2004).   
The Vinca alkaloids are a group of microtubule destabilizing drugs that 
were first isolated from the leaves of the periwinkle plant, Catharanthus roseus, 
and include the naturally occurring vinblastine and vincristine, as well as 
synthetically made vinorelbine and vindesine (Johnson, Armstrong et al. 1963, 
Zhou and Rahmani 1992).  The Vinca alkaloids are commonly used for the 
treatment of Hodgkin’s lymphoma, non-small cell lung cancer, breast cancer, 
lymphomas, and head and neck cancers (Himes 1991, Moudi, Go et al. 2013).  
The Vinca alkaloids bind to two sites on the β-tubulin, and upon binding, 
microtubule dynamics and polymerization are interrupted (Wilson, Creswell et al. 
1975).    The Vinca  alkaloids can also bind free tubulin dimers to prevent tubulin 
polymerization as well as the ends and outer surface of microtubules in a domain 
referred to as the vinca domain (Himes 1991, Dumontet and Jordan 2010).   In 
this manner, Vinca alkaloids inhibit microtubule polymerization.  While the Vinca 
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alkaloids are effective antineoplastic agents, their use is accompanied by 
common side effects including reversible myelosuppression, neutropenia, 
anemia, acute cardiac ischemia, gastrointestinal toxicities, and peripheral 
neuropathy (Moudi, Go et al. 2013).   
Another commonly used class of antineoplastics are the taxanes, 
paclitaxel and docetaxel, which are microtubule stabilizing agents.  Paclitaxel 
was first isolated from the bark of the yew tree, Taxus brevifola, in 1967 by 
Monroe Wall and Mansukh Wani (Wani, Taylor et al. 1971).  The semi-synthetic 
analog, docetaxel, was derived decades later.  Docetaxel is derived 
semisynthetically through a process using the needles of the tree.  Taxus 
baccata (Ringel and Horwitz 1991, Horwitz 1992).  The taxanes are used as 
treatments for several types of cancer including breast, ovarian, gastric, and lung 
cancers (Rowinsky, Gilbert et al. 1991).  Taxanes alter microtubule 
polymerization by binding specifically to the β-tubulin subunit at one 31-amino 
acid binding site on the N-terminal tail (Manfredi, Parness et al. 1982, Rao, 
Horwitz et al. 1992, Rao, Krauss et al. 1994).  This domain is separate from the 
vinca domain and along the lumen of the tubular microtubule polymer (Manfredi, 
Parness et al. 1982).  It is hypothesized that upon binding to tubulin, paclitaxel 
induces a conformational change in the microtubule that increases the binding 
between tubulin subunits, making the microtubule more stable (Rao, Krauss et al. 
1994).  In this way, taxanes enhance microtubule polymerization as well as 
prevent depolymerization of the polymer (Manfredi, Parness et al. 1982)  At high 
concentrations, paclitaxel (> 1 µM) increases microtubule polymerization, hence 
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the microtubule polymer mass increases, with nearly 1:1 stoichiometry of 
paclitaxel binding to tubulin, creating microtubule bundles within cells (Schiff and 
Horwitz 1980, Carboni, Farina et al. 1993), and free tubulin concentrations are 
decreased (Schiff, Fant et al. 1979, Horwitz 1992).  Lower concentrations of 
paclitaxel (10-100 nM) suppress the extent and rate of microtubule shortening 
without altering the microtubule polymer mass.  At intermediate concentrations of 
paclitaxel (100 nM-1 µM), microtubule dynamics are inhibited at both ends of the 
microtubule; however, significant changes in the microtubule polymer mass are 
still not observed (Derry, Wilson et al. 1995).  The taxanes are effective 
anticancer agents, although their use is sometimes limited by side effects.  
Common taxane-induced side effects include neutropenia, myalgias, alopecia, 
cardiac rhythm abnormalities, and peripheral neuropathy (Rowinsky, Chaudhry et 
al. 1993, Rowinsky, Eisenhauer et al. 1993, Pronk, Stoter et al. 1995, Kuppens 
2006).  Neutropenia was a major dose-limiting side effect of paclitaxel; however, 
concurrent treatment with granulocyte-colony stimulating factor and increasing 
infusion time of the taxanes to 24 hours can alleviate the neutropenia side effect, 
leaving peripheral neuropathy as the major dose-limiting side effect of taxane 
therapy (Sarosy, Kohn et al. 1992, Reichman, Seidman et al. 1993, Seidman, 
Norton et al. 1993, Verweij, Clavel et al. 1994). 
Epothilones are another class of microtubule stabilizing compounds that 
are primarily used in the treatment of metastatic breast cancer (Lee, Borzilleri et 
al. 2008).  The epothilones, EpoA, EpoB and the synthetic EpoB analog, 
ixabepilone, are macrolides that were first isolated from the bacterium, 
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Sorangium cellulosum, and have been found to have similar effects on 
microtubules as paclitaxel, although the structures of the Epos and paclitaxel are 
different.  EpoA and EpoB induce tubulin polymerization and enhance the 
stabilization of microtubule polymers similarly to paclitaxel (Bollag, McQueney et 
al. 1995).  Both Epos are competitive inhibitors of the binding of paclitaxel to 
microtubules, suggesting that they bind tubulin at the same site as paclitaxel or 
near the same site (Bollag, McQueney et al. 1995, Kowalski, Giannakakou et al. 
1997).  While the exact tubulin binding site of the Epos is still unknown, 
molecular modeling suggests that the Epos bind tubulin within the paclitaxel-
binding domain (Giannakakou, Gussio et al. 2000).  The Epos were originally 
thought to be promising drug candidates because they are not as susceptible to 
cellular extrusion via the multidrug-resistant phenotype as paclitaxel.  Multidrug-
resistant cancer cells are capable of increasing efflux of drugs via the ATP 
binding cassette proteins, which results in a reduction of intracellular drug 
concentrations (Dumontet and Jordan 2010).  Unlike paclitaxel and vincristine, 
the Epos are not substrates of P-glycoprotein, which is a transport protein 
commonly overexpressed in drug-resistant cancer (Arias, Gatmaitan et al. 1990, 
Dumontet and Jordan 2010).  Furthermore, the Epos are more effective in 
reducing tumor volumes in human multidrug-resistant tumor xenograft mouse 
models than paclitaxel (Chou, O'Connor et al. 2001).  Use of ixabepilone is 
accompanied by side effects including neutropenia, myalgias, alopecia, and 
peripheral neuropathy (Lee, Borzilleri et al. 2008). 
. 
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5) MTA-Induced Peripheral Neuropathy 
MTA-induced peripheral neuropathy is a common, dose-limiting side effect 
of many different classes of MTA agents including Vinca alkaloids, taxanes, and 
Epos.  MTA-induced peripheral neuropathy symptoms are experienced in the 
hands and feet of patients, termed a “glove and stocking” distribution.  Peripheral 
neuropathy can be characterized by gain in function manifestations including 
burning pain, tingling, or paresthesia as well as loss of function characteristics 
including loss of proprioception, decreased perception of vibrations, or 
numbness, although peripheral neuropathy symptoms vary between patients 
(Lipton, Apfel et al. 1989, Forsyth, Balmaceda et al. 1997, Iniguez, Larrode et al. 
1998, Miltenburg and Boogerd 2014).  Sensory deficits occur more frequently 
than motor deficits; however, myopathy and decreased motor skills do 
occasionally occur in patients (Wiernik, Schwartz et al. 1987, Lipton, Apfel et al. 
1989, Forsyth, Balmaceda et al. 1997, Dougherty, Cata et al. 2004).  While less 
common, autonomic neuropathy, characterized by orthostatic hypotension and 
paralytic ileus, occurs in some patients receiving high-dose paclitaxel and 
vincristine therapy, although it is debated that autonomic neuropathy is more 
common in patients receiving vincristine therapy (Legha 1986, Jerian, Sarosy et 
al. 1993, Rowinsky, Eisenhauer et al. 1993, Miltenburg and Boogerd 2014).  The 
peripheral neuropathy symptoms range in intensity from mild to severe, and 
although these symptoms resolve in some patients following cessation of 
treatment, they may be irreversible and can persist as chronic neuropathic pain 
(Connelly, Markman et al. 1996).    
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The development of MTA-induced peripheral neuropathy cannot currently 
be predicted, but there are several risk factors associated with the occurrence 
and intensity of MTA-induced peripheral neuropathy.  The risk factors include 
frequency of treatment, duration of chemotherapeutic infusion, dose given per 
treatment cycle, the cumulative dose of the chemotherapeutic received, and co-
administration with drugs that also cause peripheral neuropathy, including the 
platinum class of chemotherapeutics (Lee and Swain 2006).  Other risk factors 
include diabetes mellitus, preexisting peripheral neuropathy, alcoholism, and age 
(Lee and Swain 2006, Windebank and Grisold 2008).  There are no known 
treatment options which specifically prevent or reverse MTA-induced peripheral 
neuropathy, and most patients resort to scaling back the bolus of 
chemotherapeutic drug per treatment or to discontinuing administration entirely to 
minimize symptoms of the neuropathy (Pachman, Barton et al. 2011).  Both of 
these interventions can interfere with optimal antineoplastic outcomes (Capri, 
Tarenzi et al. 1996, Pachman, Barton et al. 2011).  
The mechanisms underlying the development of MTA-induced peripheral 
neuropathy are unknown, but there are several theories that are currently being 
explored.  Since the peripheral neuropathy affects the hands and feet, which are 
innervated by the longest, distal axons of sensory neurons, and because 
microtubules are crucial for the transport of proteins along neuronal axons, it is 
theorized that the MTAs induce peripheral neuropathy by altering retrograde and 
anterograde transportation of proteins throughout neurons (Carlson and Ocean 
2011).  The cell bodies of sensory neurons in the DRG and their peripheral 
19 
 
nerves are not protected by the blood-brain barrier, making them more 
susceptible to toxicity from MTAs (Cavaletti, Cavalletti et al. 2000, van der Sandt, 
Gaillard et al. 2001, Kemper, Cleypool et al. 2004).  While the ganglia of the 
autonomic system are also not protected by the blood-brain barrier, no studies 
have been performed comparing the relative accumulation of paclitaxel in 
sensory versus autonomic ganglia.  It is theorized that peripheral neuropathy 
may be a combination effect of MTA-induced toxicity of the cell body as well as 
the axon, and since the neuropathy develops in the distal extremities where 
axons are the longest, neurite length may be an important variable in MTA-
induced toxicity (Lee and Swain 2006).  This is supported by the finding that 
paclitaxel exposure to the sensory nerve axon in a microfluidics cell culture 
model is essential for development of paclitaxel-induced nerve retraction, and 
exposure to the cell body alone did not induce retraction (Yang, Siddique et al. 
2009).  While exposure to the axon is necessary for paclitaxel-induced retraction, 
the role of accumulated paclitaxel within the cell body is currently unknown, but it 
may have important implications for changes in trafficking of proteins from the 
soma to the axons as well as transcription, and translation of proteins necessary 
for neuronal function (Kashihara, Sakaguchi et al. 1989, Watson and Latchman 
1995, Freeland, Liu et al. 2000)   Motor neuron function is also affected by MTAs; 
however, the cell bodies of motor neurons are protected by the blood-brain 
barrier within the spinal cord and the axons of motor neurons are highly 
myelinated, presumably decreasing their exposure to MTAs (Schmalbruch 1986, 
Fetcho 1987).  This also suggests that exposure of the neuronal cell body to 
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MTAs is important in the development of peripheral neuropathy.  Motor 
neuropathies are more common at higher doses of paclitaxel (500 mg/m2 or 
higher) (Iniguez, Larrode et al. 1998).  Generally, MTA-induced peripheral 
neuropathy is believed to be a length-dependent distal sensory neuropathy; 
however, to a lesser extent, motor neurons and autonomic neurons are also 
implicated in MTA-induced neuropathy (Carlson and Ocean 2011). 
 
6) Clinical Incidence of MTA-induced Peripheral Neuropathy 
Peripheral neuropathy is graded using several different scales in order to 
categorize the severity of the neuropathy experienced.  Although there is not a 
universal scale, many studies employ scales established by the World Health 
Organization, Eastern Cooperative Oncology Group, or the National Cancer 
Institute (Miller, Hoogstraten et al. 1981, Oken, Creech et al. 1982, Postma and 
Heimans 2000).  Generally, a grade 1 neuropathy indicates mild neuropathy that 
does not interfere with daily life, grade 2 indicates a moderate neuropathy, grade 
3 describes severe symptoms of neuropathy that limit activities of daily living, and 
grade 4 indicates life threatening neuropathy (Postma and Heimans 2000, 
Carlson and Ocean 2011).  While these scales are mainly subjective in nature 
(Cavaletti and Marmiroli 2012), there are several other approaches used to 
measure peripheral neuropathy within patients.  Commonly used approaches 
include quantitative sensory testing, which are techniques to assess changes in 
discriminative touch, sharpness, temperature, vibration, pressure and nociceptive 
function (Rolke, Baron et al. 2006).  Clinicians also use neurophysiological 
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testing to assess changes in the conduction velocity of nerve fibers in patients 
(Cavaletti, Frigeni et al. 2007).   
Incidence and severity of peripheral neuropathy from paclitaxel 
chemotherapy depends on treatment schedule and dose, with an increased 
incidence of toxicity with larger cumulative dose and more frequent dosing 
(Winer, Berry et al. 2004, Seidman, Berry et al. 2008).  In one study, breast 
cancer patients received weekly treatment of a 100 mg/m2 dose for 6 weeks 
followed by a 80 mg/m2 dose of paclitaxel, which was continued until disease 
progression or limited by toxicity (Seidman, Berry et al. 2008).  This dosing 
paradigm resulted in the development of grade 3 or 4 neuropathy in 9-24% of the 
patients (Seidman, Berry et al. 2008).  In studies where higher doses of paclitaxel 
were administered, the incidence of peripheral neuropathy also increased;  a 24-
hour infusion of 250 mg/m2 paclitaxel every 21 days caused peripheral 
neuropathy in 40% of the patients (Wiernik, Schwartz et al. 1987).  In another 
study using a range of paclitaxel doses infused every 3 weeks in metastatic 
breast cancer patients, doses of 175 mg/m2, 210 mg/m2 , and 250 mg/m2   dose 
dependently enhanced the incidence and severity of peripheral neuropathy 
(Winer, Berry et al. 2004).  Pharmacokinetic studies have shown that dosing 
patients with 125-225 mg/m2 of paclitaxel results in maximal plasma 
concentrations between 1 and 10 μM (Rowinsky, Jiroutek et al. 1999, 
Henningsson, Karlsson et al. 2001), with a reduction in concentration to between 
10 nM and 1 μM by 20 hours.        
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Vincristine treatment also causes neuropathy in patients.  In non-
Hodgkin’s lymphoma patients, a dosing paradigm of 1.5 mg/m2  per week resulted 
in the development of 1-3 grade neuropathy in 35.2% of the patients (Dorchin, 
Masoumi Dehshiri et al. 2013).  In another study of patients with non-Hodgkin’s 
lymphoma using a liposomal encapsulation of vincristine to increase the 
therapeutic efficacy, a dosing paradigm of 2.0 mg/m2 of liposomal vincristine 
every 2 weeks resulted in the development of grade 3 or 4 neuropathy in 31% of 
the patients (Sarris, Hagemeister et al. 2000). 
Peripheral neuropathy is observed at a similar rate in patients receiving 
ixabepilone therapy.  In a clinical trial including patients with metastatic breast 
cancer, a dosing regimen of 40 mg/m2  every 3 weeks caused grade 3 peripheral 
neuropathy in 12% of the patients, whereas a dosing regimen of 20 mg/m2  every 
week for 3 weeks followed by one week off caused grade 3 neuropathy in 27% of 
the patients, suggesting that frequency of therapy greatly affects the 
development of peripheral neuropathy (Fountzilas, Kotoula et al. 2013). 
The onset of MTA-induced peripheral neuropathy symptoms varies 
between patients due to differences in the doses of drugs administered and upon 
the presence of risk factors described previously.  Generally, burning pain and 
tingling symptoms are the first to appear within 24 to 72 hours after MTA-
treatment, and these symptoms typically resolve within a week following the first 
infusion (Lipton, Apfel et al. 1989, Iniguez, Larrode et al. 1998).  With succeeding 
MTA treatments, symptom severity increases in patients, and they show an 
increased incidence of loss of proprioception, decreased reflexes, and loss of 
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vibratory sensations (Wiernik, Schwartz et al. 1987, Lipton, Apfel et al. 1989, 
Sarosy, Kohn et al. 1992, Forsyth, Balmaceda et al. 1997).  Motor neuropathy is 
less commonly experienced by patients, but decreases in fine motor skills and 
gait disturbances can be observed following high-dose infusions of paclitaxel 
(>500 mg/m2) (Sarosy, Kohn et al. 1992, Schiller, Storer et al. 1994, Iniguez, 
Larrode et al. 1998).  In most patients, neuropathy symptoms resolve after a few 
months following discontinuation of MTA therapy (Postma, Vermorken et al. 
1995, Roche, Yelle et al. 2007); however, in some patients, neuropathy can 
persist for months and even years following cessation of treatment (Verstappen, 
Koeppen et al. 2005, Balayssac, Ferrier et al. 2011, Osmani, Vignes et al. 2012).  
There is also a “paclitaxel-associated acute pain syndrome” that occurs in up to 
70% of patients receiving taxane therapy and is characterized by aching and 
sharp pain in the extremities as early as 24 hours after paclitaxel infusion 
(Loprinzi, Maddocks-Christianson et al. 2007, Saibil, Fitzgerald et al. 2010, 
Reeves, Dakhil et al. 2012).  This syndrome has not been well characterized, but 
the development of the paclitaxel-associated acute pain syndrome is correlated 
with development of more severe paclitaxel-induced peripheral neuropathy with 
further treatment (Pachman, Barton et al. 2011).  The development of MTA-
induced neuropathy, although not fully characterized within all trials, appears to 
be dose and frequency dependent, and patients tend to develop sensory 
neuropathies before motor neuropathies. 
 
 
24 
 
7) Animal Models of Peripheral Neuropathy 
Several animal models have been developed to examine the in vivo 
effects of paclitaxel on neuronal activity.  A low-dose model, whereby paclitaxel 
(cumulative doses of 4, 8, or 16 mg/kg) is injected systemically, either by 
intravenous or intra peritoneal injection, over the course of 7 days, results in 
mechanical hyperalgesia and allodynia, as well as cold allodynia, without causing 
overt nerve damage, alterations in nerve conduction velocity, or changes in 
neuronal survival (Polomano, Mannes et al. 2001, Flatters and Bennett 2006, 
Matsumoto, Inoue et al. 2006).  This dosing paradigm is similar to clinical doses 
of 200 mg/m2, which is approximately 6 mg/kg in patients who have an 
approximate body surface area of 1.7 m2 and weigh 55 kg (Redal-Baigorri, 
Rasmussen et al. 2014).   A cumulative dose of 4 mg/kg of paclitaxel also results 
in a decrease of capsaicin-evoked bloodflow within the hindpaw of the rat, 
suggesting that paclitaxel alters the function of small diameter sensory neurons 
involved in vasodilatation of the skin (Gracias, Cummins et al. 2011).  In an 
alternative high-dose animal model, paclitaxel (cumulative doses of 80-135 
mg/kg) is injected systemically over the course of 5-9 weeks. This model 
produces impairments in pain-like behaviors using the tail-flick test and thermal 
withdrawal latencies as endpoints, decreases in coordination as measured by the 
rota-rod test, and decreases in nerve conduction velocity in the tail nerve 
accompanied by swollen, degenerated axons (Cavaletti, Cavalletti et al. 1997, 
Authier, Gillet et al. 2000).  These data suggest that increases and decreases in 
neuronal sensitivity occur, dependent upon the endpoint measured and the 
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dosing paradigm of paclitaxel administered, which is similar to the clinical 
observations of MTA-induced peripheral neuropathy in patients. 
The most commonly used models to examine the in vivo effects of 
vincristine use daily intravenous or systemic injections of the drug for 2 weeks 
(cumulative dose of 1 mg/kg).  Mechanical allodynia and hyperalgesia develop as 
early as 5-7 days following injection, and motor performance is not altered as 
measured by a rota-rod test (Aley, Reichling et al. 1996, Weng, Cordella et al. 
2003).  Rats experienced increased spontaneous discharges in neurons of the 
lumbar DRG as well as increased A- and C-fiber responses to electrical 
stimulation (Weng, Cordella et al. 2003), suggesting a functional change in 
sensory neurons.  Investigators do not have a clear understanding of what 
population of neurons is affected by paclitaxel and vincristine or the mechanisms 
underlying these changes in sensitivity; however, axonal damage is also minimal 
in low-dose vincristine animal models (Tanner, Levine et al. 1998).  This 
suggests that MTA-induced changes in neuronal sensitivity after low-dose 
treatment with MTAs may be mediated by mechanisms that do not involve overt 
axonal damage, whereas decreases in motor function may be secondary to 
axonal damage following high doses of MTA drugs (Cavaletti, Cavalletti et al. 
1997, Authier, Gillet et al. 2000).   
Animal models for epothilones have been less extensively characterized 
than models for paclitaxel and vincristine (Authier, Balayssac et al. 2009).  One 
study using female rats found that weekly intravenous administration of .25 or .5 
mg/kg of EpoB for 4 weeks (cumulative dose of 1-2 mg/kg) resulted in decreased 
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tail nerve conduction velocities, mild sciatic nerve axonal degeneration, and a 
dose-related prolongation of foot withdrawal latency on a hot plate (Chiorazzi, 
Nicolini et al. 2009).  Another study using female rats found that intravenous 
administration of 1.2 or 2.4 mg/kg for 4 weeks (cumulative dose of 4.8-9.6 mg/kg) 
of sagopilone, a synthetic epothilone similar to ixabepilone, caused a dose-
dependent reduction in tail nerve conduction velocities and decreased 
myelination of the sciatic nerve (Chiorazzi, Hochel et al. 2012).  These studies 
have analogous findings to the high-dose paclitaxel in vivo models (Cavaletti et 
al., 1997, Authier et al., 2000), and it would be interesting to investigate if lower 
doses of epothilones would result in increased nociceptive behaviors within 
animal models. 
 
8) Paclitaxel- and Vincristine-induced Alterations of Neurite Length in vitro 
In vitro model systems have also been developed in an attempt to 
examine the effects of MTAs on neurons in culture, and most studies have 
investigated the effects of MTAs on neurite length.  Most in vitro studies use 
clinically relevant concentrations (10 nM- 2 µM) of MTAs as pharmacokinetic 
studies have shown that dosing patients with 125-225 mg/m2 of paclitaxel results 
in maximal plasma concentrations between 1 and 10 μM (Rowinsky, Jiroutek et 
al. 1999, Henningsson, Karlsson et al. 2001), with a reduction in concentration to 
between 10 nM and 1 μM by 20 hours.  Paclitaxel and vincristine have been 
found to alter neurite length in several different in vitro model systems.  Using 
embryonic DRG explant cultures, treatment with paclitaxel (10 nM-10 µM) for 24-
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28 hours prevented neurite outgrowth from the explants in a concentration- and 
time-dependent manner (Scuteri, Nicolini et al. 2006).  Similarly, when paclitaxel 
(29.3 nM) was applied to distal axons of embryonic DRG using a 
compartmentalized microfluidic culture platform, paclitaxel caused degeneration 
of the neurites; however, paclitaxel did not alter neurite length when application 
was limited to the soma (Yang, Siddique et al. 2009).  In an autonomic, adult rat 
superior cervical ganglion explant culture model, paclitaxel (100 nM- 2 µM) and 
vincristine (100 nM-2 µM) prevented neurite outgrowth from the explant in a 
concentration- and time-dependent manner (Hayakawa, Sobue et al. 1994, 
Hayakawa, Itoh et al. 1999).  Finally, using an adult sensory neuron culture 
model, paclitaxel (1 µM) and vincristine (0.1 nM) were added to the cultures after 
a 24 hour attachment and growth period.  After an additional 24 hours in culture 
in the presence of the MTAs, neurite length was decreased compared to vehicle-
treated controls (Malgrange, Delree et al. 1994).  This collective body of work 
suggests that paclitaxel and vincristine can decrease neurite length (Malgrange, 
Delree et al. 1994, Yang, Siddique et al. 2009) and prevent neurite outgrowth 
from axotomized explants in vitro (Hayakawa, Sobue et al. 1994, Hayakawa, Itoh 
et al. 1999, Scuteri, Nicolini et al. 2006).  The mechanisms underlying the MTA-
induced reduction in neurite length are unknown, and the role of these MTA-
induced morphological changes in the development of neuronal sensitization is 
still a subject needing further investigation. 
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9) Putative Mechanisms for MTA-induced Changes in Neuronal 
Sensitivity and Morphology 
a. MTA-Induced Alterations of Intracellular Trafficking in Neurons 
In peripheral sensory neurons, the majority of protein synthesis occurs 
within the neuronal cell body, and the resultant proteins and organelles 
necessary for axonal functioning must be delivered to the periphery, which can 
be approximately 1 meter in length in some instances (Gallant 2000, Xu and 
Tung 2001).  In order to achieve transport of necessary components throughout 
axons, sensory neurons have developed an intricate system of microtubules that 
allow for anterograde transport of proteins to the periphery and retrograde 
transport of components from the periphery to the cell body (Conde and Caceres 
2009).  The microtubules form a polar configuration within the axons, meaning 
that their plus ends point uniformly towards the axon tips (Conde and Caceres 
2009, Shemesh and Spira 2010).  Disruption of this polar configuration is thought 
to be involved in neuronal degenerative processes as microtubule polarity is 
important for proper trafficking of proteins and organelles, such as mitochondria, 
along the microtubules (Shemesh and Spira 2010).  This transport of cell 
components along the polar microtubules is mediated by microtubule motor 
proteins including kinesins and dyneins (Goldstein and Yang 2000).  Thus axonal 
transport is a crucially important cellular process for neuronal function and 
depends on several factors including proper microtubule polar configuration and 
functional microtubule motor proteins, and alterations of axonal transport have 
been implicated in peripheral neuropathy and several neurodegenerative 
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diseases (Shemesh and Spira 2010, Power, Srinivasan et al. 2012, Kanaan, 
Pigino et al. 2013). 
MTAs have been shown to alter axonal microtubule function, reconfigure 
microtubule polar configurations within axons, and decrease organelle transport 
along axons.  Paclitaxel (11.7 µM) has been shown to inhibit the anterograde 
transport of microinjected horseradish peroxidase in a reversible and time-
dependent manner in cultured chick DRGs.  This treatment paradigm also 
caused aggregation of axonal and cytoplasmic microtubules within the DRG 
cultures (Theiss and Meller 2000).  In a cultured Aplysia neuronal model, 
application of paclitaxel (100 nM) changed microtubular polar orientations, 
decreased the number of dynamically polymerizing microtubules, and inhibited 
the transport of organelles along the axon (Shemesh and Spira 2010).  
Vincristine has also been shown to alter mitochondrial transport in cultured cells.  
Using a differentiated, neuronal-like SK-N-SH cell culture model, treatment with 
vincristine (100 nM) decreased the velocity of mitochondrial movement along 
axons (Rovini, Carre et al. 2010).  Similarly, in a comparison study of paclitaxel, 
vincristine, and ixabepilone on vesicle motility in isolated giant squid axons, 
vincristine (1 µM) decreased both anterograde and retrograde transport rates of 
vesicles.  Perfusion of paclitaxel (10 µM) decreased anterograde transport but 
did not alter retrograde transport, and treatment with ixabepilone (1 µM ) 
decreased both anterograde and retrograde fast axonal transport.  All three MTA 
drugs altered fast axonal transport in the giant squid axons without inducing 
detectable microtubule bundling (LaPointe, Morfini et al. 2013).  Thus, MTA-
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induced alterations of microtubule polar configuration, axonal transport, and 
organelle trafficking could all contribute to the development of MTA-induced 
peripheral neuropathy since disruptions in these processes have been linked to 
neuronal degeneration (Shemesh and Spira 2010).  These disruptions could 
cause alterations in the trafficking of peptides, including CGRP, and organelles 
necessary for maintenance of sensory neurite function and morphology, like 
mitochondria, to the periphery.  This may underlie changes in neurite length and 
sensitivity of sensory neurons following treatment with MTAs.   
 
b. MTA-induced Alterations in Reactive Oxygen Species Generation and 
Nitroxidative Stress 
Another possible mechanism that may underlie the development of MTA-
induced neuronal sensitization is increased generation of reactive oxygen 
species (ROS).  A classic ROS and reactive nitrogen species pathway can be 
seen in Figure 1.   
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 Figure 1.  Reactive oxygen and nitrogen species pathway.  Adapted from 
(Djamali 2007). 
  
Peroxynitrite 
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MTAs increase ROS generation in several model systems.  In a human 
lung cancer cell model, paclitaxel treatment (0.1 µM- 5 µM) increased ROS 
generation in a concentration-dependent manner (Alexandre, Batteux et al. 
2006).  Additionally, exposing cortical neuronal cultures to paclitaxel (300 nM) 
increased ROS within the neurons, and this increase was reversed by treatment 
with the antioxidant, vitamin E (Jang, Hwang et al. 2008).  Vincristine (10 µM) 
has also been shown to increase ROS in a concentration-dependent manner 
within lymphoblastoma cells.  This vincristine-induced increase of ROS was 
partially attenuated by treatment with N-acetyl-L-cysteine (NAC) (20 mM), which 
is a compound that acts to recycle glutathione and scavenge free radicals (Tsai, 
Sun et al. 2007).  Glutathione is an intracellular thiol compound that acts as a 
substrate for reduction reactions, thereby decreasing reactive species levels 
(Ribas, Garcia-Ruiz et al. 2014).  NAC also attenuated ROS produced by 
paclitaxel and EpoB.  In a study conducted with mouse ovarian cells and human 
ovarian cancer cells, pre-treatment with NAC (3 mM) attenuated both paclitaxel 
(199 nM)- and EpoB (27.4 nM)-induced increases of ROS production (Rogalska, 
Marczak et al. 2013).  Although the cell types, MTA agents used, and drug 
concentrations vary among the above described studies, in vitro administration of 
MTAs increase ROS in several different model systems.  While this may 
contribute to the development of MTA-induced neuronal sensitivity, there is also 
a current theory that MTA-induced generation of ROS may contribute to the 
oncolytic action of MTAs.  Previous work has shown that reducing MTA-induced 
generation of H2O2 within cancer cells and mice decreased the antitumor effects 
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of the MTA (Alexandre, Batteux et al. 2006, Alexandre, Hu et al. 2007).  This 
suggests that reducing MTA-induced ROS as a treatment to prevent peripheral 
neuropathy may be a poor strategy as it may negatively impact the antineoplastic 
activity of the MTAs.  However, an increased production of ROS can result in a 
subsequent increase of reactive nitrogen species levels including peroxynitrite 
(Figure 1), and peroxynitrite has been implicated in the development of pain 
states without having known beneficial roles within systems, like superoxide’s 
role in memory and learning (Massaad and Klann 2011, Salvemini, Little et al. 
2011).  Thus, targeting reactive nitrogen species may be a better strategy for 
preventing MTA-induced peripheral neuropathy.   
The role of nitroxidative stress in paclitaxel-induced neuronal 
hypersensitivity and nociception has been intimated based upon studies where 
administration of free radical scavengers, superoxide dismutase mimetics, and 
peroxynitrite decomposition catalysts (PNDC) have prevented, reversed, or 
attenuated paclitaxel-induced nociception in in vivo models.  In a paclitaxel 
animal model, systemic administration of the general free radical scavenger, 
phenyl N-tert-butylnitrone (PBN), or a superoxide dismutase mimetic, 4-hydroxy-
2,2,6,6-tetramethylpiperidine-1-oxyl (TEMPOL), prevented and reversed 
mechanical allodynia and hyperalgesia (Kim, Zhang et al. 2010, Fidanboylu, 
Griffiths et al. 2011), and PBN attenuated cold allodynia (Fidanboylu, Griffiths et 
al. 2011).  The non-specific PNDCs and superoxide dismutase mimetics, 
FeTMPyP5+ and MnTE-2-PyP5+, were administered by subcutaneous injections 
or intrathecally to rats beginning on the day of paclitaxel injections.  Both 
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FeTMPyP5+ and MnTE-2-PyP5+ attenuated the development of paclitaxel-induced 
mechanical hyperalgesia and allodynia in a dose-dependent manner without 
altering baseline nociceptive behavior.  Intraperitoneal or intrathecal injections of 
FeTMPyP5+ and MnTE-2-PyP5+ on day 16, after the development of paclitaxel-
induced mechanical hyperalgesia and allodynia, reversed the mechanical 
hypersensitivity (Doyle, Chen et al. 2012).  Selective PNDCs, SRI110 and SRI6 
(Rausaria, Ghaffari et al. 2011, Rausaria, Kamadulski et al. 2011) were given 
orally to rats at the beginning of paclitaxel injections, and both compounds 
blocked the development of mechanical hyperalgesia and allodynia (Doyle, Chen 
et al. 2012), suggesting that peroxynitrite may be the reactive species 
responsible for the development of hypersensitivity in MTA animal models.  
These findings collectively show that preventing the formation of or decreasing 
the concentrations of non-specific ROS, superoxide, and/or peroxynitrite can 
prevent and reduce paclitaxel-induced mechanical hypersensitivity within animal 
models.  This suggests that the nitroxidative stress likely plays a role in the 
underlying mechanisms of paclitaxel-induced changes in neuronal function. 
Unexpectedly, the positive effects of decreasing ROS and reactive 
nitrogen species within animal models of MTA-induced peripheral neuropathy 
have not been translated to the clinic.  Antioxidant therapy has had no effect on 
paclitaxel-induced peripheral neuropathy within patients (Argyriou, Chroni et al. 
2006, Kottschade, Sloan et al. 2011).  Additionally, treatment with glutathione, as 
a method to decrease reactive species, did not alleviate paclitaxel/carboplatin-
induce peripheral neuropathy (Leal, Qin et al. 2014).  This suggests that the 
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generation and role of reactive species in MTA-induced peripheral neuropathy is 
complicated and perhaps multifactorial, and more work in understanding the 
production and effects of MTA-induced nitroxidative stress is necessary. 
The source and function of the reactive species generated within neurons 
after insult with an MTA are currently unknown.  Classically, the two possible 
sources for reactive species are from the mitochondrial electron transport chain 
and membrane-bound NADPH oxidase (Herrero and Barja 2000, Turrens 2003, 
Chinopoulos and Adam-Vizi 2006, Doyle, Chen et al. 2012, Gao, Zhou et al. 
2012), and mitochondrial dysfunction and NADPH oxidase activation have both 
been observed after paclitaxel exposure in vivo and in vitro within neurons 
(Flatters and Bennett 2006, Jang, Hwang et al. 2008, Melli, Taiana et al. 2008).  
Nitroxidative stress can cause a range of damage within cells including DNA 
damage, lipid peroxidation, and protein alterations and dysfunction (Rutkowski, 
Pancewicz et al. 2007, Schieber and Chandel 2014).  Within neurons, 
nitroxidative stress can also alter neuronal sensitivity by several mechanisms 
including altering channel activity  (Naziroglu, Cig et al. 2013, Nesuashvili, 
Hadley et al. 2013, Nishio, Taniguchi et al. 2013), enhancing kinase activity 
involved in neuronal sensitization signaling cascades (Balafanova, Bolli et al. 
2002, Hongpaisan, Winters et al. 2004, Chakraborti, Das et al. 2005, Ibi, 
Matsuno et al. 2008), and inducing redox sensitive transcription factor activity 
(Bar-Shai and Reznick 2006, Yakovlev, Barani et al. 2007).  The initial source 
and effects of MTA-generated nitroxidative stress are currently under 
investigation within the field.  
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c. MTA-induced Alterations in Mitochondrial Function 
Another possible mechanism underlying MTA-induced peripheral 
neuropathy is via toxicity to the mitochondria, which suggests that MTAs alter 
and/or damage neuronal mitochondria, thereby altering energy production within 
the cell.  This can create deficits in energy production needed for neuronal 
functions, ultimately causing neuronal sensitivity and dysfunction (Flatters and 
Bennett 2006, Xiao, Zheng et al. 2011, Janes, Doyle et al. 2013).  In in vitro 
studies of non-neuronal cell cultures, paclitaxel depolarized the mitochondrial 
membrane potential, decreased mitochondrial calcium levels, and increased 
release of cytochrome c from the mitochondria, all indicators of mitochondrial 
dysfunction (Evtodienko, Teplova et al. 1996, Andre, Braguer et al. 2000, Kidd, 
Pilkington et al. 2002).   In in vivo animal models, paclitaxel has been shown to 
increase the number of atypical and swollen mitochondria in C-fibers and 
myelinated axons within saphenous nerves of treated animals (Flatters and 
Bennett 2006).  Paclitaxel also decreased mitochondrial respiration and ATP 
production within rat sciatic nerves, which is further support that paclitaxel 
impairs mitochondrial energy production within neurons (Xiao, Zheng et al. 2011, 
Zheng, Xiao et al. 2011).  This paclitaxel-induced impairment in mitochondrial 
respiration was prevented with prophylactic treatment with the mitochondrial 
protective agent, acetyl-L-carnitine (ALCAR) (Zheng, Xiao et al. 2011).  
Furthermore, concurrent treatment of ALCAR with paclitaxel prevented and 
reversed paclitaxel-induced mechanical allodynia and hyperalgesia as well as 
prevented paclitaxel-induced increases in swollen and vacuolated mitochondria 
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of C-fibers (Flatters, Xiao et al. 2006, Jin, Flatters et al. 2008).  This collective 
evidence suggests that one possible mechanism underlying MTA-induced 
changes in neuronal activity is mitochondrial dysfunction, which could contribute 
to calcium deregulation, reactive species generation, and cellular energy deficits 
(Xiao and Bennett 2008, Xiao, Zheng et al. 2009, Zheng, Xiao et al. 2011).  
Contrary to the in vivo  ALCAR findings, the administration of ALCAR to breast 
cancer patients undergoing paclitaxel chemotherapy resulted in an increased 
incidence of peripheral neuropathy (Hershman, Unger et al. 2013).  Thus, the 
involvement of mitochondria in the development of MTA-induced peripheral 
neuropathy is not fully understood, and further investigation is warranted. 
 
d. MTA-induced Alterations in Membrane Channels 
Membrane ion channels are key regulators of neuronal excitability and 
play a fundamental role in the detection of stimuli in nociceptive sensory neurons 
(Bennett and Woods 2014).  Alterations in membrane channel expression and/or 
function may underlie changes in neuronal sensitivity following paclitaxel 
treatment.  Spontaneous axonal activity was measured from the sural nerves of 
animals treated with paclitaxel or vincristine, and the spontaneous activity of 
myelinated and unmyelinated primary afferent fibers increased in MTA-treated 
animals (Xiao and Bennett 2008).  The spontaneous activity of DRG from 
paclitaxel-treated animals has also been shown to be increased.  Within the 
sensory neurons that exhibited an increase in spontaneous activity, the mRNA 
expression of several membrane channels, including potassium, sodium and 
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TRP channels, was altered (Zhang and Dougherty 2014), providing a possible 
mechanism by which paclitaxel alters excitability in the nerve fibers and DRG.  
Alterations of several different channel types have been investigated as possible 
mechanisms mediating MTA-induced changes in nociception, including several 
TRP channel family members and voltage-dependent calcium channels (VDCC) 
(Chen, Yang et al. 2011, Kawakami, Chiba et al. 2012, Materazzi, Fusi et al. 
2012, Hara, Chiba et al. 2013). 
 MTA agents may be altering neuronal function and inducing peripheral 
neuropathy by altering a family of ion channels known as Transient Receptor 
Potential (TRP) channels, which are non-selective cation channels (Clapham, 
Runnels et al. 2001, Montell, Birnbaumer et al. 2002, Jara-Oseguera, Simon et 
al. 2008).  The Transient Receptor Potential Vaniloid 1 (TRPV1) channel is an 
important ion channel responsible for the perception of noxious chemical stimuli 
including capsaicin and acidic pH as well as noxious heat and some endogenous 
lipids (Caterina, Schumacher et al. 1997, Tominaga, Caterina et al. 1998, Julius 
and Basbaum 2001, Bhave, Hu et al. 2003, Tominaga and Caterina 2004, 
Cortright and Szallasi 2009, Patwardhan, Scotland et al. 2009).  Systemic 
administration of paclitaxel in the rat resulted in an increase in TRPV1 mRNA 
and protein expression in the DRG (Hara, Chiba et al. 2013), while in a paclitaxel 
mouse model, treatment with a TRPV1 antagonist, capsazepine, reversed 
paclitaxel-induced thermal hyperalgesia without affecting mechanical 
hyperalgesia (Chen, Yang et al. 2011).  These data suggest that TRPV1 may 
mediate paclitaxel-induced changes in thermal sensitivity within animal models.   
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The Transient Receptor Potential Ankyrin 1 (TRPA1) channel is activated 
by a wide variety of stimuli, including noxious mechanical, noxious cold, and 
environmental chemicals (see review by Kwan, Allchorne et al. 2006).  Several 
investigators have examined the role of TRPA1 in mediating paclitaxel-induced 
mechanical and cold allodynia by systemically administering a TRPA1 antagonist 
or by using TRPA1-deficient animals and examining the effects of these 
manipulations in animals treated with paclitaxel.  Antagonism of the TRPA1 
channel attenuated paclitaxel-induced mechanical allodynia and reversed cold 
allodynia, while TRPA1-deficient animals did not develop paclitaxel-induced cold 
allodynia (Chen, Yang et al. 2011, Materazzi, Fusi et al. 2012).  Collectively, 
these data suggest that TRPA1 mediates mechanical allodynia and cold 
allodynia induced by paclitaxel. 
Transient Receptor Potential Vanilloid 4 (TRPV4) is activated by a diverse 
range of stimuli including heat, phorbol esters, acidic pH, and hypo-osmotic 
stimuli (Guler, Lee et al. 2002, Watanabe, Davis et al. 2002, Gao, Wu et al. 2003, 
Suzuki, Mizuno et al. 2003, Suzuki, Watanabe et al. 2003).  Knocking down 
TRPV4 protein expression within L4 and L5 DRG with TRPV4-targeting 
oligonucleotides reversed paclitaxel-induced mechanical hyperalgesia within a 
rat model (Alessandri-Haber, Dina et al. 2004), suggesting that TRPV4 may be 
involved in paclitaxel-induced mechanical hyperalgesia and neuropathy.  
Another type of membrane channel that has been implicated in MTA-
induced peripheral neuropathy are the VDCCs, which are voltage-gated ion 
channels that are selectively permeable to calcium (McCleskey 1999).  Paclitaxel 
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administration in an in vivo animal resulted in an increase in VDCC current in 
DRG neurons, which was inhibited by gabapentin, an antagonist of VDCCs 
expressing the α2δ-1 and α2δ-2 subunits.  Paclitaxel also increased α2δ-1 
protein expression in DRG (Kawakami, Chiba et al. 2012).  Systemic 
administration of ethosuximide, a putative T-type VDCC blocker, reversed 
paclitaxel-induced mechanical allodynia and hyperalgesia and cold allodynia as 
well as vincristine-induced mechanical allodynia and hyperalgesia, suggesting 
that T-type VDCCs may be involved in both paclitaxel- and vincristine-induced 
hypersensitivity in the rat (Flatters and Bennett 2004).  Inhibition of VDCCs with 
gabapentin therapy does not translate clinically, however.  Patients with 
established chemotherapy-induced peripheral neuropathy received either 
gabapentin or placebo therapy for 6 weeks, and there was no difference in 
peripheral neuropathy symptoms at the completion of the trial compared to 
placebo treatment (Rao, Michalak et al. 2007).   
Alterations in the VDCC and TRP channel expression and/or function by 
MTAs would likely alter the intrinsic membrane properties of DRG neurons and 
could lead to enhanced and attenuated neuronal sensitivity, depending on the 
specific modifications of the channels.  Membrane channels could be modified by 
MTAs by several possible mechanisms including transcription and localization 
abnormalities as well as post-translational modifications from aberrant signaling 
cascades. 
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e. MTA-induced Alterations of Intraepidermal Nerve Fibers and 
Neuroimmune Regulation 
Despite there not being any overt axonal damage, defined by 
degeneration or structural abnormalities of axons within the sciatic nerve 
(Polomano, Mannes et al. 2001) at the level of the peripheral nerve in rats after 
low-dose paclitaxel or vincristine treatment, the terminals of the peripheral nerves 
degenerate.  The number of intraepidermal nerve fibers (IENF) innervating the 
hindpaws of rats decreased to 24% and 44% of that in vehicle-treated animals in 
in vivo models of paclitaxel- and vincristine-induced hypersensitivity, respectively, 
and the decrease in IENF corresponded to the peak of hypersensitivity in the 
animals (Siau, Xiao et al. 2006).  Whether the decreased number of innervating 
IENFs was a result of MTA-induced retraction or MTA-prevention of nerve fiber 
maintenance and growth is unknown.  As described above, alterations of 
microtubule dynamics can lead to both neurite retraction and inhibition of neurite 
outgrowth by altering growth cones.  The specific mechanisms underlying MTA-
induced decreases in IENFs are under investigation; however, an alteration of 
microtubule dynamics by MTAs may be involved in these phenomena.   
The involvement of the immune system in paclitaxel- and vincristine-
induced decreases in IENFs has also been suggested.  Paclitaxel and vincristine 
treatment increased epidermal Langerhans cells in the hindpaws of rats 
corresponding to the paclitaxel- and vincristine-induced decreases in IENFs 
(Siau, Xiao et al. 2006, Jin, Flatters et al. 2008).  Langerhans cells are antigen-
presenting immune cells of the skin (Siau, Xiao et al. 2006).  In a similar study, 
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administration of paclitaxel increased the number of macrophages in the hindpaw 
(Liu, Lu et al. 2010).  The paclitaxel-induced decrease of IENFs in rat hindpaws 
was reversed with co-treatment with minocycline, a tetracycline-derived antibiotic 
that is known to have immunomodulatory properties.  Treatment with minocycline 
also prevented paclitaxel-induced mechanical hyperalgesia and allodynia (Liu, Lu 
et al. 2010, Boyette-Davis, Xin et al. 2011).  This suggests that one possible 
mechanism of MTA-induced hypersensitivity may be that MTAs decrease 
innervating IENFs in the peripheral skin, perhaps caused by a neuroimmune 
interaction in the skin; however, the mechanistic link between decreased 
peripheral IENFs and hypersensitivity is still under investigation.  
 
f. Vincristine and Paclitaxel Bind and Activate Neuronal-Calcium 
Sensor 1 
While the investigations of MTA effects on neuronal function have 
primarily been focused on mechanisms involving alterations of microtubule 
dynamics, MTAs may alter neuronal function and cause peripheral neuropathy by 
other, microtubule-independent mechanisms. Paclitaxel binds neuronal-calcium 
sensor 1 (NCS-1) and B-cell lymphoma 2 (Bcl-2) (Rodi, Janes et al. 1999, 
Boehmerle, Splittgerber et al. 2006, Ferlini, Cicchillitti et al. 2009, Benbow, Mann 
et al. 2012), but a direct involvement of this binding has not been shown to 
mediate neurotoxicity. Dr. Barbara Ehrlich’s group found that paclitaxel and 
vincristine bind to NCS-1, which is a high affinity calcium binding protein 
important in many calcium signaling events and cascades (Benbow, Mann et al. 
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2012).  Upon binding paclitaxel or vincristine, NCS-1 signaling is enhanced, and 
interaction between NCS-1 and the inositol 1,4,5-triphosphate receptor (InsP3R) 
is increased (Boehmerle, Splittgerber et al. 2006, Benbow, Mann et al. 2012).  
Acute application of paclitaxel (937 nM) on neuroblastoma cells caused 
oscillations in cytosolic calcium levels that were mediated by NCS-1 and were 
InsP3R dependent (Boehmerle, Splittgerber et al. 2006).  This suggests that MTA 
agents may alter neuronal calcium homeostasis in a microtubule-independent 
manner.  Although paclitaxel and vincristine bind NCS-1, epothilone B was used 
as a negative control in paclitaxel/NCS-1-induced calcium oscillation 
experiments, suggesting that not all MTAs activate the NCS-1 signaling cascade 
(Zhang, Heidrich et al. 2010). 
 
g. Nerve Growth Factor Alters MTA-induced Effects in vitro and in vivo 
NGF may be an important variable in the development or maintenance of 
MTA-induced peripheral neuropathy, and in vivo and in vitro investigations 
suggest NGF may be protective against the effects of MTAs.  Within several in 
vitro systems, NGF attenuates MTA-induced changes of different endpoints 
including cell survival and neurite length.  In a study investigating the effects of 
paclitaxel and NGF on cell survival, embryonic DRG explants were exposed to 
paclitaxel (1 µM) for 4 days, and this caused 90% of the neurons to degenerate 
and die; however, when the explants were concurrently exposed to paclitaxel and 
NGF (300 U/ml), the DRG neurons survived comparably to control neurons 
(Peterson and Crain 1982).  This suggests that paclitaxel may mediate changes 
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in neuronal function by decreasing viability of the neurons, which can be 
reversed with NGF treatment.  A limitation to this study, however, is that 
embryonic neurons are dependent on NGF for survival, and the decrease in 
survival observed in this study may be a result of NGF deprivation as opposed to 
paclitaxel exposure (Buchman and Davies 1993, Acosta, Fabrega et al. 2001). 
NGF can also rescue MTA-induced alterations of neurite length.  As 
described above, paclitaxel and vincristine prevented neurite outgrowth from 
superior cervical ganglia explants in concentration- and time-dependent 
manners; however, growth of the neurites was augmented in the paclitaxel- and 
vincristine-treated cultures by exogenous application of 100 ng/ml NGF 
(Hayakawa, Sobue et al. 1994, Hayakawa, Itoh et al. 1999).  Whether NGF can 
protect the neurites from the effects of the MTAs or whether NGF independently 
stimulates growth of the neurites and therefore reduces the impact of the MTAs 
on neurite length is unknown.   
NGF also reverses MTA-induced alterations within animal models.  Using 
a high-dosing paclitaxel schedule, mice received 6 injections of 21.6 mg/kg 
(129.6 mg cumulative) of paclitaxel, which resulted in thermal hypoalgesia and 
decreased substance P in the DRG of the mice.  Concomitant injections of 
paclitaxel with 10 µg/ml NGF prevented the paclitaxel-induced hypoalgesia.  
Systemic NGF also prevented the paclitaxel-induced decrease of substance P in 
the murine DRG (Apfel, Lipton et al. 1991), suggesting that NGF may be capable 
of preventing paclitaxel-induced neurotoxicity in high-dose animal models, in 
which the development of paclitaxel-induced thermal hypoalgesia is apparent. 
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In another high-dose paclitaxel model, rats were injected with 8 mg/kg 
paclitaxel twice a week for 4 weeks (64 mg cumulative), and the rats developed 
paclitaxel-induced mechanical allodynia.  NGF levels decreased in the sciatic 
nerves of paclitaxel-treated rats at the end of the 4 week treatment schedule 
compared to vehicle-treated control animals (Arrieta, Hernandez-Pedro et al. 
2011).  Whether the decrease in NGF levels was causally related to the 
development of the mechanical allodynia is unknown, but these data suggest that 
paclitaxel alters the baseline NGF concentrations within tissues that may be 
important for homeostatic cell maintenance and/or signaling cascades. 
Collectively these studies suggest that the MTA-induced changes in neuronal 
morphology and sensitivity may be attenuated by NGF treatment; however, the 
underlying mechanisms mediating this attenuation and/or the possible 
convergent signaling pathways activated by MTA and NGF are currently 
unknown.   
 
h. Paclitaxel Alters NGF Levels Clinically 
Circulating NGF levels have been shown to be correlated with the 
development of paclitaxel-induced peripheral neuropathy in the clinic. Cervical 
cancer patients who did not have prior peripheral neuropathy had their circulating 
NGF levels measured at baseline, before receiving paclitaxel and cisplatin 
chemotherapy, and again at the end of the trial.  A significant correlation existed 
between patients with the greatest decrease in circulating NGF levels after 
treatment with paclitaxel and cisplatin and the severity of peripheral neuropathy 
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developed (Cavaletti, Bogliun et al. 2004).  Similar observations were made in a 
trial of non-small-cell lung cancer patients who did not have prior peripheral 
neuropathy.  Changes in baseline and post-treatment circulating NGF levels 
were determined, and there was a correlation between the greatest decrease in 
circulating NGF levels and development of peripheral neuropathy (Arrieta, 
Hernandez-Pedro et al. 2011).  These correlations suggest that changes in NGF 
levels may be important markers in predicting the development and severity of 
peripheral neuropathy; however, it is unknown if NGF protects against the 
development of peripheral neuropathy.  The role of NGF and its downstream 
signaling cascades in MTA-induced peripheral neuropathy are unknown, and 
further investigation is warranted as NGF may attenuate MTA-induced 
alterations. 
 
As described throughout the introduction, there are several putative 
mechanisms thought to underlie the development of MTA-induced peripheral 
neuropathy including alterations in microtubule dynamics, intracellular trafficking, 
reactive species generation, membrane channel expression and/or function, 
mitochondrial function, and IENF innervation.  It is likely that all of these changes 
occur within sensory neurons following MTA-treatment; however, the relative 
contribution of these different mechanisms is still under investigation.  These 
described mechanisms may be linked and could propagate each other following 
MTA treatment; for example, MTA-induced changes in mitochondrial function 
may result in an increase in mitochondria-produced reactive oxygen species.  
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Interactions between all the proposed mechanisms need to be further 
investigated.  This will aid in the development of effective therapies since the 
possible interconnected relationships of the mechanisms may be important in the 
development of MTA-induced peripheral neuropathy.  
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SPECIFIC AIMS OF THE THESIS 
 
The studies in this thesis investigated the effects of three cancer 
chemotherapeutic microtubule targeting agents, paclitaxel, EpoB, and vincristine, 
on the function and morphology of sensory neurons in culture and the 
contribution of NGF to these effects.  Therefore, the aims of this thesis are: 
1.  To determine the effects of paclitaxel, EpoB, and vincristine on the 
release of CGRP from sensory neurons in culture in the presence and 
absence of NGF. 
2. To determine the effects of paclitaxel, EpoB, and vincristine on sensory 
neurite length and branching in culture in the presence and absence of 
NGF. 
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MATERIALS AND METHODS 
 
1) Materials 
All materials unless stated otherwise were purchased from Sigma-Aldrich 
(St. Louis, MO).  F-12 media, horse serum, and antibiotics, were purchased from 
Invitrogen (Carlsbad, CA). NGF was purchased from Harlan Laboratories 
(Indianapolis, IN).  Alexa Fluor 488 donkey anti-rabbit antibody was purchased 
from Life Technologies (Grand Island, NY), and the rabbit anti-human protein 
gene product 9.5 (PGP9.5) antibody was purchased from AbD Serotec, a Bio-
Rad company (Raleigh, NC).  The AITC was purchased from Fisher Scientific 
(Pittsburgh, PA).  CGRP for radioimmunoassay was purchased from Tocris 
Bioscience (Ellisville, MO).  Rat (Tyr27)-αCGRP27-37 for radioimmunoassay was 
purchased from Bachem (Torrence, CA).   Radiolabeled sodium iodine (125NaI) 
for iodination of CGRP27-37  was purchased from Perkin-Elmer (Shelton, CT). 
 
2) Animals 
The Animal Care and Use Committee at Indiana University School of 
Medicine (Indianapolis, IN) approved all procedures used in the experiments 
described in this body of work, and all experiments were carried out in 
accordance with the approved protocols.  Animals were stored in group cages in 
light controlled rooms (light from 6:00 to 19:00), and food and water were 
available ad libitum.  Animals were allowed to acclimate in the animal room upon 
delivery for at least 3 days before use. All experiments were performed on 
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primary cultures of sensory neurons derived from the DRG of adult male Sprague 
Dawley rats (150-200 g; Harlan Laboratories, Indianapolis, IN).  
 
3) Isolation of Primary Sensory Neuron Cultures 
Plates for cell culture were precoated starting 2 days before the harvest by 
exposing them to 1 ml (12-well plate) or 250 µl (48-well plate) of poly-D-lysine 
(PDL) (0.1 mg/ml) and storing them overnight in a 37° C, 3% CO2 incubator.  The 
following day, the wells were rinsed 1 time with 1 ml or 250 µl of sterile H2O and 
were subsequently exposed to 1 ml or 250 µl of laminin (1 mg/ml) overnight.  The 
laminin was removed from the wells immediately before addition of the 
dissociated neurons. 
Adult rat DRG cultures were prepared as follows:  adult rats were 
asphyxiated with CO2 and then decapitated.  DRG were harvested from the 
entire length of the vertebral column, and the DRG were digested by incubating 
them for 1 hr in F-12 media containing 0.125% collagenase.  After the 1 hr 
incubation period, the DRG were centrifuged for 1 min to pellet the DRG, the 
media containing collagenase was removed, and the DRG pellet was 
resuspended in culture media, which was F-12 media supplemented with 10% 
heat-inactivated horse serum, 2 mM glutamine, 100 µg/ml normocin, 50 µg/ml 
penicillin and streptomycin, 50 µM 5-fluoro-2-deoxyuridine, and 150 µM uridine in 
the absence of added nerve growth factor (NGF) or in the presence of 30 or 250 
ng/ml NGF.  The DRG were then dissociated into a single-cell suspension by 
mechanically agitating the pellet with a fire-polished glass pipette.  The 
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suspension was diluted with culture media, and approximately 30,000-40,000 
cells were plated per well on the 12-well plates, and approximately 3,300-4,300 
cells were plated in each well of the 48-well plates.  The sensory neuron cultures 
were maintained in culture media in a 37° C and 3% CO2 incubator throughout 
the duration of the experiments, and culture media was changed in the cultures 
every other day. 
 
4) Drug Stocks and Treatments 
Drug stocks of 10 mM were prepared for paclitaxel, EpoB, and vincristine 
in 1-methyl-2-pyrrolidinone (MPL) and stored at -20°C.  These stocks were 
further diluted in culture media to 50 µM and then to the subsequent, appropriate 
concentrations immediately prior to treatment of the cultures.  N-acetyl-L-cysteine 
(NAC) stocks of 200 mM were prepared in sterile H2O and stored at 4°C for up to 
1 month.  The stock was further diluted to 10 mM in culture media and then to 
lower concentrations immediately prior to addition to culture wells.  Acetyl-L-
carnitine (ALCAR) stocks of 100 mM were prepared in sterile H2O and stored for 
up to 1 month at 4°C.  For experiments, ALCAR was further diluted to 100 µM in 
culture media.   Cultures were treated with the MTA drugs or MPL vehicle control 
(0.003%) in media starting on day 7, 9, or 12 in culture, and media containing the 
drug was refreshed every other day.  ALCAR and NAC, when appropriate, were 
added to the culture media concomitantly with paclitaxel beginning on day 7 and 
refreshed every other day.   Experiments were performed on day 7, before drug 
exposure, or on day 12 in culture. 
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5) Calcitonin Gene-Related Peptide Release 
Release experiments were performed as described previously (Hingtgen 
and Vasko 1994, Vasko, Campbell et al. 1994).  The wells were rinsed one time 
with HEPES buffer containing 25 mM HEPES, 135 mM NaCl, 3.5 mM KCl, 2.5 
mM CaCl2, 1 mM MgCl2, 3.3 mM D-glucose, and 0.1% bovine serum albumin, pH 
7.4. The cells were then maintained in HEPES +/- a stimulatory agent at 37°C for 
4, 10 min incubations. During the first and second 10 min intervals, cells were 
incubated with HEPES buffer to establish resting basal release of 
immunoreactive CGRP (iCGRP), which will be referred to as CGRP. During the 
third interval, cells were incubated with HEPES containing 30 nM capsaicin, 30 
µM AITC, or 50 mM KCl (substituted for equimolar NaCl) in order to stimulate 
CGRP release.  The fourth incubation was in HEPES to reestablish resting basal 
release.  Supernatants were collected after every interval, and CGRP was 
measured using radioimmunoassay as described below.  At the completion of the 
release experiment, cells were incubated for 20 min in 0.1 N HCl, and the 
supernatant was collected to determine total CGRP content.  Total content for 
each well was determined by adding the CGRP released during each incubation 
period with the CGRP released during the HCl incubation.  For the experiments 
using cells grown in the absence of added NGF, a slight adjustment was made 
for the basal release fractions; instead of collecting the fractions every 10 min 
and having 2 basal fractions, the cells were incubated in HEPES buffer for 20 
min, and only 1 basal fraction was collected.  This modification was made in 
order to ensure detection of the basal CGRP fractions by the radioimmunoassay.  
53 
 
Since total content of CGRP is lower in neurons grown in 0 added NGF, CGRP in 
10 min basal fractions often falls below the level of detection of the assay. 
For the acute paclitaxel experiments, neurons were grown in culture for 12 
days, and the neurons were naïve at the time of the release experiment, meaning 
they had not been treated with an MTA drug or vehicle. At the time of the 
experiment, the wells were exposed to 4 successive, 10 min incubations.  The 
first incubation was HEPES buffer alone to establish a resting basal release of 
CGRP.  For the 3 following incubations, the cells were incubated for 10 min in 
300 nM paclitaxel in HEPES buffer.  The CGRP in the fractions was determined 
using a radioimmunoassay.  The CGRP released in the last 3 fractions was 
compared to the CGRP released in the 1st fraction in order to determine if 
paclitaxel causes acute release in the absence of a known stimulatory agent.      
 
6) CGRP Radioimmunoassay 
Radioimmunoassays were performed to measure the CGRP released 
from the neuronal cultures. On the day of the CGRP release experiment, aliquots 
from the release assays were pipetted into 5 ml Sarstedt tubes, and an equal 
volume of CGRP antibody (100 µl), approximately 1:65,000 dilution, was added 
to each tube.  A standard curve was made in triplicate with known CGRP 
concentrations ranging from 3 fmol to 300 fmol, and CGRP antibody was added 
to the standard curve samples.  All tubes, including unknown samples and 
standard curve, were brought up to equal volume with HEPES buffer and 
incubated overnight at 4°C.  The following day, 125I-[0Tyr]-iCGRP27-37 (125I-
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CGRP)(100 µl) containing approximately 3500 cpm  was added to each tube and 
incubated for a second night at 4°C.  Samples were also prepared to determine 
max binding of the assay; tubes received HEPES, CGRP antibody, and 125I-
CGRP.  Nonspecific binding samples were made by combining HEPES and 125I-
CGRP only.  On the third day, charcoal solution (0.1 M phosphate buffer, 50 mM 
NaCl, 1% bovine serum, 1% charcoal, pH 7.4) was added to each sample, and 
the tubes were centrifuged at 3000 X g for 20 min. The charcoal absorbed any 
CGRP not bound to the antibody and pelleted it to the bottom of the tube. The 
supernatant containing CGRP (125I-CGRP or unlabeled) bound to antibody was 
decanted to fresh tubes, and the radioactivity was measured by gamma 
scintillation spectrometry.  The amount of CGRP in unknown samples was then 
calculated based upon the standard curve and was reported as fmol of CGRP 
per sample. 
 
7) Viability Assay 
The viability of sensory neurons grown in 30 ng/ml or 0 added NGF 
following exposure to paclitaxel was assessed by staining with propidium iodide 
(PI).  Sensory neuron cultures were exposed to vehicle (.003% MPL), 10 nM, or 
300 nM paclitaxel for 5 days.  As a positive control for neuronal death, vehicle-
treated neurons were exposed to 300 μM H2O2 for 1-2 hours at 37°C.   At the 
end of the 1-hour incubation, the neurons were returned to culture media. 
Approximately 24 hours later, all neurons were rinsed one time with phosphate 
buffered saline (PBS), rinsed once more with staining buffer, and incubated with 
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0.5 ml of the staining solution containing 6 μM PI for 1 hour.  Cells were 
visualized after the 1 hour incubation period using a Nikon Eclipse Ti-S inverted 
microscope. The PI was excited at 530 nm and the emitted light was monitored 
at 645 nm.  Neurons in 3 random fields were counted and scored as either viable 
(unstained) or non-viable (red), and the total number of neurons per treatment 
group was also counted.  The investigator was blinded to the treatment paradigm 
until after assessment of the data.  The data are expressed as mean ± standard 
error of the mean (SEM) of percent non-viable cells per total number of neurons 
as well as total number of neurons per field. 
 
8) Neurite Length and Branching 
Neurite length and branching were determined using the Neurite 
Outgrowth module software of the ImageXpress Micro XL instrument (Molecular 
Devices, Sunnyvale, CA).  Neurons were fixed with 4% paraformaldehyde for 20 
minutes on day 7 or on day 12 following MTA treatment.  Fixed neuronal cultures 
were then stored in filtered blocking buffer (1:25 dilution of normal donkey serum 
in 0.3% Triton X-100 in PBS) at 4°C for 1-10 days prior to incubation with 
antibody.  Cultures were incubated overnight with primary antibody against 
PGP9.5 (1:1000, rabbit), which is a neuronal-specific protein (Wilkinson, Lee et 
al. 1989), in filtered blocking buffer.  The following day, cultures were rinsed 3 
times for 10 minutes with PBS, incubated for 2 hours with Alexa Fluor 488 
donkey anti-rabbit secondary antibody (1:200) in filtered blocking buffer, and 
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rinsed again in PBS 3 times for 10 minutes.  Cultures were imaged while 
submerged in PBS.   
Neurons were imaged with the ImageXpress Micro XL System (Molecular 
Devices, Sunnyvale, CA) using the FITC filter set at 10X magnification; the Alexa 
Fluor 488 fluorophore was excited at 482 nm and the emitted light was monitored 
at 536 nm.  One image was taken in the center of each well, and each image 
captured a total area of 1.96 mm2 (1.4 X 1.4 mm).  Data is reported as average 
neurite length or branching segments per field.  Total neurite length and 
branching was determined using the Neurite Outgrowth module software using 
established parameters for cell bodies (max width of cell body: 54 µm, intensity 
above local background: 30000 graylevels, minimum area: 100 µm2) and 
outgrowths (maximum width: 8 µm, intensity above local background: 5000 
graylevels, minimum cell growth to log as significant: 10 µm).  
 
9) Statistical Analysis 
Data were analyzed by one-way analysis of variance (ANOVA) or two-way 
ANOVA as indicated, and post-hoc analyses were performed using the 
Bonferroni’s, Tukey’s, or Dunnett’s test, as indicated. Statistical calculations were 
performed with the GraphPad Prism version 6.02 statistical package (GraphPad 
Software, La Jolla, CA).  Data are presented as mean ± SEM, and differences 
are considered significant if p < 0.05. 
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RESULTS 
 
1) Paclitaxel Alters Stimulated CGRP Release from Sensory Neurons in 
Culture 
Systemic administration of paclitaxel has various effects on the sensitivity 
of sensory neurons, reducing the sensitivity of sensory neurons in some studies 
(Gracias, Cummins et al. 2011) and increasing sensitivity in others (Polomano, 
Mannes et al. 2001, Flatters and Bennett 2006, Matsumoto, Inoue et al. 2006).  
The cumulative dose of paclitaxel also affects neuronal sensitivity as lower 
cumulative doses (cumulative doses of 4, 8, or 16 mg/kg) result in mechanical 
hyperalgesia and allodynia, as well as cold allodynia in rats, whereas higher 
cumulative doses (cumulative doses of 80-135 mg/kg) produce impairments in 
pain-like behaviors and thermal hypoalgesia (Cavaletti, Cavalletti et al. 1997, 
Authier, Gillet et al. 2000).  These data suggest that, dependent upon the 
endpoint measured and the dosing paradigm administered, both increases and 
decreases in neuronal sensitivity occur; however, there is still not a clear 
understanding of the mechanisms by which these changes in sensitivity develop.  
To determine the direct effects of long-term paclitaxel exposure on sensory 
neurons, sensory neurons were maintained in culture for 7 days after which cells 
were treated for 5 days in the presence of various concentrations of paclitaxel 
and stimulated with capsaicin.  Capsaicin stimulates the release of neuropeptides 
from small diameter sensory neurons expressing the TRPV1 receptor (Holzer 
1988) by increasing the permeability of the channel to calcium and inducing an 
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inward calcium current (Clapham et al., 2001).  The basal release of CGRP and 
the release of CGRP stimulated with 30 nM capsaicin were measured.  Five-day 
treatment with vehicle (.003% MPL), 10 nM, or 300 nM paclitaxel did not alter the 
resting basal release of CGRP (first B column of each treatment group, Figure 
2A).  Capsaicin stimulated the release of CGRP from a basal level of 29 ± 2 
fmol/well/10min to 274 ± 23 fmol/well/10min in vehicle-treated neurons (Figure 
2A). Five-day treatment with 10 nM paclitaxel enhanced the stimulated release of 
CGRP from the neurons.  The capsaicin-evoked release was augmented to 329 
± 24 fmol/well/10min in neurons treated with 10 nM paclitaxel (C columns, Figure 
2A).  In contrast, treatment with 300 nM paclitaxel significantly decreased 
capsaicin-evoked release to 150 ± 9 fmol/well/10min. The changes in release of 
CGRP were not secondary to an altered content of CGRP in the neurons, as the 
total content of CGRP was similar in cultures treated with vehicle, 1207 ± 80 
fmol/well, 10 nM paclitaxel, 1359 ± 97, or 300 nM paclitaxel,1165 ± 59, (Figure 
2B).  
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Figure 2.  Paclitaxel alters capsaicin-evoked release of CGRP from sensory neurons 
in culture.  A) Each column represents the mean ± SEM of CGRP released in 
fmol/well/10 min from wells treated with 10 nM or 300 nM paclitaxel for 5 days.  The 
first open column of each group represents basal release (B), the shaded column 
represents release in the presence of 30 nM capsaicin (C), and the second open 
column of each group represents the recovery of basal release following stimulation 
(B).  An (*) indicates a significant difference in capsaicin-evoked release compared to 
release from the vehicle-treated neurons (p<0.05, N=9) using a two-way ANOVA with 
Bonferroni’s post-hoc test.  B)  Each column represents the mean ± SEM of total 
CGRP content in fmol/well from vehicle treated cultures (Veh) or paclitaxel treated 
cultures (Pac) as indicated (N=9).   
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To determine if paclitaxel alters the sensitivity of the TRPA1 channel, 
sensory neurons were stimulated with 30 µM AITC, a TRPA1 agonist, after 
treatment with 10 or 300 nM paclitaxel for 5 days.  AITC-evoked CGRP release 
was significantly greater from neurons treated with 10 nM paclitaxel as compared 
to vehicle-treated neurons: the stimulated release was increased from 347 ± 26 
fmol/well/10min in vehicle-treated neurons to 472 ± 29 fmol/well/10min in 
neurons treated with 10 nM paclitaxel (A columns, Figure 3A).  Treatment for 5 
days with 300 nM paclitaxel decreased AITC-evoked release to 117 ± 16 
fmol/well/10min (Figure 3A).  Total CGRP content in the neurons was not 
changed by paclitaxel treatment. Content levels were 1107 ± 77, 1343 ± 93, and 
895 ± 85 fmol/well in the vehicle, 10 nM, and 300 nM-treated groups, respectively 
(Figure 3B).  
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Figure 3.  Paclitaxel alters AITC-evoked release of CGRP from sensory neurons in 
culture.  A) Each column represents the mean ± SEM of CGRP released in 
fmol/well/10 min from wells treated with 10 nM or 300 nM paclitaxel for 5 days.  The 
first open column of each group represents basal release (B), the shaded column 
represents release in the presence of 30 µM AITC (A), and the second open column 
of each group represents the recovery of basal release following stimulation (B).  An 
(*) indicates a significant difference in AITC-evoked release compared to release 
from the vehicle-treated neurons (p<0.05, N=10-12) using a two-way ANOVA with 
Bonferroni’s post-hoc test.  B)  Each column irepresents the mean ± SEM of total 
CGRP content in fmol/well from vehicle treated cultures (Veh) or paclitaxel treated 
cultures (Pac) as indicated (N=10-12). 
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To examine whether the effects of paclitaxel were dependent on altered 
sensitivity of TRP channels, neuronal cultures treated with vehicle, 10 nM 
paclitaxel or 300 nM paclitaxel for 5 days were stimulated with a general 
depolarizing stimulus, 50 mM potassium chloride.  In vehicle-treated cultures, 
high extracellular potassium increased the release of CGRP from basal levels of 
25 ± 2 fmol/well/10min to 291 ± 12 fmol/well/10min (open vs shaded HK 
columns, Figure 4A).  Exposing cultures to 10 nM paclitaxel for 5 days resulted in 
an increase in the potassium-stimulated release of CGRP to 353 ± 16 
fmol/well/10min without altering resting basal release in a manner analogous to 
that observed when release was stimulated by the TRP channel agonists (Figure 
4A).  In contrast to the results with capsaicin- and AITC-evoked release, 
exposing cultures to 300 nM paclitaxel for 5 days also augmented the CGRP 
release evoked by potassium to 346 ± 16 fmol/well/10min (Figure 4A).  
Differences in potassium-evoked release were not due to an alteration of 
neuropeptide content, as total content for the vehicle, 10 nM, and 300 nM treated 
cultures was 1219 ± 78, 1277 ± 87, and 1190 ± 63 fmol/well, respectively (Figure 
4B).   
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Figure 4.  Paclitaxel augments potassium-evoked release of CGRP from sensory 
neurons in culture.  A) Each column represents the mean ± SEM of CGRP released 
in fmol/well/10 min from wells treated with 10 nM or 300 nM paclitaxel for 5 days.  
The first open column of each group represents basal release (B), the shaded 
column represents release in the presence of 50 mM KCl (HK), and the second open 
column of each group represents the recovery of basal release following stimulation 
(B).  An (*) indicates a significant difference in HK-evoked release compared to 
release from the vehicle-treated neurons (p<0.05, N=9) using a two-way ANOVA with 
Bonferroni’s post-hoc test.  B)  Each column represents the mean ± SEM of total 
CGRP content in fmol/well from vehicle treated cultures (Veh) or paclitaxel treated 
cultures (Pac) as indicated (N=9). 
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2) Paclitaxel Does Not Alter Neuronal Viability 
Previous reports demonstrate that paclitaxel treatment can cause 
significant neuronal death in embryonic (E16) DRG cultures and that this death is 
mediated through necrosis (Scuteri, Nicolini et al. 2006). To determine whether 
paclitaxel’s alteration in transmitter release could be secondary to a change in 
sensory neuron viability in adult DRG cultures, neuronal cultures were stained 
with propidium iodide (PI) to differentiate between live and dead neurons.  The 
total number of neurons per field was also counted, based upon the cellular 
morphology using a phase contrast image.  The total number of neurons per field 
was counted to ensure that the % of PI-positive neurons was not skewed by non-
viable neurons lifting from the plates.  In cultures treated with vehicle for 5 days, 
the percentage of neurons that stained positive for PI was 6 ± 1% of the total 
number of neurons counted, and the total number of neurons per field was 21 ± 1 
neurons/field (Figure 5A and B).  In cultures exposed to 10 nM paclitaxel for 5 
days, the percentage of neurons that stained positive for PI was 10 ± 2%, and 
the total number of neurons per field was 24 ± 1 (Figure 5A and B).  Five days of 
exposure to 300 nM paclitaxel did not significantly affect cell viability; the 
percentage of PI-positive staining neurons was 8 ± 2%, and the total number of 
neurons per field was 20 ± 1 (Figure 5A and B).  As a positive control for 
decreases in cell viability, neuronal cultures were exposed to 300 µM H2O2 for 1-
2 hours at 37°C, which has previously been shown to produce a significant loss 
in cell viability (Vasko, Guo et al. 2005).  As seen in Figure 5A, H2O2 treatment 
significantly increased the percentage of PI-positive cells to 20 ± 3% of the total 
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number of neurons.  The total number of neurons per field was not altered by 
treatment with H2O2 as there were 22 ± 1 neurons/field.       
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Figure 5.  Paclitaxel does not decrease the survival of sensory neurons grown in 30 
ng/ml NGF.  Sensory neuron cultures were treated with vehicle (open columns, Veh) 
or with 10 nM or 300 nM paclitaxel for 5 days (Pac; gray columns) and cell viability 
was measured. As a positive control, vehicle-treated cultures were exposed to H2O2 
(300 µM) for 1-2 hours 24 hours prior to analysis of cell survival (black columns).  A)  
The number of propidium iodine (PI) positive cells were counted in a minimum of 3 
fields from 3 different harvests and normalized to the total number of neurons in the 
field.  Each column represents the mean ± SEM of % positively stained neurons.  An 
(*) indicates a significant difference from vehicle-treated controls (p<0.05, N=3) using 
a one way-ANOVA and Tukey’s post-hoc test.  B) The total number of neurons in 
each treatment group was also counted.  Each column represents the mean ± SEM 
of the total number of neurons counted per field (N=3). 
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3) Paclitaxel Alters Capsaicin-evoked CGRP Release in a Time-dependent 
Manner 
To investigate if paclitaxel-induced alterations in capsaicin-evoked CGRP 
release were dependent on the duration of paclitaxel exposure, sensory neuron 
cultures were treated with 10 nM or 300 nM paclitaxel for 1, 3, or 5 days or with 
vehicle for 5 days.  The basal release of CGRP and release upon stimulation with 
30 nM capsaicin was then measured.  The treatment with vehicle (.003% MPL), 
10 nM or 300 nM paclitaxel did not alter the resting basal release of CGRP (B 
columns, Figures 6A and 7A) over the course of treatment.  The capsaicin-
evoked CGRP release from neurons treated with 10 nM paclitaxel for 1 day did 
not differ from the vehicle controls; the release was 339 ± 11 and 353 ± 10 
fmol/well/10min in the vehicle and 1-day-treated neurons, respectively (C 
columns, Figure 6A).  However, the capsaicin-evoked CGRP release from the 3-
day and 5-day 10 nM paclitaxel-treated wells significantly increased to 380 ± 14 
and 395 ± 17 fmol/well/10min, respectively.  The increase in capsaicin-evoked 
release of CGRP was not secondary to an altered content of CGRP in the 
neurons since treatments with 10 nM paclitaxel did not alter the content of the 
peptide in the cultures and was 1482 ± 29, 1512 ± 32, 1580 ± 39, and 1615 ± 53 
fmol/well in the vehicle, 1-day, 3-day, and 5-day treated groups, respectively 
(Figure 6B). 
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Figure 6.  Paclitaxel (10 nM) increases the release of CGRP from sensory neurons in 
culture in a time-dependent manner.  A) Each column represents the mean ± SEM of 
CGRP released in fmol/well/10 min from wells treated with vehicle or 10 nM 
paclitaxel for 1, 3, or 5 days as indicated.  The first open column of each group 
represents basal release (B), the shaded column represents release in the presence 
of 30 nM capsaicin (C), and the second open column of each group represents the 
recovery of basal release following stimulation (B).  An (*) indicates a significant 
difference in capsaicin-evoked release compared to release from the vehicle-treated 
neurons (p<0.05, N=10-12) using a two-way ANOVA with Bonferroni’s post-hoc test.  
B) Each column represents the mean ± SEM of total CGRP content in fmol/well from 
cultures treated with vehicle (Veh) or paclitaxel (Pac) for the duration of time as 
indicated (N=10-12). 
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A small, but significant, augmentation in the capsaicin-evoked release of 
CGRP following 1 day of exposure of neuronal cultures to 300 nM paclitaxel was 
observed.  The release of CGRP in vehicle- and paclitaxel-treated neurons was 
328 ± 9 and 369 ± 15 fmol/well/10min, respectively (C columns, Figure 7A).  This 
increase in CGRP release, however, was likely because of an increase in the 
content of CGRP in the cultures, since 300 nM paclitaxel increased the peptide 
content levels from 1470 ± 30 to 1623 ± 40 (Figure 7B).  Calculating the 
capsaicin-stimulated release as the % of total peptide content, release from 
vehicle-treated neurons was 22 ± 1%, and it was 23 ± 1% from cultures treated 
with 300 nM paclitaxel for 1 day (Figure 7C). Following 3 or 5 days of treatment 
with paclitaxel (300 nM), the capsaicin-evoked release was significantly reduced 
to 275 ± 10 and 169 ± 5 fmol/well/10min, respectively.  The total content of 
CGRP in the neurons following 3 and 5 days of treatment was 1626 ± 49 and 
1332 ± 47 fmol/well (Figure 7B).  Thus the capsaicin-stimulated release at 3 and 
5 days of paclitaxel exposure represents 17 ± 1% and 13 ± 1% of the total 
content of CGRP, demonstrating that the reduced release was not secondary to 
changes in peptide levels (Figure 7C).  
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Figure 7.  Paclitaxel (300 nM) increases and decreases release of CGRP from 
sensory neurons in culture in a time-dependent manner.  A) Each column represents 
the mean ± SEM of CGRP released in fmol/well/10 min from wells treated with 
vehicle or 300 nM paclitaxel for 1, 3, or 5 days as indicated.  The first open column of 
each group represents basal release (B), the shaded column represents release in 
the presence of 30 nM capsaicin (C), and the second open column of each group 
represents the recovery of basal release following stimulation (B).  An (*) indicates a 
significant difference in capsaicin-evoked release compared to release from the 
vehicle-treated neurons (p<0.05, N=10-12) using a two-way ANOVA with 
Bonferroni’s post-hoc test.  B)  Each column represents the mean ± SEM of total 
CGRP content in fmol/well (N=10-12) from cultures treated with vehicle (Veh) or 
paclitaxel (Pac) for the duration of time as indicated.  An (*) indicates a significant 
difference in the total content of CGRP compared to the vehicle-treated cultures 
(p<0.05, N=10-12) using a one way-ANOVA and Dunnett’s post-hoc test. C)  Each 
column represents the mean ± SEM of the percent CGRP release normalized to total 
content.  An (*) indicates a significant difference from vehicle-treated neurons 
(p<0.05, N=10-12) using a one-way ANOVA with Dunnett’s post-hoc test. 
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4) Epothilone B Alters Stimulated CGRP Release from Sensory Neurons in 
Culture 
To determine if a microtubule stabilizing agent with a similar mechanism of 
action to paclitaxel alters CGRP release, cultured sensory neurons were treated 
with a range of EpoB concentrations for 5 days, and I then measured the basal 
and stimulated release of CGRP.  The effective concentrations of EpoB on 
neuronal neuropeptide release were unknown within our model system; 
therefore, a concentration-response curve of EpoB and capsaicin-evoked CGRP 
release ranging from 1-300 nM of EpoB was performed.  These concentrations 
were chosen since previous work has shown that EpoB binds microtubules with 
approximately 10 times higher affinity than paclitaxel, and cancer cells are 3-30-
fold more sensitive to EpoB than paclitaxel (Zhang 2010, Kowalski 1997).  
Neurons were treated with a range of EpoB concentrations including vehicle 
(0.003%), 1, 3, 10, 30, 100, or 300 nM EpoB for 5 days and then stimulated with 
capsaicin (30 nM).  EpoB did not alter basal release of CGRP from the sensory 
neurons (first B column of each treatment group, Figure 8A).  Capsaicin-evoked 
(30 nM) CGRP release was augmented by 5-day treatment with 1 and 3 nM 
EpoB compared to vehicle and was 386 ± 17, 395 ±22, and 300 ±16 fmol/well/10 
min, respectively (Figure 8A).  The higher concentrations of EpoB: 10, 30, 100, 
and 300 nM, decreased capsaicin-evoked release to 148 ± 4, 139 ± 13, 129 ± 6, 
and 108 ± 10 fmol/well/10 min respectively (Figure 8A).  EpoB did not alter total 
content of CGRP in the neurons, and total content levels were 1340 ± 52, 1480 ± 
47, 1526 ± 70, 1361 ± 106, 1184 ± 89, 1155 ± 68, and 1105 ± 81 fmol/well for the 
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vehicle, 1, 3, 10, 30, 100, 300 nM EpoB treatment groups, respectively (Figure 
8B).      
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Figure 8.  EpoB alters capsaicin-evoked release of CGRP from sensory neurons in 
culture.  A) Each column represents the mean ± SEM of CGRP released in 
fmol/well/10 min from wells treated with 1, 3, 10, 30, 100, or 300 nM EpoB for 5 days.  
The first open column of each group represents basal release (B), the shaded 
column represents release in the presence of 30 nM capsaicin (C), and the second 
open column of each group represents the recovery of basal release following 
stimulation (B).  An (*) indicates a significant difference in capsaicin-evoked release 
compared to release from the vehicle-treated neurons (p<0.05, N=8-9) using a two-
way ANOVA with Bonferroni’s post-hoc test.  B)  Each column irepresents the mean 
± SEM of total CGRP content in fmol/well from vehicle treated cultures (Veh) or EpoB 
treated cultures (EpoB) as indicated (N=8-9).   
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To determine if EpoB alters CGRP release independent of TRPV1 activity, 
sensory neurons were cultured in vehicle, 1 nM, or 30 nM EpoB, and CGRP 
release was stimulated with high extracellular potassium (50 mM).  Potassium-
evoked release was not changed after 5-day treatment with 1 nM EpoB 
compared to vehicle-treated neurons, and was 372 ± 22 and 353 ± 21 
fmol/well/10 min, respectively (Figure 9A).  Five-day treatment with 30 nM EpoB 
increased potassium-evoked CGRP release compared to vehicle and was 416 ± 
21 fmol/well/10 min (Figure 9A).  Treatment with EpoB did not alter total content 
of CGRP in the neurons and was 1353 ± 80, 1473 ± 85, 1477 ± 64 fmol/well in 
the vehicle, 1 nM and 30 nM EpoB treatment groups, respectively (Figure 9B).   
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Figure 9.  EpoB augments potassium-evoked release of CGRP from sensory 
neurons in culture.  A) Each column represents the mean ± SEM of CGRP released 
in fmol/well/10 min from wells treated with 1 nM or 30 nM EpoB for 5 days.  The first 
open column of each group represents basal release (B), the shaded column 
represents release in the presence of 50 mM KCl (HK), and the second open column 
of each group represents the recovery of basal release following stimulation (B).  An 
(*) indicates a significant difference in HK-evoked release compared to release from 
the vehicle-treated neurons (p<0.05, N=10-12) using a two-way ANOVA with 
Bonferroni’s post-hoc test.  B)  Each column represents the mean ± SEM of total 
CGRP content in fmol/well from vehicle treated cultures (Veh) or EpoB treated 
cultures (EpoB) as indicated (N=10-12). 
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5) Vincristine Alters Potassium-evoked CGRP Release from Sensory 
Neurons in Culture 
In order to ascertain if the alterations of stimulated CGRP release by 
paclitaxel and EpoB are specific to microtubule stabilization or are a result of 
general changes in microtubule dynamics, neurons were cultured for 5-days in 
the presence of vehicle, 1 nM or 30 nM vincristine, which is a microtubule 
destabilization agent.  These concentrations of vincristine were chosen since 
previous unpublished work from Dr. Vasko’s laboratory showed that treating 
neurons with 1 nM vincristine for 5-days augmented capsaicin-evoked (30 nM) 
release compared to a vehicle control, whereas treatment with 30 nM vincristine 
decreased capsaicin-evoked CGRP release.  This suggests that, when using 
capsaicin as a stimulus, treatments with low concentrations of MTAs for 5 days 
increase capsaicin-evoked CGRP release, and treatments with high 
concentrations of MTAs decrease capsaicin-evoked CGRP release.   
To determine if vincristine alters basal or potassium-evoked CGRP 
release, neurons were cultured for 5 days in vehicle, 1 nM, or 30 nM vincristine 
and stimulated with high extracellular potassium.  Vincristine did not alter basal 
CGRP release from the neurons (first B column of each treatment group, Figure 
10A).  Treatment with 1 nM vincristine for 5 days augmented potassium-evoked 
CGRP release compared to vehicle and was 539 ± 21 and 498 ± 22 fmol/well/10 
min, respectively, whereas treatment with 30 nM vincristine decreased 
potassium-evoked release to 182 ± 10 fmol/well/10 min (Figure 10A).  Total 
content of CGRP did not change with 1 nM vincristine; however, treatment with 
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30 nM vincristine decreased total content.  Total content was 1208 ± 44, 1165 ± 
34, and 582 ± 23 fmol/well in the vehicle, 1 nM and 30 nM vincristine treatment 
groups, respectively (Figure 10B).  In order to determine if the changes in 
potassium-evoked release are secondary to the changes in total content, the 
potassium-evoked release was normalized by total content for each group.  
There was no difference in normalized CGRP release between the vehicle and 1 
nM treatment group at 42 ± 2% and 46 ± 2% of total content, respectively, and 
the normalized CGRP release for the 30 nM group was decreased to 31 ± 2% of 
total content (Figure 10C).  The normalized CGRP release values, 31-46%, were 
higher than the commonly observed range of 10-15% CGRP release from 
sensory neurons stimulated with 50 mM potassium (Park, Fehrenbacher et al. 
2010).  It is suspected that the NGF concentrations in the media may have been 
lower than 30 ng/ml, and further experiments are being conducted to investigate 
this potential issue.  
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Figure 10.  Vincristine alters potassium-evoked release of CGRP from sensory 
neurons in culture.  A) Each column represents the mean ± SEM of CGRP released 
in fmol/well/10 min from wells treated with 1 nM or 30 nM vincristine for 5 days.  The 
first open column of each group represents basal release (B), the shaded column 
represents release in the presence of 50 mM KCl (HK), and the second open column 
of each group represents the recovery of basal release following stimulation (B).  An 
(*) indicates a significant difference in HK-evoked release compared to release from 
the vehicle-treated neurons (p<0.05, N=14-15) using a two-way ANOVA with 
Bonferroni’s post-hoc test.  B)  Each column represents the mean ± SEM of total 
CGRP content in fmol/well (N=14-15) from vehicle treated cultures (Veh) or 
vincristine treated cultures (Pac) as indicated.  An (*) indicates a significant difference 
from vehicle-treated neurons (p<0.05, N=14-15) using a one-way ANOVA with 
Dunnett’s post-hoc test.  C)  Each column represents the mean ± SEM of the percent 
CGRP release normalized to total content.  An (*) indicates a significant difference 
from vehicle-treated neurons (p<0.05, N=14-15) using a one-way ANOVA with 
Dunnett’s post-hoc test. 
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6) Acute Treatment with Paclitaxel Does Not Alter CGRP Release from 
Sensory Neurons in Culture 
 Although 5-day treatment with paclitaxel did not alter basal release of 
CGRP release from the neurons in culture, an acute effect of paclitaxel on the 
neurons may be missed with this dosing paradigm.  In order to determine if 
paclitaxel has an acute effect on CGRP release from sensory neurons, untreated 
sensory neurons in culture were treated with either HEPES buffer and vehicle for 
10 min or HEPES buffer and 300 nM paclitaxel for 3, 10 min incubations.  CGRP 
release during the 1st, 2nd, and 3rd incubations with paclitaxel did not differ from 
the release during the vehicle incubation.  Release was 48 ± 1, 50 ± 2, 42 ± 2, 
and 40 ± 3 fmol/well/10 min from the vehicle, 1st, 2nd, and 3rd paclitaxel 
incubations, respectively (Figure 11). 
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Figure 11.  Acute administration of paclitaxel does not alter CGRP release from 
sensory neurons in culture.  Each column represents the mean ± SEM of CGRP 
released in fmol/well/10 min from wells treated with vehicle in HEPES buffer (open 
bar) or 300 nM paclitaxel for 10-30 min (gray bars) (N=9). 
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7) Acetyl-L-carnitine Does Not Reverse Paclitaxel-induced Alterations of 
CGRP Release 
Previous work in animal models has shown that ALCAR prevents and 
reverses paclitaxel-induced nociception and impairment in mitochondrial 
respiration within sciatic nerves by presumably protecting mitochondria (Flatters 
Bennett 2006, Zheng 2011).  To determine if ALCAR protects against paclitaxel-
induced alterations of CGRP release, neurons were cultured with either 100 µM 
ALCAR alone for 5 days or 100 µM ALCAR in the presence of 10 nM or 300 nM 
paclitaxel.  This concentration of ALCAR was chosen because similar 
concentrations of ALCAR (100 µM, 250 µM and 1 mM) have been previously 
used in experiments of cultured neurons (Manfridi, Forloni et al. 1992, Kano, 
Kawakami et al. 1999, Abdul Muneer, Alikunju et al. 2011).   In preliminary 
experiments, treatment with 10 mM ALCAR alone for 5 days decreased 
capsaicin-evoked CGRP release and 100 µM ALCAR did not alter capsaicin-
evoked release.  I wanted to use a concentration of ALCAR that would not alter 
stimulated release of CGRP alone, and I therefore used 100 µM ALCAR for the 
experiments described below.  Five-day treatment with 100 µM ALCAR did not 
alter basal release of CGRP or capsaicin-stimulated (30 nM) release, and the 
release was 259 ± 21 fmol/well/10 min from ALCAR treated neurons and 254 ± 
19 fmol/well/10 min from vehicle-treated neurons (Figure 12A).  In addition, 
treatment with 100 µM ALCAR did not alter capsaicin-evoked release from 
neurons treated with low or high concentrations of paclitaxel; 5-day treatment 
with ALCAR + 10 nM paclitaxel  or 10 nM paclitaxel alone augmented capsaicin-
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evoked CGRP release to 363 ± 24 and 373 ± 30 fmol/well/10 min, respectively, 
and treatment with ALCAR + 300 nM paclitaxel or 300 nM paclitaxel alone 
decreased capsaicin-evoked release from the neurons, and the release was 84 ± 
14 and 87 ± 14 fmol/well/10 min, respectively (Figure 12A).  ALCAR alone or in 
combination with paclitaxel did not alter total content of CGRP in the neurons, 
and total content was 981 ± 82, 942 ± 73, 1085 ± 57, 1200 ± 79, 839 ± 70, and 
826 ± 52 fmol/well from the vehicle, 100 µM ALCAR, 10 nM paclitaxel, 100 µM 
ALCAR + 10 nM paclitaxel, 300 nM paclitaxel, and 100 µM ALCAR + 300 nM 
paclitaxel treated groups, respectively (Figure 12B).   
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Figure 12.  Acetyl-L-carnitine does not alter paclitaxel-induced changes in capsaicin-
stimulated CGRP release from sensory neurons in culture.  A) Each column 
represents the mean ± SEM of CGRP released in fmol/well/10 min from wells treated 
with 10 nM or 300 nM paclitaxel ± 100 µM ALCAR for 5 days.  The first open column 
of each group represents basal release (B), the shaded column represents release in 
the presence of 30 nM capsaicin (C), and the second open column of each group 
represents the recovery of basal release following stimulation (B).  An (*) indicates a 
significant difference in capsaicin-evoked release compared to release from the 
vehicle-treated neurons (p<0.05, N=11-12) using a two-way ANOVA with 
Bonferroni’s post-hoc test.  B)  Each column represents the mean ± SEM of total 
CGRP content in fmol/well (N=11-12) from vehicle treated cultures (Veh) or paclitaxel 
treated cultures (Pac) ± ALCAR as indicated.   
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8) N-acetyl-L-cysteine Does Not Reverse Paclitaxel-induced Alterations of 
CGRP Release 
 Administration of NAC in in vitro models has been shown to reverse ROS 
produced by exposure to paclitaxel, vincristine, and EpoB (Tsai Chao 2007, 
Rogalska Jozwiak 2013).  Since administration of free radical scavengers has 
prevented and reversed paclitaxel-induced nociceptive behaviors in vivo (Kim 
Abdi 2010, Fidanboylu 2011), I wanted to investigate if using a free radical 
scavenger and glutathione recycler, such as NAC, would alter paclitaxel-induced 
changes on sensory neuronal activity.  To determine if NAC reverses paclitaxel-
induced changes of stimulated CGRP release from sensory neurons, neurons 
were cultured in media containing 0.5 mM or 1 mM NAC for 5 days alone or in 
the presence of 10 nM or 300 nM paclitaxel.  These concentrations of NAC were 
used because a similar concentration (2 mM) has been used in another study 
using sensory neuron cultures (Naziroglu, Cig et al. 2013).  NAC did not alter 
basal CGRP release (first B column of each treatment group, Figure 13A).  Both 
concentrations of NAC increased capsaicin-evoked CGRP release compared to 
vehicle-treated neurons, and release was 268 ± 18, 544 ± 37, 708 ± 53 
fmol/well/10 min from the vehicle, 0.5 mM, and 1 mM NAC treatment groups, 
respectively (Figure 13A).  Five-day treatment with 10 nM paclitaxel or 1 mM 
NAC + 10 nM paclitaxel caused an increase in capsaicin-evoked CGRP release 
to 392 ± 35 and 752 ± 87 fmol/well/10 min, respectively (Figure 13A).  The 300 
nM paclitaxel, 0.5 mM NAC + 300 nM paclitaxel, and the 1 mM NAC + 300 nM 
paclitaxel treatments resulted in a decrease in capsaicin-evoked CGRP release 
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compared to vehicle and were 91 ± 15, 146 ± 17, 144 ± 33 fmol/well/10 min, 
respectively (Figure 13A).  Total content of CGRP increased in the 0.5 mM NAC, 
1 mM NAC, and 1 mM NAC + 10 nM paclitaxel groups; however, total content did 
not change compared to vehicle in the 10 nM paclitaxel, 300 nM paclitaxel, 0.5 
mM NAC + 300 nM paclitaxel, and 1 mM NAC + 300 nM paclitaxel groups.  Total 
content in the neurons was 1209 ± 117, 2702 ± 312, 3378 ± 322, 1476 ± 129, 
2909 ± 335, 848 ± 57, 1253 ± 64, and 1281 ± 148 fmol/well in the vehicle, 0.5 
mM NAC, 1 mM NAC, 10 nM paclitaxel, 1 mM NAC + 10 nM paclitaxel, 300 nM 
paclitaxel, 0.5 mM NAC + 300 nM paclitaxel, and 1 mM NAC + 300 nM paclitaxel 
groups, respectively (Figure 13B).  To determine if the increases in capsaicin-
evoked release were secondary to an increase in total content, the released 
CGRP was normalized to the total content for each group and was 22 ± 1, 21 ± 
2, 22 ± 1, 27 ± 1, 28 ± 1, 10 ± 1, 11 ± 1, 11 ± 2% total content, respectively, in the 
vehicle, 0.5 mM NAC, 1 mM NAC, 10 nM paclitaxel, 1 mM NAC + 10 nM 
paclitaxel, 300 nM paclitaxel, 0.5 mM NAC + 300 nM paclitaxel, and 1 mM NAC + 
300 nM paclitaxel groups (Figure 13C).  Normalized stimulated release increased 
compared to vehicle in the 10 nM paclitaxel and 1 mM NAC + 10 nM paclitaxel 
groups, and normalized stimulated release decreased compared to vehicle in the 
300 nM paclitaxel, 0.5 mM NAC + 300 nM paclitaxel, and 1 mM NAC + 300 nM 
paclitaxel groups (Figure 13C). 
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Figure 13.  N-acetyl-L-cysteine does not alter paclitaxel-induced changes in 
capsaicin-stimulated CGRP release from sensory neurons in culture.  A) Each 
column represents the mean ± SEM of CGRP released in fmol/well/10 min from wells 
treated with 10 nM or 300 nM paclitaxel ± 0.5 or 1 mM NAC for 5 days.  The first 
open column of each group represents basal release (B), the shaded column 
represents release in the presence of 30 nM capsaicin (C), and the second open 
column of each group represents the recovery of basal release following stimulation 
(B).  An (*) indicates a significant difference in capsaicin-evoked release compared to 
release from the vehicle-treated neurons (p<0.05, N=6-9) using a two-way ANOVA 
with Tukey’s post-hoc test.  B)  Each column represents the mean ± SEM of total 
CGRP content in fmol/well from vehicle treated cultures (Veh) or paclitaxel treated 
cultures (Pac) ± NAC as indicated.  An (*) indicates a significant different from the 
vehicle-treated neurons using a one-way ANOVA (p<0.05, N=6-9) with Dunnett’s 
post-hoc test. C)  Each column represents the mean ± SEM of the percent CGRP 
release normalized to total content.  An (*) indicates a significant difference from 
vehicle-treated neurons (p<0.05, N=6-9) using a one-way ANOVA with Dunnett’s 
post-hoc test. 
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9) Paclitaxel Alters Stimulated CGRP Release and Decreases Total CGRP 
Content in the Absence of NGF 
All experiments previously described in this work were conducted with 
cultures that had been maintained in media containing 30 ng/ml NGF.  Because 
NGF alters neuronal sensitivity (Zhu, Galoyan et al. 2004, Zhang, Huang et al. 
2005, Zhu and Oxford 2007) and other groups have found that NGF can alter 
paclitaxel-induced changes in cells (Peterson and Crain 1982, Apfel, Lipton et al. 
1991), we asked if paclitaxel alters neuronal activity in the absence of added 
NGF.  To determine if NGF alters the effects of paclitaxel on neuronal activity, I 
cultured sensory neurons in media with 0 added NGF and treated them with a 
low (10 nM) or high (300 nM) concentration of paclitaxel for 5 days.  I then 
measured the basal release of CGRP as well as the release of CGRP following 
stimulation with capsaicin (30 nM).  Five-day treatment with paclitaxel in the 
absence of added NGF did not alter basal release of CGRP from sensory 
neurons treated with vehicle (0.003% MPL), 10 nM paclitaxel, or 300 nM 
paclitaxel (first B column of each treatment group, Figure 14A).  Five-day 
treatment of both 10 nM and 300 nM paclitaxel significantly decreased capsaicin-
evoked release of CGRP compared to vehicle and was 20 ± 2, 10 ± 1, and 31 ± 3 
fmol/well/10 min, respectively (Figure 14A).  The total content of CGRP within the 
neurons also decreased following paclitaxel treatment and was 390 ± 13 
fmol/well in vehicle cultures, 281 ± 9 fmol/well in 10 nM paclitaxel cultures, and 
212 ± 7 fmol/well in 300 nM paclitaxel cultures (Figure 14B).  In order to 
determine if the changes in capsaicin-evoked release were secondary to a 
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decrease in total content, I determined the capsaicin-evoked release normalized 
to the total content for each group; there was no difference in normalized CGRP 
release following treatment with 10 nM paclitaxel compared to vehicle treatment, 
7 ± 2% and 8 ± 2% of total content, respectively.  Treatment with 300 nM 
paclitaxel decreased normalized CGRP release and was 5 ± 2% of total content 
(Figure 14C).  
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Figure 14.  Paclitaxel attenuates capsaicin-evoked release of CGRP from sensory 
neurons grown in the absence of NGF.  A) Each column represents the mean ± SEM 
of CGRP released in fmol/well/10 min from wells treated with vehicle, 10 nM, or 300 
nM paclitaxel for 5 days.  The first open column of each group represents basal 
release (B), the shaded column represents release in the presence of 30 nM 
capsaicin (C), and the second open column of each group represents the recovery of 
basal release following stimulation (B).  An (*) indicates a significant difference in 
capsaicin-evoked release compared to release from the vehicle-treated cultures 
(p<0.05, N=12) using a two-way ANOVA with Tukey’s post-hoc test.  B)  Each 
column represents the mean ± SEM of total CGRP content in fmol/well from vehicle-
treated cultures (Veh) or paclitaxel-treated cultures (Pac) as indicated.  An (*) 
indicates a significant difference in total CGRP content compared to the vehicle-
treated cultures (p<0.05, N=12) using a one-way ANOVA with Dunnett’s post-hoc 
test.  C) Each column represents the normalized mean ± SEM of the capsaicin-
evoked CGRP divided by the total CGRP content for each group.  An (*) indicates a 
significant difference in normalized CGRP compared to vehicle-treated cultures 
(p<0.05, N=12) using a one-way ANOVA with Dunnett’s post-hoc test. 
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In order to bypass possible effects of NGF on TRP channel activity 
(Zhang, Huang et al. 2005, Zhu and Oxford 2007), I examined the effects of 0 
added NGF on potassium-stimulated CGRP release after treatment with 
paclitaxel.   I stimulated the release of CGRP from paclitaxel-treated cultures 
using a general depolarizing stimulus, high extracellular potassium chloride (50 
mM), from neurons grown in 0 added NGF.  The profile of potassium-evoked 
release from the cultures treated with vehicle, 10 nm, or 300 nM paclitaxel was 
similar to when I stimulated with capsaicin; both concentrations of paclitaxel 
decreased CGRP release compared to vehicle.  The potassium-stimulated 
release was 50 ± 4 fmol/well/10 min from vehicle cultures, 34 ± 3 fmol/well/10 
min from 10 nM paclitaxel cultures, and 22 ± 2 fmol/well/10 min from 300 nM 
paclitaxel cultures (Figure 15A).  Total content decreased in the cultures treated 
with paclitaxel and was 412 ± 21, 287 ± 16, and 215 ± 10 fmol/well from the 
vehicle, 10 nM, and 300 nM paclitaxel treated cultures, respectively (Figure 15B).  
When potassium-stimulated release was normalized to the total content for each 
group, there was no difference in normalized CGRP release from cultures treated 
with 10 nM paclitaxel or vehicle and was 12 ± 1% and 12 ± 1% of total content, 
respectively (Figure 15C).  Normalized CGRP release decreased in cultures 
treated with 300 nM paclitaxel, and was 10 ± 1% of total content (Figure 15C).  
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Figure 15.  Paclitaxel attenuates potassium-evoked release of CGRP from sensory 
neurons grown in the absence of NGF.  A) Each column represents the mean ± SEM 
of CGRP released in fmol/well/10 min from wells treated with vehicle, 10 nM, or 300 
nM paclitaxel for 5 days.  The first open column of each group represents basal 
release (B), the shaded column represents release in the presence of 50 mM 
potassium (C), and the second open column of each group represents the recovery 
of basal release following stimulation (B).  An (*) indicates a significant difference in 
potassium-evoked release compared to release from the vehicle-treated cultures 
(p<0.05, N=12) using a two-way ANOVA with Tukey’s post-hoc test.  B)  Each 
column represents the mean ± SEM of total CGRP content in fmol/well from vehicle-
treated cultures (Veh) or paclitaxel-treated cultures (Pac) as indicated.  An (*) 
indicates a significant difference in total CGRP content compared to the vehicle-
treated cultures (p<0.05, N=12) using a one-way ANOVA with Dunnett’s post-hoc 
test.  C) Each column represents the normalized mean ± SEM of the potassium-
evoked CGRP divided by the total CGRP content for each group.  An (*) indicates a 
significant difference in normalized CGRP compared to vehicle-treated cultures 
(p<0.05, N=12) using a one-way ANOVA with Dunnett’s post-hoc test. 
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10) Paclitaxel Does Not Alter Neuronal Viability in the Absence of NGF 
Previously I have shown that 5-day treatment with 10 nM or 300 nM 
paclitaxel does not alter neuronal viability when neurons are grown in media 
containing 30 ng/ml of NGF.  To ascertain whether the decrease in total CGRP 
content level in neurons grown in 0 added NGF was due to neuronal death, I 
performed PI viability assays.  Neurons were cultured in media with 0 added 
NGF, treated with vehicle, 10 nM, or 300 nM paclitaxel for 5 days, and stained 
with PI.  In cultures treated with vehicle, the percentage of neurons that stained 
positive for PI was 7 ± 2% and the total number of neurons per field was 22 ± 2 
(Figure 16A and B).  Paclitaxel did not alter the percent of positive PI-staining 
neurons in the cultures, and 8 ± 1 and 9 ± 2% of the neurons stained positive for 
PI in the 10 nM and 300 nM paclitaxel groups, respectively (Figure 16A and B).  
Paclitaxel also did not alter the total number of neurons per field as there were 24 
± 2 and 21 ± 1 neurons/field in the 10 nM and 300 nM paclitaxel groups, 
respectively (Figure 16A and B).  As a positive control for increasing PI-staining 
(induction of neuronal death), neurons were treated with 300 µM H2O2 for 1-2 
hours at 37°C in media, and PI-staining was performed approximately 24 hours 
after the removal of the H2O2.  This has previously been shown to decrease 
neuronal viability (Gracias published thesis, Indiana University).  The percentage 
of positively stained neurons increased to 21 ± 2% after H2O2 exposure; 
however, the total number of neurons per field did not change and was 24 ± 1 
neurons/field (Figure 16A and B). 
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Figure 16.  Paclitaxel does not decrease the survival of sensory neurons grown in the 
absence of NGF.  Sensory neuronal cultures were treated with vehicle (open 
columns, Veh) or with 10 nM or 300 nM paclitaxel for 5 days (Pac; gray columns) and 
cell viability was measured. As a positive control, vehicle-treated cultures were 
exposed to H2O2 (300 µM) for 1-2 hours 24 hours prior to analysis of cell survival 
(black columns).  A)  The number of propidium iodine (PI) positive cells were counted 
in a minimum of 3 fields from 3 different harvests and normalized to the total number 
of neurons in the field.  Each column represents the mean ± SEM of % positively 
stained neurons.  An (*) indicates a significant difference from vehicle-treated 
controls (p<0.05, N=3) using a one way-ANOVA and Tukey’s post-hoc test.  B) The 
total number of neurons in each treatment group was also counted.  Each column 
represents the mean ± SEM of the total number of neurons counted per field. 
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11) Epothilone B Alters Stimulated CGRP Release and Decreases Total 
CGRP Content in the Absence of NGF 
Paclitaxel alters CGRP release differently in the presence and absence of 
NGF, suggesting that the presence of NGF alters the effects of MTAs on  
sensory neuron function or that the differential effects of paclitaxel on CGRP 
release, depending on the presence of NGF, is caused by NGF interacting with 
one of paclitaxel’s microtubule-independent actions.  In order to determine if NGF 
alters CGRP release induced by another microtubule stabilizer, neurons were 
cultured in media with 0 added NGF and treated with 1 nM or 30 nM EpoB for 5 
days.  Basal and capsaicin-evoked release were then measured.  In cultures 
grown in 0 added NGF, 1 nM EpoB increased capsaicin-evoked CGRP release 
compared to vehicle treated neurons, and the release was 30 ± 2 and 37 ± 4 
fmol/well/10 min from vehicle and 1 nM EpoB cultures, respectively (Figure 17A).  
Five-day treatment with 30 nM EpoB decreased release to 12 ± 3 fmol/well/10 
min (Figure 17A).  Total content of CGRP was not changed after treatment with 1 
nM EpoB but was decreased in neurons treated with 30 nM EpoB.  Total content 
of CGRP was 316 ± 12, 321 ± 8, 144 ± 18 fmol/well the vehicle, 1 nM, and 30 nM 
EpoB groups, respectively (Figure 17B).  Since total content was altered with 30 
nM EpoB, stimulated CGRP release was normalized by total content.  There was 
no difference in the % release of total content between the groups and was 9 ± 1, 
12 ± 1, and 8 ± 2 % of total CGRP in the vehicle, 1 nM, and 30 nM EpoB groups, 
respectively (Figure 17C).     
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Figure 17.  EpoB alters capsaicin-evoked release of CGRP from sensory neurons 
grown in the absence of NGF.  A) Each column represents the mean ± SEM of 
CGRP released in fmol/well/10 min from wells treated with vehicle, 1 nM, or 30 nM 
EpoB for 5 days.  The first open column of each group represents basal release (B), 
the shaded column represents release in the presence of 30 nM capsaicin (C), and 
the second open column of each group represents the recovery of basal release 
following stimulation (B).  An (*) indicates a significant difference in capsaicin-evoked 
release compared to release from the vehicle-treated cultures (p<0.05, N=10-11) 
using a two-way ANOVA with Tukey’s post-hoc test.  B)  Each column represents the 
mean ± SEM of total CGRP content in fmol/well from vehicle-treated cultures (Veh) or 
EpoBl-treated cultures (EpoB) as indicated.  An (*) indicates a significant difference 
in total CGRP content compared to the vehicle-treated cultures (p<0.05, N=10-11) 
using a one-way ANOVA with Dunnett’s post=hoc test.  C) Each column represents 
the normalized mean ± SEM of the capsaicin-evoked CGRP divided by the total 
CGRP content for each group (N=10-11). 
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Potassium-evoked CGRP release was also measured from neurons 
grown in 0 added NGF and treated with 1 nM or 30 nM EpoB for 5 days.  
Treatment with 1 nM EpoB did not alter potassium-evoked CGRP release from 
the neurons and was 63 ± 3 and 61 ± 4 fmol/well/10 min from the vehicle and 1 
nM EpoB groups, respectively (Figure 18A).  Treatment with 30 nM EpoB 
decreased potassium-evoked release to 22 ± 3 fmol/well/10 min (Figure 18A).  
Total content was altered similarly to the capsaicin groups; there was no change 
in content between the vehicle and 1 nM EpoB groups, and 30 nM EpoB 
decreased total content of the neurons.  Total content was 328 ± 11, 305 ± 13, 
and 160 ± 8 fmol/well, respectively (Figure 18B).  Stimulated CGRP release was 
normalized to total content for each group, and normalized release was not 
different between the vehicle and 1 nM EpoB groups and was 19 ± 1 and 20 ± 
1% of total content, respectively; however, 30 nM EpoB decreased normalized 
CGRP release to 13 ± 2% of total content (Figure 18C). 
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Figure 18.  EpoB attenuates potassium-evoked release of CGRP from sensory 
neurons grown in the absence of NGF.  A) Each column represents the mean ± SEM 
of CGRP released in fmol/well/10 min from wells treated with vehicle, 1 nM, or 30 nM 
EpoB for 5 days.  The first open column of each group represents basal release (B), 
the shaded column represents release in the presence of 50 mM potassium (C), and 
the second open column of each group represents the recovery of basal release 
following stimulation (B).  An (*) indicates a significant difference in potassium-
evoked release compared to release from the vehicle-treated cultures (p<0.05, N=10-
12) using a two-way ANOVA with Tukey’s post-hoc test.  B)  Each column represents 
the mean ± SEM of total CGRP content in fmol/well from vehicle-treated cultures 
(Veh) or EpoB-treated cultures (EpoB) as indicated.  An (*) indicates a significant 
difference in total CGRP content compared to the vehicle-treated cultures (p<0.05, 
N=10-12) using a one-way ANOVA with Dunnett’s post-hoc test.  C) Each column 
represents the normalized mean ± SEM of the potassium-evoked CGRP divided by 
the total CGRP content for each group.  An (*) indicates a significant difference in 
normalized CGRP compared to vehicle-treated cultures (p<0.05, N=10-12) using a 
one-way ANOVA with Dunnett’s post-hoc test. 
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12) NGF and Paclitaxel Alter Neurite Length and Branching of Sensory 
Neurons in Culture 
Since NGF alters the effects of paclitaxel on CGRP release and NGF has 
been suggested to be protective against paclitaxel-induced inhibition of neurite 
growth, I investigated: 1) if NGF alone alters neurite length and branching within 
our cultures; 2) if paclitaxel alters neuronal length and branching in established 
neuronal cultures; and 3) if NGF protects against paclitaxel-induced changes in 
neurite length and branching.  Sensory neurons were grown in the presence of 0 
added NGF, 30 ng/ml NGF, or 250 ng/ml NGF for 7 days or 12 days.  For the 12-
day treatment groups, neurons were maintained in culture for 7 days and then 
treated with 300 nM paclitaxel for an additional 5 days.  After 7 days in culture, 
there was no difference in the total length of neurites between the different NGF 
groups; total lengths in the cultures were 126.0 ± 3.1, 122.3 ± 3.0, and 121.4 ± 
4.1 mm in the 0 added, 30 ng/ml, and 250 ng/ml NGF cultures, respectively 
(Figure 19A).  Total branching also did not change in the groups.  Total 
branching segments in the 0 added, 30 ng/ml, and 250 ng/ml NGF cultures were 
9289 ± 388, 8916 ± 400, and 9102 ± 533 total segments, respectively (Figure 
19B).  Representative images for each day 7 treatment group can be seen in 
Figure 19C.   
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Figure 19.  NGF does not alter neurite length or branching of sensory neurons after 7 
days in culture.  Neurite length and branching were determined in sensory neurons 
maintained in culture media with 0 added NGF, 30 ng/ml NGF, or 250 ng/ml NGF 
and fixed on day 7.  A) There were no differences in neurite length between the NGF 
groups. Each column represents the mean ± SEM of the total neurite outgrowth per 
well (N=32-34).  B) There were no differences in neurite branching between the NGF 
groups. Each column represents the mean ± SEM of the total number of branch 
points per well (N=32-34).  C) Representative images of PGP9.5 immunoreactivity 
(green fluorescence) in cultures grown in increasing concentrations of NGF and fixed 
on day 7.    
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After 12 days in culture, the 5-day vehicle treated neurons maintained in 
30 ng/ml NGF and 250 ng/ml NGF had greater total length and branching 
compared to the vehicle treated neurons in 0 added NGF.  Total lengths were 
140.6 ± 2.5, 140.7 ± 3.1, and 117.8 ± 7.9 mm in the 30 ng/ml, 250 ng/ml, and 0 
added NGF groups, respectively (Figure 20A).  Total branching segments were 
10944 ± 356, 11154 ± 452, and 8118 ± 795 total segments in the 30 ng/ml, 250 
ng/ml, and 0 added NGF groups, respectively (Figure 20B).  Five-day treatment 
with 300 nM paclitaxel decreased total length and branching in all 3 NGF groups 
compared to the corresponding vehicle-treated neurons, and lengths were 
reduced to 67.9 ± 7.0, 85.9 ± 6.7, and 87.9 ± 7.0 mm in the 0 added, 30 ng/ml, 
and 250 ng/ml NGF groups, respectively (Figure 20A).  Total branching 
segments also decreased to 3301 ± 487, 5055 ± 567, and 5245 ± 626 total 
segments in the 0 added, 30 ng/ml, and 250 ng/ml NGF groups, respectively 
(Figure 20B).  There was no difference between the NGF groups after paclitaxel 
treatment except between the total branching of the 0 added NGF and 250 ng/ml 
NGF cultures (Figure 20B).  Representative images for each day 12 treatment 
group can be seen in Figure 20C. 
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Figure 20.  NGF and paclitaxel alter neurite length and branching of sensory neurons 
after 12 days in culture.   Sensory neurons were grown in 0 added NGF, 30 ng/ml 
NGF, or 250 ng/ml NGF and treated with vehicle (open bars) or 300 nM of paclitaxel 
(hashed bars) on day 7 and fixed on day 12.  A)  Each column represents the mean ± 
SEM of total neurite length.  An (*) indicates a significant difference in neurite length 
from the 0 added NGF vehicle treatment (p<0.05, N= 13-17) using a two-way 
ANOVA and Tukey’s post-hoc test.  B) Each column represents the mean ± SEM of 
total segments.  An (*) indicates a significant difference in neurite branching from the 
12 day, 0 added NGF vehicle treatment, a (#) indicates a significant difference in 
neurite branching from the corresponding 12 day NGF vehicle treatment, and a (&) 
indicates a significant difference from the 0 NGF 300 nM paclitaxel treatment 
(p<0.05, N= 13-17) using a two-way ANOVA and Tukey’s post-hoc test .  C) 
Representative images of PGP9.5 immunoreactivity (green fluorescence) in cultures 
grown in increasing concentrations of NGF and fixed on day 12.  
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13) Epothilone B Alters Neurite Length and Branching of Sensory Neurons in 
Culture 
 Paclitaxel alters neurite length and branching, but the underlying 
mechanisms for paclitaxel-induced alterations of neurite morphology are 
unknown.  In order to determine if paclitaxel’s effect on neurite length and 
branching is microtubule dependent, neurons treated with a different microtubule 
stabilizing drug, EpoB, were measured for neurite length and branching changes 
after 5 days.  These experiments were performed in 0 added NGF, 30 ng/ml 
NGF, and 250 ng/ml NGF in order to determine if EpoB-induced alterations in 
neurite length and branching can be reversed by NGF.  Similarly to what was 
observed in the paclitaxel experiments, neurite length and branching increased in 
the 30 ng/ml and 250 ng/ml NGF treatment groups compared to the 0 added 
NGF group.   The neurite lengths were 139.0 ± 2.6, 141.7 ± 4.1, and 107.6 ± 10.3 
mm in the 30 ng/ml, 250 ng/ml, and 0 added NGF groups, respectively (Figure 
21A).  Total branching segments were 10697 ± 321, 11329 ± 555, and 7525 ± 
721 total segments in the 30 ng/ml, 250 ng/ml, and 0 added NGF groups, 
respectively (Figure 21B).  Treatment with 30 nM EpoB for 5 days decreased 
neurite length and branching compared to the corresponding vehicle control 
group.  Neurite lengths decreased to 66.3 ± 8.4, 66.4 ± 11.6, and 71.8 ± 11.4 mm 
and branching segments decreased to 3467 ± 619, 3858 ± 930, and 4331 ± 936 
total segments in the 30 nM EpoB groups for the 0 added, 30 ng/ml, and 250 
ng/ml NGF conditions, respectively (Figure 21A and B).  NGF did not reverse the 
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EpoB-induced decreases in neurite length and branching.  Representative 
images for each day 12 treatment group can be seen in Figure 21C.     
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Figure 21.  NGF and EpoB alter neurite length and branching of sensory neurons 
after 12 days in culture.   Sensory neurons were grown in 0 added NGF, 30 ng/ml 
NGF, or 250 ng/ml NGF and treated with vehicle (open bars) or 30 nM of EpoB 
(hashed bars) on day 7 and fixed on day 12.  A) Each column represents the mean ± 
SEM of total neurite length.  An (*) indicates a significant difference in neurite length 
from the 12 day, 0 added NGF vehicle treatment, and a (#) indicates a significant 
difference in neurite length from the corresponding 12 day NGF vehicle treatment  
(p<0.05, N= 9-12) using a two-way ANOVA and Tukey’s post-hoc test.  B) Each 
column represents the mean ± SEM of total segments.  An (*) indicates a significant 
difference in neurite branching from the 12 day, 0 added NGF vehicle treatment, and 
a (#) indicates a significant difference in neurite branching from the corresponding 12 
day NGF vehicle treatment  (p<0.05, N= 9-12) using a two-way ANOVA and Tukey’s 
post-hoc test.  C) Representative images of PGP9.5 immunoreactivity (green 
fluorescence) in cultures grown in increasing concentrations of NGF and fixed on day 
12.  
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14) Vincristine Alters Neurite Length and Branching of Sensory Neurons in 
Culture 
Both microtubule stabilizing agents, paclitaxel and EpoB, decreased 
neurite length and branching.  It is unknown whether this phenomenon is due to 
the microtubule stabilization mechanism or is a result of a change in microtubule 
dynamics.  In order to determine if inhibition of microtubule dynamics is 
underlying the decrease in neurite length and branching caused by paclitaxel and 
EpoB, I treated neurons for 5 days with 30 nM vincristine, a microtubule 
destabilization agent, and measured neurite length and branching in 0 added 
NGF, 30 ng/ml, and 250 ng/ml NGF.  Similarly to what was observed above, 
growth in 30 ng/ml and 250 ng/ml NGF increased neurite length and branching 
compared to the 0 added NGF groups.  Neurite lengths were 119.5 ± 7.2, 105.6 
± 7.9, and 81.1 ± 7.1 mm,  and branching segments were 8728 ± 813, 8455 ± 
609, and 5810 ± 6444 total segments in the 30 ng/ml, 250 ng/ml, and 0 added 
NGF vehicle treated groups, respectively (Figure 22A and B).  Treatment for 5 
days with 30 nM vincristine decreased neurite lengths and branching segments 
in all NGF groups to 28.6 ± 3.6, 49.6 ± 7.2, and 30.2 ± 39.0 mm and 1021 ± 167, 
2488 ± 458, and 1241 ± 204 total segments in the 0 added, 30 ng/ml, and 250 
ng/ml NGF groups, respectively (Figure 22A and B).  NGF did not protect against 
a decrease in neurite length or branching except for the neurite length of the 30 
ng/ml NGF group; neurite length was higher in the 30 ng/ml NGF group 
compared to the 0 added NGF group when treated with vincristine (Figure 22A).  
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Representative images for each day 12 treatment group can be seen in Figure 
22C.         
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Figure 22.  NGF and vincristine alter neurite length and branching of sensory 
neurons after 12 days in culture.   Sensory neurons were grown in 0 added NGF, 30 
ng/ml NGF, or 250 ng/ml NGF and treated with vehicle (open bars) or 30 nM of 
vincristine (hashed bars) on day 7 and fixed on day 12.  A) Each column represents 
the mean ± SEM of total neurite length.  An (*) indicates a significant difference in 
neurite length from the 0 added NGF vehicle treatment (p<0.05, N= 12-18) using a 
two-way ANOVA and Tukey’s post-hoc test.  B) Each column represents the mean ± 
SEM of total segments.  An (*) indicates a significant difference in neurite branching 
from the 12 day, 0 added NGF vehicle treatment, and a (#) indicates a significant 
difference in neurite branching from the corresponding 12 day NGF vehicle treatment  
(p<0.05, N= 12-18) using a two-way ANOVA and Tukey’s post-hoc test.  C) 
Representative images of PGP9.5 immunoreactivity (green fluorescence) in cultures 
grown in increasing concentrations of NGF and fixed on day 12.  
 
 
 
 
 
 
 
121 
 
DISCUSSION 
Currently there are no recommendations for preventing MTA-induced 
peripheral neuropathy and only limited recommendations for treating MTA-
induced peripheral neuropathy in the clinic (Hershman, Lacchetti et al. 2014).  
One of the reasons for this paucity of treatment options for MTA-induced 
peripheral neuropathy is that the mechanisms underlying the development of the 
neuropathy have not been carefully and systematically investigated in neuronal 
systems.  The goal for this thesis was to develop and characterize in vitro 
sensory neuron models of MTA-induced neurotoxicity in order to answer two 
basic questions: 1) do MTAs alter sensory neuronal function and/or morphology, 
and 2) what are the cellular mechanisms mediating these MTA-induced 
changes?   
The work presented in this thesis demonstrates that MTAs alter the 
stimulated release of CGRP from sensory neurons as well as the length and 
branching of the neurite processes.  This work has also begun to elucidate the 
underlying mechanisms involved in these MTA-induced alterations.  We 
observed differential effects on CGRP release dependent on MTA agent, CGRP 
evoking stimulus, duration of exposure to the MTA agent, and presence of added 
NGF, and we now have the infrastructure in place to start to construct a 
preliminary understanding of the cellular machinery and signaling cascades 
changed in sensory neurons by MTAs.  We have also attempted to prevent, 
although unsuccessfully, paclitaxel-induced changes in CGRP release with 
agents targeting specific, previously hypothesized mechanisms; however, the 
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interpretation of these studies is limited by a lack of understanding of the 
physiological effects of the agents on sensory neurons.  For example, agents that 
prevent the development of paclitaxel-induced hypersensitivity in animals, like 
ALCAR, do not prevent paclitaxel-induced changes of neuronal activity within our 
culture model; however our interpretation of these experiments is limited as we 
do not know if the concentrations of ALCAR within our experiments were 
sufficient to increase mitochondrial energy production.  Finally, we have 
established an in vitro method to investigate sensory neurite length and 
branching, and we have shown that the MTAs decreased neurite length and 
branching in established cultures, independent of the surrounding NGF 
environment.  My thesis work has utilized two in vitro, sensory neuronal assays 
that can be implemented in future mechanistic studies.  This comprehension of 
MTA-induced alterations of sensory neurons will undoubtedly be used as a tool 
to help elucidate the mechanisms underlying MTA-induced peripheral 
neuropathy.        
The nociceptive behavioral changes observed in MTA-induced peripheral 
neuropathy animal models mimic the side effects in cancer patients treated with 
MTAs, and therefore they have been useful in the initial work involved in 
understanding the mechanisms of MTA-induced peripheral neuropathy.  For 
example, initial findings that ALCAR, a mitochondrial protective agent, prevented 
the development of paclitaxel-induced mechanical hyperalgesia and allodynia 
within animal models (Flatters, Xiao et al. 2006, Jin, Flatters et al. 2008) have 
caused investigators to question the involvement of mitochondrial dysfunction in 
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peripheral neuropathy.  Also, the MTA-induced decrease in IENFs of rat hindpaw 
skin suggested that the MTA-induced hypersensitivity could be secondary to a 
loss of skin nerve innervation, and this hypothesis has since guided 
investigations in patients where a similar paclitaxel-induced loss of IENF has 
been observed (Boyette-Davis, Cata et al. 2013).  While the animal models have 
been helpful in developing hypotheses about the physiological alterations that 
may underlie MTA-induced peripheral neuropathy, the animal model findings 
have not translated clinically.  Both gabapentin and ALCAR therapy decreased 
nociceptive hypersensitization within the animal models; however, gabapentin 
had no effect on reducing MTA-induced peripheral neuropathy within patients 
(Rao, Michalak et al. 2007), and ALCAR administration increased the incidence 
of paclitaxel-induced peripheral neuropathy in cancer patients (Hershman, Unger 
et al. 2013).  These findings suggest that the etiologies underlying MTA-induced 
peripheral neuropathy are complex and likely multifactorial, and the complexity of 
the condition cannot be fully explored in an animal model.  Findings may differ 
between animal models and human patients due to several reasons including 
differences in the pharmacokinetics of the drugs in the two species.  The in vitro 
models developed in this body of work provide a reductionist approach in which 
the effects of the MTAs responsible for altering neuronal function and sensitivity 
can be thoroughly characterized on a cellular level, independent of 
pharmacokinetic variables like differences in drug metabolism or distribution.  In 
this way, the different animal model-generated hypotheses can be carefully 
explored with a reductionist and causative methodology, and the underlying 
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mechanisms of MTA-induced changes, specifically within sensory neurons, can 
be elucidated.  
 
1) Paclitaxel Alters Stimulus-evoked Release of CGRP from Sensory 
Neurons 
Paclitaxel impairs the function of several subpopulations of sensory 
nerves including large, medium, and it has been suggested, to a lesser extent, 
small diameter neurons (Dougherty, Cata et al. 2004).  We chose to limit our 
investigation to the effects of paclitaxel, and other MTAs, on the activity of 
CGRP-expressing sensory neurons since the MTAs alter nociceptive endpoints 
in animal models (Aley, Reichling et al. 1996, Polomano, Mannes et al. 2001, 
Weng, Cordella et al. 2003) and produce pain symptoms in patients (Forsyth, 
Balmaceda et al. 1997, Carlson and Ocean 2011).  Our collaborators have also 
previously shown that capsaicin-induced bloodflow is altered in rats treated with 
paclitaxel, suggesting a functional change in the release of CGRP from 
nociceptive neurons in the periphery (Gracias, Cummins et al. 2011).  CGRP is 
expressed and released by the nociceptive C and A δ fibers (McCarthy and 
Lawson 1990, Lawson, McCarthy et al. 1996, Lawson, Crepps et al. 2002), and 
therefore, we can use the basal and stimulated release of CGRP as a direct 
marker of nociceptive sensory nerve activity within our cultures. 
There are several limitations to our model system.  Although we are using 
CGRP release as an endpoint to measure activity of nociceptive small and 
medium diameter sensory neurons, not all small and medium diameter sensory 
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neurons express CGRP (Cavanaugh, Chesler et al. 2011).  This suggests that 
there is a subset of small and medium diameter sensory neurons of which we 
cannot determine changes in activity.  Also, peripheral neuropathy is 
characterized by symptoms likely involving large diameter sensory neurons 
including loss of proprioception, touch, and vibration (Sarosy, Kohn et al. 1992, 
Forsyth, Balmaceda et al. 1997).  Our assay cannot address changes in activity 
of the large diameter sensory neurons as they do not express CGRP (Lawson, 
Perry et al. 1993).  In order to investigate changes of activity in all sensory 
neurons in culture, we could employ a glutamate release assay so not to limit our 
studies to only CGRP-expressing neurons (Lever, Bradbury et al. 2001, Bardoni, 
Torsney et al. 2004, Seal, Wang et al. 2009).  We could also use calcium 
imaging or electrophysiology methods in order to observe MTA-induced changes 
of the entire population of neurons in our system.  Another limitation to our model 
is that maintaining our cultures in media containing NGF enriches them with 
TRPV1- and trkA-expressing sensory neurons (Khodorova, Richter et al. 2009, 
Park, Fehrenbacher et al. 2010).  Alternatively, we could grow the neurons in 
other growth factors including GDNF and NT-3/BDNF to enrich for TRPV1-
negative small diameter sensory neurons and myelinated sensory neurons, 
respectively (Khodorova, Richter et al. 2009, Park, Fehrenbacher et al. 2010).    
The experiments investigating MTA-induced alterations of CGRP release 
within this thesis were performed with cultures maintained for 12 days.  This 
treatment paradigm was chosen because we wanted to examine the effects of 
MTAs on fully regenerated neurons (Gracias 2011), so not to confound our 
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findings with other variables such as neurite outgrowth; for example, MTAs may 
affect sensory neurons that are in a process of regeneration differently than 
neurons that have reached their maximum length.  It is suggested that 
competence for axonal growth is decreased in mature DRG neurons, and there is 
a switch in signaling pathways and gene regulation between embryonic neurons 
undergoing the process of elongation versus mature neurons undergoing 
maintenance and reorganization of terminal arbors (Hall and Sanes 1993, Smith 
and Skene 1997, Liu and Snider 2001).  After nerve axotomy, the profile of gene 
transcription transitions from an arborizing profile to an elongation profile to allow 
for axonal growth and regeneration within mature DRG (Smith and Skene 1997).  
Another consideration is that MTAs are administered to patients who have 
mature peripheral nerves likely expressing arborizing signaling pathway and 
gene transcription profiles at the time of treatment, and modeling the effects of 
MTAs on fully extended neurons in culture more closely mimics the clinical 
setting. 
The majority of release experiments were conducted after 5 days 
treatment with MTAs in an attempt to model clinically-relevant, long-term 
administration with the chemotherapeutic agents.  The clinical onset of peripheral 
neuropathy symptoms is typically 3-6 weeks following the first dose of paclitaxel 
(Forsyth, Balmaceda et al. 1997), and we chose 5 days exposure to paclitaxel to 
best model long-term exposure of MTAs.  There are previous studies in which a 
direct excitatory effect of paclitaxel on neuropeptide release has been observed, 
and paclitaxel and vinorelbine induce release of substance P from DRG cultures 
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in time- and concentration-dependent manners (Miyano, Tang et al. 2009, 
Materazzi, Fusi et al. 2012).  Furthermore, some patients receiving paclitaxel 
treatment feel immediate or acute pain with paclitaxel infusions (Loprinzi, 
Maddocks-Christianson et al. 2007, Reeves, Dakhil et al. 2012).  We therefore 
decided to also examine the acute effects of paclitaxel, 10-30 min following 
paclitaxel exposure, on CGRP release as well as a time course of paclitaxel 
exposure, including 1, 3, and 5 days following treatment with paclitaxel.  With the 
findings of the time course experiments, we hoped to gain a better understanding 
of the paclitaxel-induced changes in neurons over time. 
Exposure to 10 nM paclitaxel for 5 days increased capsaicin- and AITC-
evoked release from the sensory neuron cultures while 300 nM paclitaxel for 5 
days decreased capsaicin- and AITC-evoked release (see Figure 23).  In 
contrast, both concentrations of paclitaxel augmented potassium-evoked release.  
This suggests that paclitaxel causes an overall sensitization or gain in function in 
the neurons that is TRP channel-independent, and it suggests that a high 
concentration of paclitaxel alters TRP channel expression and/or function.  Had 
potassium-evoked CGRP release not been augmented by 300 nM paclitaxel, it 
might suggest that the decrease in capsaicin- and AITC-evoked release was due 
to a decrease in neuronal viability or dysfunctional release machinery. A 
decrease in neuronal viability is unlikely as 300 nM paclitaxel did not change total 
CGRP content in the neurons and because this high concentration of paclitaxel 
augmented potassium-evoked release. This was confirmed as there was no 
difference in neuronal viability after exposure to paclitaxel, as evidenced by the  
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Figure 23.  Changes in evoked CGRP release after treatment with MTAs.  
N.c.= no change in release compared to control.  An up arrow indicates an 
augmentation of CGRP release, and a down arrow indicates an attenuation of 
CGRP release compared to control. 
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Figure 24.  Changes in total CGRP content after treatment with MTAs.  N.c.= 
no change in total CGRP content compared to control.  A down arrow 
indicates a decrease in total CGRP content compared to control. 
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PI assay and total neuron cell counts (Figure 5).  Augmentation of potassium-
evoked release after 300 nM paclitaxel also argues against a possible 
microtubule-induced defect in the synthesis and/or release of CGRP as a 
potential mechanism by which paclitaxel induced a decrease in capsaicin- and 
AITC-evoked release. 
Since a decrease in neuronal viability and an alteration in CGRP release 
machinery are ruled out as possible explanations for the paclitaxel-induced 
decrease in capsaicin- and AITC-evoked release, paclitaxel likely alters TRP 
channel expression and/or function.  Previous unpublished work found that 
paclitaxel decreased TRPV1 protein and mRNA expression in neuronal cultures 
(Gracias 2011).   In preliminary work not described in this manuscript, we tried to 
reproduce these findings, but we observed that paclitaxel exposure caused a 
slight increase or no change in TRPV1 protein expression, although our findings 
were not predictable or reproducible.  We first presumed that the protein isolation 
techniques used in Gracias’ work and ours must be different, resulting in 
differential isolation of membrane-bound versus cytoplasmic proteins.  The 
laboratory therefore attempted to carefully isolate and perform Western blotting 
for TRPV1 with membrane and cytoplasmic fractions, and we attempted 
biotinylation experiments with TRPV1 with variable results.  Our findings were not 
reproducible, and further investigation involving in vitro paclitaxel-induced 
changes in TRPV1 protein expression are warranted.  These results suggest that 
there is an unknown variable within our cultures that affects TRPV1 
immunoreactivity and/or expression.  Interestingly, Hara et al. found that 
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systemic administration of paclitaxel in the rat increased TRPV1 mRNA and 
protein expression in the DRG (Hara, Chiba et al. 2013), suggesting that the 
observed reduction in capsaicin-stimulated release is not due to a decrease in 
TRPV1 protein expression.  Currently there is not an effective antibody available 
to ask whether paclitaxel exposure changes TRPA1 protein expression within 
sensory neurons.  We contemplated using mRNA levels to determine whether 
the expression of TRPA1 and/or TRPV1 was altered by paclitaxel, but mRNA 
expression does not always strongly correlate with or predict protein expression 
(Chen, Gharib et al. 2002, Greenbaum, Colangelo et al. 2003, Guo, Xiao et al. 
2008), and we were interested in paclitaxel-induced changes of the channel 
proteins, which confer function.  
It is likely that the decrease in capsaicin- and AITC-evoked release after 
exposure to high concentrations of paclitaxel is caused by a change in activity of 
TRP channels.  The mechanisms underlying this change in activity are unknown, 
but paclitaxel may be causing a desensitization of the TRP channels.  TRPV1 is 
desensitized by a calcium-dependent mechanism involving dephosphorylation of 
the channel by calcineurin (Mohapatra and Nau 2005).  TRPV1 can also be 
internalized upon desensitization and degraded by lysosomes in order to mediate 
long-term TRPV1 desensitization (Sanz-Salvador, Andres-Borderia et al. 2012), 
which would support unpublished findings from Gracias’ work (Gracias 2011).  
TRPA1 is also desensitized by calcium-dependent mechanisms; TRPA1 can be 
desensitized following calcium-dependent depletion of phosphatidylinositol 4,5-
bisphosphate (PIP2), which has been shown to regulate the activity of several 
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TRP channels (Clapham 2003, Akopian, Ruparel et al. 2007).  Calcium-
dependent desensitization mechanisms may be candidates for a decrease in 
TRPV1 and TRPA1 function after exposure to paclitaxel; acute application of 
paclitaxel, on the scale of seconds to 15 minutes, has been shown to increase 
intracellular calcium levels within neuroblastoma cells and DRG (Boehmerle, 
Splittgerber et al. 2006, Miyano, Tang et al. 2009).  The effects of long-term 
paclitaxel exposure on intracellular calcium levels within DRG are unknown, and 
these questions are currently being investigated within our laboratory.  
Intracellular calcium levels would likely be altered if paclitaxel modifies 
mitochondrial function (Flatters and Bennett 2006, Zheng, Xiao et al. 2011, Xiao, 
Zheng et al. 2012); however, it is still unclear whether paclitaxel-induced changes 
in mitochondria precede or follow neuronal sensitivity.  Experiments could be 
performed in the future to investigate if the reduction in TRP channel function is 
caused by calcium-dependent desensitization.  Since calcineurin has been found 
to mediate calcium-dependent TRPV1 desensitization (Docherty, Yeats et al. 
1996, Mohapatra and Nau 2005), calcineurin could be inhibited with cyclosporin 
A to see if paclitaxel-induced decreases in TRP activity are reversed.  
Alternatively, agents that are known to phosphorylate and reverse calcium-
dependent TRPV1 desensitization, including forskolin, could be used (Mohapatra 
and Nau 2005).  Another possibility would be to use a PLC inhibitor to investigate 
the role of calcium-dependent PLC-mediated PIP2 depletion, as PIP2 has been 
shown to regulate the activity of several TRP channels (Akopian, Ruparel et al. 
2007, Rohacs 2009).  With these proposed experiments, it may be difficult to 
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differentiate between changes in release caused by sensitization of the TRP 
channels versus inhibition of desensitization of the channels.  Investigating the 
effects of paclitaxel on TRP channel current in a heterologous expression 
system, where point mutations can systematically be made to the calcineurin and 
PKA consensus sites, may be necessary to fully understand this possible 
mechanism.  Our laboratory has also performed preliminary calcium imaging 
experiments that suggest that exposure to paclitaxel (1 µM) for 24 hours may 
increase basal intracellular calcium levels within sensory neurons (Darby, 
personal communication, March 2014), suggesting that changes in intracellular 
calcium levels occur in sensory neurons following exposure to paclitaxel.  The 
exact mechanisms mediating the reduced function of the TRPV1 and TRPA1 
channels after paclitaxel exposure are unknown, but future studies should be 
directed towards investigating the possibility of calcium-dependent 
desensitization mechanisms in mediating the reduced capsaicin- and AITC-
evoked CGRP release from the neurons in culture.   
 One possibility for paclitaxel and EpoB alterations of TRPV1 activity could 
be that tubulin interactions with TRPV1 may be important and/or necessary for 
proper TRPV1 activity.  It has been shown that several membrane proteins, 
including membrane channels, interact with microtubule complexes and with 
membrane tubulin (Goswami 2012).  It has also been shown that TRPV1 
specifically binds tubulin dimers at its C-terminal and N-terminal cytoplasmic tail 
regions (Goswami, Dreger et al. 2004, Lainez, Valente et al. 2010), and the 
tubulin binding sequence of TRPV1 is conserved among several other TRP 
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channels (Goswami, Kuhn et al. 2010, Sardar, Kumar et al. 2012).  The exact 
role for tubulin binding to TRPV1 is still under investigation, but it has been 
suggested that TRPV1 insertion at the membrane is aided by the microtubule 
cytoskeleton (Storti, Bizzarri et al. 2012); however, the exact form of tubulin, 
whether it be microtubule filaments, free tubulin, or tubulin dimers, that interacts 
with TRPV1 is also unclear at this point.  It has also been suggested that the 
TRPV1 and tubulin interaction regulates the ability of the TRPV1 channel to be 
sensitized (Goswami, Kuhn et al. 2011).  The binding of TRPV1 and tubulin 
blocks a serine residue on the TRPV1 C-terminal tail, which is a site that is 
phosphorylated by PKCƐ and involved in TRPV1 sensitization (Mandadi, 
Tominaga et al. 2006, Goswami, Kuhn et al. 2011).  This suggests that the 
sensitivity of TRPV1 is directly linked to its binding with tubulin, and the effects of 
tubulin on TRPV1 activity need to be considered when investigating possible 
TRPV1 desensitization mechanisms by MTAs, as discussed above.  Although 
still a subject of speculation, further studies should be performed to determine if 
an alteration of tubulin and/or microtubule dynamics with TRPV1 channels could 
be the mechanism underlying paclitaxel- and EpoB-induced alterations of 
capsaicin- and perhaps AITC-evoked release.  Although there is no evidence that 
tubulin binds TRPA1, tubulin has been found to physically interact with TRPV4 
(Goswami, Kuhn et al. 2010), and the tubulin binding sequence is conserved 
among several TRP channels including TRPV4, TRPC5, and TRPM8 (Sardar, 
Kumar et al. 2012).  Tubulin may also interact with TRPA1, and a disruption of 
tubulin and/or microtubule dynamics may mediate alterations in TRPA1 channel 
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function, which should also be investigated in future work.  Since TRP channel 
activity is tightly regulated and can be affected by calcium signaling and tubulin 
interactions, it is likely that a combination of altered calcium signaling and 
aberrant tubulin/TRP interactions causes desensitization of the TRP channels 
following exposure to MTA agents.  The specific mechanisms mediating a 
possible MTA-induced desensitization of TRP channels needs to be carefully 
explored in future investigations. 
The mechanisms for paclitaxel-induced increases in CGRP release are 
also unknown, but they are TRP-channel independent.  Similarly as described 
above, possible paclitaxel-mediated alterations in calcium homeostasis, whether 
it be through mitochondria dysfunction, NCS-1 activation, increases in VDCC 
subunit expression and current (Kawakami, Chiba et al. 2012), and/or other 
possible unknown mechanisms, could all contribute to enhanced neuronal 
sensitivity and activity.  Although speculative, the concomitant increase in 
potassium-evoked release and decrease in capsaicin- and AITC-evoked release 
from the same culture of CGRP-containing neurons could underlie the 
simultaneous gain and loss of function experienced in patients receiving MTA 
therapy.  This suggests that patients may experience a perceived gain or loss of 
function depending on the stimulating agent acting on their peripheral sensory 
neurons. 
 Because some patients experience acute pain from paclitaxel therapy 
whereas others develop peripheral neuropathy over time, we decided to 
investigate the effects of 10 nM and 300 nM paclitaxel on capsaicin-evoked 
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release over a time course of 1, 3, and 5 days.  We were also interested in 
investigating the time course of the paclitaxel-induced decrease in neuropeptide 
release we observed with TRP channel activation.  The low concentration of 
paclitaxel did not increase CGRP release until day 3 of exposure, whereas the 
high concentration of paclitaxel increased capsaicin-evoked release after 1 day 
exposure but decreased release after 3 and 5 days.  This suggests that the 
effects of paclitaxel on CGRP release are a function of concentration and time.  A 
low concentration for a long time or a high concentration for a short period 
augmented release, while a high concentration over a longer period of time, 
decreased capsaicin-evoked release.  This suggests that the paclitaxel-induced 
decrease of TRPV1 channel activity, and likely that of TRPA1, is dependent on a 
high magnitude of paclitaxel exposure, which supports the findings that high 
cumulative doses of paclitaxel in vivo produced impairments in pain-like 
behaviors and thermal hypoalgesia (Cavaletti, Cavalletti et al. 1997, Authier, 
Gillet et al. 2000). 
 Previous groups have found that paclitaxel acutely stimulated the release 
of CGRP from esophagus tissue and the release of substance P from cultured 
DRG neurons (Miyano, Tang et al. 2009, Materazzi, Fusi et al. 2012).  We did not 
observe an acute paclitaxel-induced increase in CGRP release.  One difference 
between our work and the previous work from other labs is that the 
concentrations of paclitaxel used in the esophagus experiments and substance P 
release experiments, 30-50 µM and 10 µM respectively, were higher than the 
300 nM used in our acute release experiments.  The magnitude of paclitaxel 
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exposure in our conditions was, therefore, not as great, and perhaps not 
sufficient for evoking CGRP release acutely.  Future experiments could be 
conducted to test if higher concentrations of paclitaxel cause acute release of 
CGRP from sensory neurons without other stimuli; however, we did not pursue 
this as we are not sure that higher concentrations of paclitaxel are physiologically 
relevant.  Although it is difficult to equate the concentrations of paclitaxel used in 
isolated cells with concentrations achieved in tissues in patients, pharmacokinetic 
studies show that dosing patients with 125-225 mg/m2 of paclitaxel results in 
maximal plasma concentrations between 1 and 10 μM (Rowinsky, Jiroutek et al. 
1999, Henningsson, Karlsson et al. 2001), with a reduction in concentration to 
between 0.01 μM and 1 μM by 20 hours.  We therefore did not attempt to test 
higher concentrations of paclitaxel on acute CGRP release.   
 Together, this work suggests that paclitaxel alters the stimulus-evoked 
release of CGRP in a concentration- and time-dependent manner, depending on 
the magnitude of paclitaxel exposure.  Paclitaxel decreases TRP channel activity, 
and paclitaxel increases neuronal sensitivity, independent of TRP channel 
function.  Our findings support a role for sensory neurons in paclitaxel-induced 
neurotoxicity.  Furthermore, the described in vitro model will facilitate future 
studies to identify the signaling pathways by which paclitaxel alters neuronal 
sensitivity. 
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2) Epothilone B and Vincristine Alter Stimulus-evoked Release of CGRP 
from Sensory Neurons 
In order to determine if the paclitaxel-induced alterations of CGRP release 
are microtubule dependent, we treated neuronal cultures with EpoB, which is a 
compound with a similar microtubule-stabilizing effect as paclitaxel.  EpoB is a 
competitive antagonist of paclitaxel binding to tubulin, and EpoB binds tubulin 
within the same paclitaxel binding domain (Bollag, McQueney et al. 1995, 
Kowalski, Giannakakou et al. 1997, Giannakakou, Gussio et al. 2000).  While 
EpoB has a similar function as paclitaxel in stabilizing microtubules, it does not 
have any known microtubule-independent actions, and EpoB has been used as a 
negative control in experiments investigating microtubule-independent effects of 
paclitaxel (Zhang, Heidrich et al. 2010).   The synthetic analog of EpoB, 
ixabepilone, also creates a profile similar to paclitaxel of peripheral neuropathy in 
patients, suggesting that microtubule stabilization may underlie paclitaxel- and 
ixabepilone-induced peripheral neuropathy (Lee, Borzilleri et al. 2008). We 
hypothesized that if the alterations of CGRP release are somehow downstream 
of microtubule stabilization, EpoB treatment would have a similar effect on 
stimulated CGRP release from sensory neurons as paclitaxel.  These results 
would rule out other possible microtubule-independent mechanisms of paclitaxel 
in altering neuronal peptide release, assuming that paclitaxel and EpoB do not 
have analogous, unknown microtubule-independent actions within sensory 
neurons.  
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Previous work has shown that EpoB binds microtubules with 
approximately 10 times higher affinity than paclitaxel, and cancer cells are 3-30-
fold more sensitive to EpoB than paclitaxel (Kowalski, Giannakakou et al. 1997, 
Zhang, Heidrich et al. 2010).  Since the effective concentrations of EpoB within 
our model system were unknown, we performed a concentration-response curve 
of EpoB and capsaicin-evoked CGRP release ranging from 1-300 nM of EpoB.  
We observed a similar capsaicin-evoked release profile as with paclitaxel, and 
EpoB was approximately 10-fold more potent at altering capsaicin-evoked CGRP 
release.  Similar to paclitaxel, treating sensory neurons for 5 days with a low 
concentration of EpoB, 1 or 3 nM, increased capsaicin-evoked CGRP release 
whereas treatment with a high concentration, 10, 30, 100, or 300 nM, decreased 
capsaicin-evoked release, suggesting that EpoB alters TRPV1 channel function.  
Also, 1 nM of EpoB did not change potassium-evoked CGRP release, and 30 nM 
EpoB augmented potassium-evoked release, suggesting that EpoB sensitizes 
sensory neurons in a TRP-independent manner.  Collectively, these data suggest 
that the paclitaxel- and EpoB-induced alterations of CGRP release are due to 
stabilization of microtubules, although the precise mechanisms mediating these 
changes in neuronal activity are unknown. 
EpoB and paclitaxel may be altering TRV1 channel activity by decreasing 
tubulin interactions with TRPV1 as described above.  Another scenario that might 
explain how paclitaxel and EpoB, which have completely different structures but 
have the same microtubule-stabilizing mechanism of action, could alter 
stimulated CGRP release from neurons may involve alterations in mitochondrial 
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function.  As discussed above, several groups propose that mitochondrial 
dysfunction is an underlying cause of neuronal alterations and peripheral 
neuropathy; however, the mechanisms by which paclitaxel and EpoB putatively 
induce mitochondrial dysfunction are currently unknown.  An alteration in 
mitochondrial trafficking and function might produce several changes that could 
alter neuronal activity such as increased ROS production, altered calcium 
buffering and subsequent calcium homeostasis, and a change in cellular energy 
production (Abou-Sleiman, Muqit et al. 2006).   
One possibility for microtubule-stabilizing-induced alterations of 
mitochondria could involve a change in tubulin binding to voltage-dependent 
anion channels (VDACs) of mitochondria, which are important regulators of the 
transport of anions and other key metabolic metabolites across the outer 
mitochondrial membrane (Blachly-Dyson and Forte 2001).  It has been shown 
that tubulin is present within isolated mitochondrial membranes and that the 
tubulin interacts with the membrane by binding to VDACs (Carre, Andre et al. 
2002).  Other investigators have shown that tubulin reversibly blocks the 
conductance of VDACs by binding and blocking the VDAC pore with the C-
terminal tail (Rostovtseva, Sheldon et al. 2008).  Microtubule stabilizing agents 
like paclitaxel and EpoB may alter mitochondrial function by disrupting the 
balance of free tubulin within the cell or by sequestering VDAC-bound tubulin, 
subsequently un-blocking the VDAC pore and altering the regulation of transport 
of anions and metabolites across the outer mitochondrial membrane.  Opening of 
VDACs can lead to mitochondrial swelling, mitochondrial calcium efflux, and 
141 
 
release of proteins from the mitochondria including cytochrome c and 
procaspases (Abou-Sleiman, Muqit et al. 2006, Rostovtseva and Bezrukov 
2008), all of which can result in mitochondrial dysfunction and possible 
alterations in neuronal sensitivity.  Future studies can investigate if paclitaxel and 
EpoB alter tubulin binding to VDACs of mitochondria and mitochondrial function. 
Mitochondrial dysfunction has been suggested to underlie other types of 
peripheral neuropathies.  In diabetic patients, hyperglycemia can alter the 
electron transport chain of the mitochondria, resulting in increased generation of 
superoxide species (Sandireddy, Yerra et al. 2014).  This is thought to cause 
neurotoxicity via ROS stress, resulting in diabetic peripheral neuropathy 
(Sandireddy, Yerra et al. 2014).  It is suggested that platinum compounds, like 
cisplatin, may induce peripheral neuropathy by creating mitochondrial DNA 
damage, which subsequently leads to defective electron transport chain 
components and an increased production of ROS (Melli, Taiana et al. 2008).  
Mitochondrial dysfunction is likely a common characteristic underlying the 
development of peripheral neuropathy resulting from several chemotherapeutics 
and diabetes; however, the mechanisms underlying the mitochondrial 
dysfunction are likely diverse.  These mechanisms may include alterations in 
tubulin interactions, mitochondrial DNA damage, and alterations of the electron 
transport chain (Jaggi and Singh 2012, Sui, Xu et al. 2013).   Subsequently, 
drug- and disease-induced mitochondrial dysfunction can result in aberrant ROS 
generation, defective calcium buffering, reduced energy production, and 
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increased apoptotic signaling, which can all cause neurotoxicity (Sui, Xu et al. 
2013).       
In order to determine if the effects of paclitaxel and EpoB on CGRP 
release are due to their common mechanism of stabilization of microtubules or 
caused by a general change in microtubule dynamics, we asked if vincristine, 
which alters microtubule dynamics by depolymerizing microtubules, alters 
stimulated CGRP release from sensory neurons.  I treated neuronal cultures for 5 
days with low and high concentrations of vincristine, 1 and 30 nM, respectively, 
and then stimulated the neurons with potassium.  Unexpectedly, treatment with 
30 nM vincristine decreased potassium-evoked CGRP release from the neurons 
and decreased the total content of CGRP.  The decrease in stimulated release 
was not dependent on total content as the normalized CGRP release was also 
attenuated compared to the vehicle-treated control neurons.  Treatment with 1 
nM vincristine augmented potassium-evoked release.  This suggests that the 
gain in function observed with high concentrations of paclitaxel and EpoB may be 
specific to microtubule stabilization.  It can also be argued that a high 
concentration of a microtubule depolymerization agent, like vincristine, may be 
more toxic to neurons than a microtubule stabilizing agent since it caused a 
decrease in total CGRP content.  Although the mechanisms mediating these 
differences are unknown, it suggests that disruption of microtubule dynamics, 
whether by stabilization or destabilization, alters neuronal sensitivity, and 
stabilizing agents and destabilizing agents differ in how they alter stimulated 
CGRP release.  
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One important question that should be answered in the future is if 
vincristine altered neuronal viability in our cultures; this might account for the 
decrease in CGRP content in the cultures after exposure to vincristine, and it 
may be another difference between high concentration exposure of microtubule 
stabilizing drugs versus microtubule depolymerizing agents.  Our laboratory is 
working to perform concentration-response curves of vincristine and capsaicin- 
and potassium-evoked CGRP release in order to determine if vincristine has a 
similar biphasic effect on capsaicin-evoked release and an augmentation of 
potassium-evoked release at lower concentrations of vincristine.   
 
3) Acetyl-L-carnitine and N-acetyl-L-cysteine Do Not Prevent or Attenuate 
Paclitaxel-induced Alterations of Stimulated CGRP Release 
Using our in vitro model, I tested the established hypothesis that paclitaxel 
alters neuronal sensitivity via decreased mitochondrial energy production.  This 
hypothesis was previously postulated since ALCAR prevents and reverses 
paclitaxel-induced changes in mechanical allodynia and hyperalgesia in vivo and 
prevents paclitaxel-induced mitochondrial swelling within C-fibers in rats, 
presumably by alleviating mitochondrial damage (Flatters and Bennett 2006, 
Flatters, Xiao et al. 2006, Jin, Flatters et al. 2008).  The exact mechanism of how 
ALCAR protects mitochondria is not fully known, but it is suggested that ALCAR 
assists in shuttling fatty acids into the mitochondria that are important for ATP 
production, thus aiding in cellular energy production (Hagen, Wehr et al. 1998).  
An ALCAR interaction with the VDAC pore has not been described in the 
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literature, which is a suggested hypothesis for MTA-induced mitochondrial 
dysfunction described above.  Treatment with ALCAR for 5 days had no effect on 
total CGRP content or on capsaicin-evoked CGRP release in the absence or 
presence of paclitaxel, suggesting that ALCAR does not protect the neurons in 
culture from paclitaxel.  One caveat to these experiments is that a positive control 
for mitochondria energy production was not included, thus the possibility exists 
that 100 µM ALCAR was not an effective concentration to protect against 
possible paclitaxel-induced decreases of mitochondrial function within our 
system.  Future experiments can be performed to determine if ALCAR aided 
cellular energy production within the cultured sensory neurons as presumed.  
Interestingly, ALCAR administration prevented and reversed paclitaxel-induced 
hypersensitivity within animal models (Flatters, Xiao et al. 2006, Jin, Flatters et 
al. 2008), whereas concurrent administration of ALCAR with paclitaxel 
chemotherapy caused an increased incidence of peripheral neuropathy within 
patients (Hershman, Unger et al. 2013).  This clinical finding, in combination with 
our in vitro data, suggests that ALCAR has either no effect or a detrimental effect 
on paclitaxel-induced changes of neuronal sensitivity, and ALCAR may be 
preventing paclitaxel-induced mechanical allodynia and hyperalgesia within 
animal models by an unknown mechanism.   
These findings do not convincingly eliminate mitochondrial dysfunction or 
aberrant trafficking as possible mechanisms underlying paclitaxel-induced 
changes of neuronal sensitivity.  If ALCAR aids mitochondria by increasing the 
transport of fatty acids into the mitochondria, ALCAR may have no effect on 
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possible paclitaxel-induced mitotoxicity.  As discussed above, paclitaxel may 
alter the gating of VDAC pores, which ALCAR administration may not affect.  
Also, ALCAR likely does not attenuate aberrant mitochondrial trafficking in axons 
of neurons after paclitaxel exposure (Shemesh and Spira 2010).  Future 
experiments should be designed to carefully investigate the effects of chronic 
exposure to paclitaxel on mitochondrial membrane potential, calcium levels, and 
gating properties within sensory neurons before further conclusions about 
paclitaxel-induced mitotoxicity and alterations of neuronal sensitivity can be 
made.  It is likely that chronic exposure to paclitaxel will alter the mitochondrial 
membrane potential as paclitaxel (293 nM) has been shown to decrease 
mitochondrial membrane potential in cultured DRG after 3 hr exposure (Melli, 
Taiana et al. 2008).   
Using our in vitro model, we also tested whether paclitaxel-induced 
alterations of stimulated CGRP release could be reversed with treatment of the 
free radical scavenger, NAC.  The MTAs have been shown to increase ROS 
within different cell model systems including DRG (Barriere, Rieusset et al. 
2012), and NAC can partially attenuate MTA-induced increases in ROS (Tsai, 
Sun et al. 2007).  Accordingly, we asked whether NAC could reverse or attenuate 
paclitaxel-induced changes in capsaicin-evoked CGRP release, which would 
suggest that the changes in capsaicin-evoked release and alterations of TRPV1 
function may be mediated by ROS generation.  The results from the NAC and 
paclitaxel combination experiments are inconclusive; we were unable to find a 
concentration of NAC (0.5 and 1 mM) that did not alter total CGRP content in the 
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neurons or capsaicin-evoked release in the absence of paclitaxel.  Lower 
concentrations of NAC were not attempted since 0.5 mM and 1 mM did not 
reverse paclitaxel-induced alterations of stimulated CGRP release.  This 
suggests that neuronal CGRP content is tightly regulated, and a shift in the 
balance of the redox environment, or reduced and oxidized states of the cell, 
may be responsible for altering neuronal CGRP content and release.  
Interestingly, the NAC-induced increase in CGRP content was prevented by 
combination treatment with 300 nM paclitaxel.  Perhaps CGRP content is 
regulated by the redox environment, and an increase in CGRP content may be 
produced by a NAC-induced decrease in ROS species, which may be balanced if 
paclitaxel increased ROS.  This idea is purely speculative at this point, and in the 
future, ROS and/or redox status of transcription factors associated with CGRP 
expression could be determined after NAC treatment with and without paclitaxel 
in order to begin investigating this observation.   
A limitation of the NAC experiments is that NAC acts as an antioxidant by 
scavenging free radicals such as the hydroxyl radical and hydrogen peroxide 
(Aruoma, Halliwell et al. 1989) as well as by recycling glutathione pools within 
cells, which mainly act to decrease hydroxyl radical and hydrogen peroxide levels 
(Kerksick and Willoughby 2005, Kalyanaraman 2013).  Attempting to reverse 
paclitaxel-induced effects on neurons with an agent that decreases only a few, 
specific ROS may miss a possible paclitaxel/reactive nitroxidative effect.  For 
example, if paclitaxel alters neuronal sensitivity by increasing the superoxide 
radical and downstream reactive nitrogen species like peroxynitrite, NAC would 
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not inhibit this since it mainly decreases hydrogen peroxide and hydroxyl radical 
levels (Aruoma, Halliwell et al. 1989).  Thus NAC could potentially have no 
impact on the nitroxidative damage caused by paclitaxel.  In order to further 
investigate if paclitaxel alters CGRP release via nitroxidative damage, it is 
important to conduct carefully designed experiments that systematically target 
specific types of nitroxidative species, one at a time.  It may also be useful to 
measure possible paclitaxel-induced increases in the production of nitroxidative 
species within neurons.  There are different techniques that can determine 
changes in specific reactive nitroxidative species or the amount of nitrotyrosine in 
proteins, and employing these techniques may assist in determining if paclitaxel 
alters reactive nitroxidative species, the specific species that are changed by 
paclitaxel, and the sources of the reactive species (Doyle, Chen et al. 2012).  
Clinically, antioxidants have not been effective at relieving peripheral neuropathy 
(Argyriou, Chroni et al. 2006, Kottschade, Sloan et al. 2011, Leal, Qin et al. 
2014); however, many of the antioxidant therapies attempted might fail given the 
same argument described above, and they may not be acting to reverse the 
reactive species actually involved in the development of peripheral neuropathy.  
By using our in vitro model system, future investigations can determine if specific 
reactive nitroxidative species may be important targets for paclitaxel-induced 
alterations of neuronal sensitivity.  
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4) Paclitaxel Alters Stimulus-evoked Release of CGRP and Content from 
Sensory Neurons in the Absence of Added NGF 
The work discussed was all performed using sensory neuronal cultures 
maintained in 30 ng/ml NGF throughout the time in culture.  This concentration of 
NGF has been chosen by our group for the maintenance of sensory neurons 
because it has been previously shown to optimize conditions for the CGRP 
release assay by enhancing the expression of CGRP without compromising the 
ability of the neurons to be sensitized by inflammatory mediators (Park, 
Fehrenbacher et al. 2010).  In an independent set of preliminary experiments not 
described in this work, we observed that removal of NGF from the culture media 
changed the paclitaxel effects on stimulated CGRP release.  Because of this 
observation and the findings by other groups that NGF can alter paclitaxel-
induced changes in cells, we asked if paclitaxel alters neuronal activity in the 
absence of added NGF.  Sensory neurons were cultured and treated with low 
and high concentrations of paclitaxel for 5 days as performed previously; 
however, the neurons were maintained for the 12 days in media with 0 added 
NGF.  We then performed capsaicin- and potassium-evoked CGRP release 
experiments. 
In the absence of added NGF, the capsaicin- and potassium-evoked 
release profiles from the neurons were similar.  The evoked release of CGRP 
decreased in a concentration-dependent manner; however, paclitaxel also 
decreased total CGRP content in a concentration dependent manner.  In order to 
determine if the decrease in evoked release was secondary to a decrease in total 
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CGRP content, we determined the normalized evoked release from the treatment 
groups.  The low concentration of paclitaxel, 10 nM, did not alter normalized 
capsaicin- or potassium-evoked release whereas the higher concentration, 300 
nM, decreased both normalized capsaicin- and potassium-evoked release.  The 
three main differences in CGRP release after treatment with paclitaxel in the 
absence of added NGF are: 1) there was no gain in function or augmentation of 
evoked CGRP release using either capsaicin or potassium as stimuli, 2) there 
was a decrease in potassium-evoked release after a high magnitude exposure to 
paclitaxel, and 3) paclitaxel decreased CGRP content in a concentration-
dependent manner. 
These findings suggest that the mechanisms underlying paclitaxel’s gain 
in function effect are NGF dependent or dependent on CGRP total content.  The 
mechanisms are currently unknown, but future investigation can be directed at 
identifying how NGF augments paclitaxel-induced CGRP release.  Perhaps the 
presence of NGF in the media supports the development of a channel milieu at 
the membrane of the neuron that is necessary for a paclitaxel-induced gain in 
function.  NGF is known to increase the expression and membrane insertion of 
channels involved in neuronal sensitivity like TRPV1 and sodium channels (Fjell, 
Cummins et al. 1999, Fjell, Cummins et al. 1999, Zhang, Huang et al. 2005).  It is 
possible that exposure to NGF increases the membrane expression of channels 
that may be responsible for mediating the paclitaxel-induced gain in function.  
NGF is known to sensitize sensory neurons by several other mechanisms 
including phosphorylation of TRPV1 channels through protein kinase C (PKC) 
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and extracellular signal-regulated kinase (Erk) signaling cascades (Nicol and 
Vasko 2007) as well as by altering purinergic P2X receptors and acid sensing ion 
channels (Ramer, Bradbury et al. 2001, Mamet, Lazdunski et al. 2003).  The 
differential effects of paclitaxel on stimulated CGRP in the absence of added 
NGF could be a result of differences in overall NGF sensitization of the neurons.  
Another possibility for an NGF-dependent gain in function of release could 
be that NGF is altering the location and distribution of organelles affected by or 
functionally changed by paclitaxel.  In accordance with the hypothesis that 
mitochondrial dysfunction is important for mediating paclitaxel-induced changes 
in neuronal sensitivity, NGF has been shown to mediate axonal transport of 
mitochondria and accumulation of mitochondria in terminals and axons of 
sensory neurons at locations of focal stimulation with NGF, which is dependent 
on actin microfilaments and PI3-K signaling cascades (Chada and Hollenbeck 
2003, Chada and Hollenbeck 2004).  In a simple scenario, perhaps NGF is 
responsible for increasing the number of mitochondria within terminals and axons 
of sensory neurons in culture prior to treatment with paclitaxel.  Paclitaxel 
exposure may then halt any further mitochondrial trafficking to the terminals and 
axons of sensory neurons; however, the neurons exposed to NGF may have a 
greater number of accumulated mitochondria within their terminals and axons.  In 
this way, application of paclitaxel to NGF-primed neurons, neurons with higher 
numbers of terminal and axonal mitochondria, may create a greater sensitizing 
effect compared to neurons that were not NGF-primed.  This could be 
investigated with future experiments designed to investigate if NGF and/or 
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paclitaxel alter mitochondria trafficking in our system or if NGF alters paclitaxel-
induced effects on mitochondria function. 
When we observed that paclitaxel decreased CGRP content in a 
concentration-dependent manner in the absence of added NGF, our first idea 
was to test if neuronal viability was altered by paclitaxel, or in other words, we 
questioned if NGF protected the neurons from paclitaxel-induced cell death.  
Although we did not observe a change in viability of sensory neurons grown in 30 
ng/ml NGF, previous reports demonstrated that paclitaxel treatment caused 
significant neuronal death in embryonic (E16) DRG cultures, mediated by 
necrosis (Scuteri, Nicolini et al. 2006), suggesting that paclitaxel may be toxic to 
sensory neurons depending on age and perhaps NGF signaling.  We found that 
paclitaxel did not decrease neuronal viability or the total number of neurons in the 
absence of added NGF, suggesting that the concentration-dependent decrease 
in CGRP content was not secondary to neuronal death and is perhaps due to 
changes in CGRP expression. 
CGRP transcriptional regulation has been shown to be mediated by 
several different pathways.  Both cAMP and NGF signaling cascades can induce 
CGRP transcription by mediating phosphorylation of the cAMP response 
element-binding protein (CREB), which then binds the cAMP response element 
(CRE) within the promoter of the CGRP gene, thereby inducing transcription of 
the gene (Watson and Latchman 1995, Freeland, Liu et al. 2000).  While 
phosphorylation of CREB is sufficient for mediating cAMP-induced CGRP 
transcription, CREB phosphorylation is necessary but not sufficient for mediating 
152 
 
NGF-induced CGRP transcription; activation of the MAPK cascade is also 
necessary for mediating NGF-induced CGRP transcription (Freeland, Liu et al. 
2000, Durham and Russo 2003).  The mechanisms mediating the NGF-
dependent maintenance of neuronal CGRP content in the presence of paclitaxel 
are unknown.  One possibility is that paclitaxel negatively alters transcriptional 
control of CGRP perhaps by interrupting signaling cascades involved in 
phosphorylation of CREB, which can be overridden when NGF is present.  
Paclitaxel could decrease phosphorylation of CREB by several different 
mechanisms including decreasing kinase activity or increasing phosphatase 
activity.  One possible way that paclitaxel could be altering kinase or 
phosphatase activity is by increasing ROS production, which may alter redox 
balance within the neurons.  There is substantial evidence that ROS are 
important mediators of gene expression by altering kinase, phosphatase, and 
transcription factor activity, including CREB (Sen and Packer 1996, Adler, Yin et 
al. 1999, Korbecki, Baranowska-Bosiacka et al. 2013).  This is also suggested by 
our findings that NAC independently increased CGRP content within neurons in 
culture, which was prevented by the presence of high concentrations of 
paclitaxel.  CGRP expression may be tightly regulated under redox-sensitive 
signaling pathways altered by paclitaxel and NGF.  The effects of NGF and 
paclitaxel on CGRP transcription could be investigated by using viruses 
containing the CGRP promoter and a reporter construct, like eGFP (Durham, 
Dong et al. 2004).  In this way, the activity of the CGRP promoter could be 
measured after treatment with paclitaxel and NGF within our system.  ROS have 
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also been shown to decrease CREB protein and mRNA levels within 
hippocampal neurons and cardiomyocytes (Pugazhenthi, Nesterova et al. 2003, 
Ozgen, Guo et al. 2009).  Although a matter of speculation, perhaps paclitaxel is 
causing ROS-dependent decreases in CREB protein expression.  This decrease 
in CREB protein and subsequent decrease in CGRP transcription and protein 
expression may be masked by a NGF-mediated phosphorylation of remaining 
pools of CREB.  This could be further studied by investigating if paclitaxel 
decreases CREB protein levels and/or alters CREB protein phosphorylation via 
ROS production.   
Another possibility that may account for the MTA-induced decrease in total 
CGRP content within the neurons in the absence of NGF could be that the 
retrograde trafficking of the trkA receptor is decreased.  Upon binding NGF, trkA 
is phosphorylated, internalized, and retrogradely trafficked to the nucleus in order 
to activate transcription factors that regulate downstream gene expression, 
including gene expression of CGRP (Ehlers, Kaplan et al. 1995).  Inhibiting 
microtubule dynamics may attenuate retrograde trafficking of trkA and 
subsequent expression of CGRP, and this may be overridden when NGF is 
present in the media.  The exact mechanisms mediating NGF-dependent gain in 
function of sensory neurons and CGRP maintenance in the presence of 
paclitaxel are unknown, but they are likely multifactorial and may involve receptor 
and channel localization, organelle transport and function, redox transcriptional 
regulation, and retrograde trafficking of trkA. 
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In vivo studies have found that NGF can reverse thermal hypoalgesia and 
the paclitaxel-induced decrease in substance P in the DRG (Apfel, Lipton et al. 
1991).  Although these in vivo findings are not directly comparable to our in vitro 
work, we also observed that NGF prevented paclitaxel-induced decreases in 
CGRP content.  This suggests that NGF is important for maintaining 
neuropeptide concentrations within the DRG after exposure to paclitaxel.  Within 
the clinic, a greater paclitaxel-induced decrease in circulating NGF levels is 
correlated with the severity of peripheral neuropathy and can predict the 
development of peripheral neuropathy in patients (Cavaletti, Bogliun et al. 2004, 
Arrieta, Hernandez-Pedro et al. 2011).  These findings are slightly contradicted 
by our results showing that paclitaxel-induced increases in CGRP release, which 
can be loosely extrapolated to neuronal sensitivity in patients and to gain of 
function side effects like pain, do not occur in the absence of added NGF.  
However, the peripheral neuropathy is not characterized in the studies described 
above; an increase in severity of neuropathy could mean an increase in gain of 
function symptoms and/or an increase in loss of function symptoms (Griffith, 
Couture et al. 2014).  In the case of a possible enhancement of loss of function 
symptoms when NGF decreases in patients, our findings may agree:  we 
observed a paclitaxel-induced decrease in CGRP release and total CGRP 
content in the absence of added NGF.  Collectively, our work suggests that NGF 
alters paclitaxel-induced effects on CGRP release in culture, and NGF is 
protective against paclitaxel-induced decreases of CGRP expression.  Future 
experiments can be conducted in vivo to determine if NGF can reverse 
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paclitaxel-induced mechanical hypersensitivity in a low-dose animal model.  
Furthermore, it will be important for future investigators to consider the NGF 
environment when investigating paclitaxel-induced alterations in all settings, 
clinical, in vivo, and in vitro.        
 
5) Epothilone B Alters Stimulus-evoked Release of CGRP from Sensory 
Neurons in the Absence of Added NGF 
NGF signaling could potentially alter microtubule-independent as well as 
microtubule-dependent mechanisms of paclitaxel within neurons.   In order to 
determine if NGF altered a microtubule-dependent effect of paclitaxel, I 
performed stimulated-release experiments after neurons were maintained in 0 
added NGF and treated with EpoB for 5 days.  In the presence of NGF, paclitaxel 
and EpoB have virtually the same effect on capsaicin- and potassium-stimulated 
CGRP release.  In the absence of added NGF, the two microtubule stabilizing 
agents affected release slightly differently, suggesting that the compounds have 
slightly different, unknown mechanisms mediating neuronal sensitivity.  Also, the 
development of peripheral neuropathy may be highly dependent on the 
circulating NGF levels within individuals (Cavaletti, Bogliun et al. 2004, Arrieta, 
Hernandez-Pedro et al. 2011).  In the absence of NGF, EpoB increased (1 nM) 
and decreased (30 nM) capsaicin-evoked release, similarly to when NGF was 
present.  When normalized to total content, there was no capsaicin-induced 
increase of CGRP release in the absence of NGF, and CGRP content decreased 
only after exposure to high concentrations of EpoB.  There was no change in 
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potassium-evoked CGRP release following treatment with 1 nM EpoB; however, 
stimulated release decreased after treatment with 30 nM EpoB.  Similarly to the 
paclitaxel experiments, there was no EpoB-induced increase in potassium-
stimulated CGRP release, suggesting that NGF is necessary for MTA-induced 
neuronal sensitization. 
Paclitaxel binds and activates NCS-1, and NCS-1 and NGF are known to 
converge on similar signaling cascades, including the PI3-K signaling cascade 
(Weiss, Hui et al. 2010).  Potentially, the differential effects of paclitaxel and 
EpoB in the absence of NGF could be due to paclitaxel-specific and microtubule-
independent functions.  For example, there may be more crosstalk and/or 
interactions between paclitaxel-enhanced NCS-1 signaling and NGF signaling 
cascades within neurons following paclitaxel exposure compared to EpoB.  
Further, paclitaxel is known to have several microtubule-independent effects 
within cells, whereas there are no known other functions of EpoB.  This may be 
due to a paucity of investigation on the molecular functions of EpoB, and EpoB 
could also have microtubule-independent functions which are currently unknown.  
Different effects of paclitaxel and EpoB on key pathways mediating neuronal 
sensitization are likely the causes of the different stimulated-release profiles in 
the absence of added NGF, and growing the neurons in NGF likely masks these 
signaling differences.  Finally, paclitaxel has been implicated in altering 
nitroxidative species in vivo while EpoB has not been investigated in this context 
(Doyle, Chen et al. 2012).  The different effects of EpoB and paclitaxel could 
result from a different effect on nitroxidative signaling and damage and/or redox-
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sensitive signaling, thus the effects of EpoB on reactive species generation and 
signaling should be further investigated. 
 
6) NGF Increases Neurite Length and Branching but Does Not Protect 
Against MTA-induced Decreases in Neurite Length and Branching 
In order to investigate the effects of MTA agents on neurite length and 
branching of sensory neurons, I implemented an in vitro system where sensory 
neurons were cultured for 7 or 12 days, fixed on the final day in culture, labeled 
with neuron-specific antibodies tagged with a fluorophore, and then imaged with 
the high-throughput imaging system, ImageXpress Micro XL instrument.  This 
system allowed for us to collect neurite length and branching data from entire 
fields with several neurons per field and from numerous wells and plates to 
increase our statistical power.  While developing this method, I first attempted to 
infect the cultures with eGFP-expressing lentiviruses in order to fluorescently 
visualize the neurons.  I moved away from this technique because the 
lentiviruses used were under the control of a CMV promoter, making the 
expression of the eGFP non-specific. Because the supporting cells were also 
expressing eGFP, I was unable to effectively discriminate between extensions 
from supporting cells and the actual neuronal processes.  In order to avoid 
confounding our neurite length and branching data with complications from viral 
infection, we decided to move to a method of culture fixation and labeling with 
antibodies.  In this way, I collected neurite data from cultures at fixed time points.  
This is a powerful method in that we can collect data from hundreds of neurons 
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within a relatively short amount of time, and we can use neuron-specific 
antibodies for labeling, therefore excluding any signal that may arise from the 
supporting cells within our cultures.  One limitation to this method is that we 
cannot follow neurite length and branching from the same neurons over time. 
Our method is also novel since we are investigating the effect of MTAs on 
neurite length and branching on established neurons in culture.  Previous work 
has mostly focused on the effects of MTAs on the initiation of neurite outgrowth, 
or in other words, the regrowth of neurites after neurite axotomy (Hayakawa, 
Sobue et al. 1994, Hayakawa, Itoh et al. 1999, Scuteri, Nicolini et al. 2006).  
There are few studies that have investigated the effects of MTAs on neurons that 
were already established in culture, and the ones that have used established 
cultures have used embryonic-derived neurons (Letourneau, Shattuck et al. 
1987, Yang, Siddique et al. 2009).  Our studies are some of the first to describe 
the effects of MTAs on adult, fully established DRGs in culture.  Dr. Gracias in 
Dr. Vasko’s laboratory performed preliminary experiments using sensory neurons 
maintained in culture for 12 days.  She found that paclitaxel (100 and 300 nM) 
decreased total neurite length of individual neurons (Gracias published thesis, 
Indiana University).  Gracias’ work and the work in this thesis more closely model 
the clinical exposure of patients to MTAs since their peripheral neurons are 
established upon commencement of MTA therapy.       
NGF has been previously shown to promote neurite length in DRG 
cultures and explant systems (Gavazzi, Kumar et al. 1999, Niwa, Hayakawa et 
al. 2002).  We confirmed this finding within our model system.  I found that 
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neurite length and branching was greater in cultures grown in 30 ng/ml or 250 
ng/ml NGF compared to 0 added NGF groups after 12 days in culture.  
Interestingly, when neurite length and branching was measured after only 7 days 
in culture, there were no differences in length or branching between neurons 
grown in 0, 30, or 250 ng/ml NGF.  This suggests that NGF is most important for 
promoting neurite length and branching days 7-12 in culture, after the neurons 
have fully established themselves, or it suggests that NGF is necessary to 
maintain neurite length and branching between days 7 and 12 in culture; 
however, the former option is more likely since neurite length and branching did 
not decrease in 0 added NGF groups between the 7 day and 12 day time points. 
Exposure to high concentrations of paclitaxel, EpoB, or vincristine over 
long periods of time decreased neurite length and branching of the sensory 
neurons, which is similar to previous work performed in embryonic DRG systems 
and in other neuronal systems (Hayakawa et al., 1994, Hayakawa et al., 1999, 
Yang et al., 2009); however, NGF did not attenuate or prevent this MTA-induced 
effect.  This is contrary to the work from Hayakawa et al. that found that 
exogenous application of NGF to superior ganglia explants attenuated the effects 
of paclitaxel on prevention of neurite outgrowth (Hayakawa et al., 1994, 
Hayakawa et al., 1999).  One possibility for this difference is that NGF has 
different effects on autonomic neurons compared to sensory neurons, and a 
second explanation could be that NGF may attenuate MTA-induced prevention of 
neurite outgrowth but have no effect on preventing MTA-induced neurite 
retraction. 
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All of the MTA agents, regardless of microtubule interaction, reduced 
neurite length and branching, independent of the NGF environment, which 
suggests that the decrease in neurite length and branching is due to an alteration 
in microtubule dynamics, as opposed to microtubule-independent effects of the 
MTAs.  This is supported by the growing body of evidence that has shown that 
microtubules are crucial factors in the maintenance of neurites; neurite length is 
maintained by opposing forces between actin microfilaments in the tip of the 
neurite and microtubules.  Disrupting this counterbalance of forces by altering 
microtubule dynamics can result in neurite retraction (Letourneau, Shattuck et al. 
1987, Ahmad, Hughey et al. 2000, Wang, Naruse et al. 2001).  The MTA-induced 
decreases in neurite length and branching in our system are likely a result of a 
disruption of microtubule dynamics, which would subsequently cause an 
alteration of the opposing structural forces within neurites.  Another possibility 
that may underlie the MTA-induced decreases in neurite length and branching is 
that the disruption in microtubule function may alter mitochondrial function, as 
discussed above, and this could be important for maintenance of neurite length 
and branching (Morris and Hollenbeck 1993, Ruthel and Hollenbeck 2003).  A 
disruption in mitochondrial-produced energy and calcium buffering could be 
important for the maintenance of neurites, and damaging mitochondria with 
MTAs may be involved in MTA-induced decreases in neurite length and 
branching.   
Since all three of the MTAs had a similar effect on neurite length and 
branching, this helps to rule out microtubule-independent mechanisms that could 
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be connected to neurite length alterations.  For example, NCS-1 is an important 
calcium regulator that has been shown to regulate neurite length via regulation of 
the TRPC5 channels (Hui, McHugh et al. 2006).  EpoB has no known interaction 
with NCS-1 (Zhang, Heidrich et al. 2010) and decreases neurite length and 
branching similarly to vincristine and paclitaxel, which suggests that the MTA-
induced deceases in neurite length and branching are not secondary to NCS-1 
and TRPC5 alterations.  MTAs are likely altering neurite length and branching 
within the established cultures by disrupting microtubule dynamics, however, 
whether the neurite alterations are due to the destruction of the fine balance of 
microfilament and microtubule interactions or via a different mechanism, like 
altering mitochondria function, is still a subject for future studies. 
Our in vitro findings mirror the effects of MTA agents on IENF in vivo and 
clinically.  Vincristine and paclitaxel decreased IENF in the rat hindpaw as well as 
in skin biopsies taken from patients receiving paclitaxel or vincristine therapy 
(Siau, Xiao et al. 2006, Boyette-Davis, Cata et al. 2013).  This suggests that our 
model is effective at modeling the actions of MTA agents on sensory neurites.  It 
is currently unknown if peripheral neuropathy develops because neurites retract 
or if neurites retract independent of changes in neuronal sensitivity; however, the 
data in this thesis suggests that changes in neuronal sensitivity may be 
independent of decreased neurite length since paclitaxel, EpoB, and vincristine 
decrease neurite length in an analogous manner but have different effects on 
CGRP release.  Although the peak of hypersensitivity in MTA animal models 
corresponds to decreases of IENF within the hindpaws of the animals (Siau, Xiao 
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et al. 2006), the hypersensitivity may not be casually related to decreases of 
IENF.  The mechanistic link between these MTA-induced symptoms needs to be 
further investigated, and our in vitro model can be used as a tool for future 
studies to investigate if neuronal sensitivity and or desensitization is secondary to 
MTA-induced decreases in neurite length. 
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CONCLUSIONS AND FUTURE DIRECTIONS 
 
This work establishes that MTAs augment and attenuate stimulated CGRP 
release from peptidergic, sensory neurons in vitro, which is dependent on the 
magnitude of MTA exposure, the CGRP-evoking stimulus, the MTA treatment 
duration, and the surrounding NGF environment.  MTAs also decrease neurite 
length and branching, independent of the surrounding NGF environment.  These 
findings are analogous to MTA-induced changes in animal models and within 
patients receiving MTA therapy as they intimate gain and loss of function of 
nociceptor fibers as well as decreases in IENF.  This suggests that our in vitro 
system is an effective model to investigate the molecular effects of MTAs on 
sensory neuron activity and morphology, and both sensitizing and desensitizing 
mechanisms may contribute to the clinical symptoms of peripheral neuropathy, 
dependent on the dosing and on the experimental endpoints measured.  Our 
model is accompanied by some limitations that can be addressed with future 
work investigating glutamate release, intracellular calcium levels, and excitability 
of the entire population of sensory neurons in culture.   
Future work should be directed at investigating the signaling pathways 
contributing to the changes in CGRP release induced by MTA agents.  This 
includes investigating possible pathways involved in MTA-induced decreases in 
TRP channel function, which may include desensitization mechanisms of the 
TRP channels and/or aberrant TRP and tubulin interactions.  Signaling pathways 
that are involved in MTA-induced gain in function should also be investigated and 
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may include tubulin-mediated mitochondrial dysfunction and/or alterations in 
membrane channels including VDCC channels. 
 Another possible avenue for future work is the investigation of ROS and 
reactive nitrogen species generation within neurons after MTA exposure.  
Aberrant nitroxidative signaling could have huge implications for neuronal activity 
as nitroxidative species have been implicated in the development of pain states 
of several different etiologies (Salvemini, Little et al. 2011), and ROS and 
reactive nitrogen species can alter signaling cascades and transcription factor 
activity (Bar-Shai and Reznick 2006, Bar-Shai and Reznick 2006, Yakovlev and 
Mikkelsen 2006).  MTA-induced changes in the generation of ROS and reactive 
nitrogen species, the source of ROS production, and the effects of altered 
nitroxidative stress and signaling within neurons are all subjects needing further 
investigation. 
 Future work should also be conducted to elucidate how NGF alters MTA-
induced changes in neuronal activity.  Investigating changes in NGF-mediated 
mitochondria localization, CGRP expression, and signaling pathways involved in 
neuronal sensitization in the presence of MTAs may be helpful in understanding 
how NGF may facilitate protection from paclitaxel clinically. 
 Finally, the mechanisms underlying MTA-induced decreases in neurite 
length and branching and whether this is involved in changes in neuronal 
sensitivity are important topics for future investigation.  It is likely that neurite 
length decreases due to microtubule alterations following treatment with MTAs, 
and future work can be directed at understanding whether neurite length is 
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affected by other possible MTA-induced alterations in calcium homeostasis 
and/or mitochondrial function.  
The model systems developed in this thesis can be used to further identify 
the underlying mechanisms resulting in MTA-induced alterations of CGRP 
release and neurite morphology.  These findings will also direct future work 
aimed at identifying and substantiating putative inhibitors of MTA-induced 
peripheral neuropathy. Further studies will test different hypothesized signaling 
pathways to determine whether they contribute to the illustrated alterations in 
neuropeptide release and neurite length.  The long-term goal for this work is that 
it will be used to further understand the underlying mechanisms of MTA-induced 
changes in neuronal sensitivity and morphology in order to develop therapies to 
specifically prevent the development of MTA-induced peripheral neuropathy 
within patients.   
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